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Chapter 1 – Total Synthesis and Analog Development of Oximidine II 
 The benzolactone enamide natural products are identified by three structural 
characteristics: a salicylate arene, a 12- or 15-membered macrolactone, and an 
enamide side chain.  These natural products exert their biological activity by 
inhibiting the vacuolar-(H+)-ATPase (V-ATPase) enzyme. 
 The benzolactone enamide oximidine II has been synthesized twice previously 
with only moderate yields realized for the key macrocyclization step.  Following a 
previous Georg group strategy, we envisioned performing the ring-closure using a 
Castro-Stephens reaction.  While optimizing this copper-mediated macrocyclization, 
we discovered an unprecedented copper-mediated reductive coupling reaction. 
 The enamide side chain of these natural products is postulated to be critical 
for biological activity.  To probe the importance of this acid-sensitive moiety, we 
synthesized an allylic amide homolog of oximidine II and tested both oximidine II 




Chapter 2 – The Search for New Antibiotics – New Inhibitors of the MurA 
Enzyme 
 The bacterial enzyme UDP-N-acetylglucosamine enolpyruvyl transferase 
(MurA) catalyzes the first committed step of cell wall biosynthesis.  Using high-
throughput screening, 5 scaffolds were identified with MurA inhibitory activity.  
Analog development of the pyrrole-benzoic acid scaffold failed to generate 
compounds with improved potency.  We then turned to structure-based drug design to 
investigate new MurA inhibitors.  Using computer-modeling software, low molecular 
weight molecules were docked into various MurA crystal structures.  Evaluation of 
these docking studies revealed 4 small molecules as potential leads for further 
optimization. 
Chapter 3 – Synthesis and Initial Biological Evaluation of 2,3,7,8-
Tetrachlorophenothiazine 
 Dioxins are environmental pollutants that cause a range of biological effects 
in a dose-dependent manner.  The exact mechanism of action for dioxins is not fully 
understood.  2,3,7,8-Tetrachlorophenothiazine (TCPT) was designed to probe 
potential mechanisms of action and biological effects of dioxin analogs.  Utilization 
of Buchwald-Hartwig coupling methodology produced TCPT in 37% yield.  
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Chapter 1 
Total Synthesis and Analog Development of Oximidine II 
 
1.1 Introduction to Benzolactone Enamides 
 Natural products are great resources for pharmaceutical lead development.1,2 
These molecules possess certain advantages when compared to molecules typically 
found in high-throughput screening (HTS) collections.  Natural products contain 
diverse structural complexity and inherent chirality that may favor binding to certain 
enzymes or protein interfaces.  Depending upon the specific biochemical role of the 
molecule inside the engineering organism, the molecule may be expected to cross cell 
membranes.  Whether this process occurs by active or passive transport, this inherent 
permeability quality gives natural products another advantage over synthesized 
molecules with respect to cellular uptake.  Natural products may or may not follow 
Lipinski’s rules for oral absorption.3 Regardless, they possess many attractive features 
that prompt their continued investigation for new therapeutic development. 
 The benzolactone enamides are a family of recently identified natural products 
with potent biological activity.  These molecules, displayed in Figure 1, have three 
characteristic structural features – a salicylate moiety, a macrolactone, and an 
enamide side chain.  There are currently five families in this natural product class: (–
)-salicylihalamide A (1) and B (2), CJ-12,950 (3) and CJ-13,357 (4), lobatamides A-F 
(5-10), apicularen A (11) and B (12), and oximidines I-III (13-15).  The lobatamide 
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molecules contain 15-membered macrolactones, while the other members contain 12-
membered macrolactones.4 
Figure 1. Members of benzolactone enamide natural product family 
 
 Salicylihalamides A and B were discovered from a cytotoxicity assay of the 
crude extract of the Haliclona sponges in 1997 by Boyd and coworkers at the 
National Cancer Institute (NCI).5,6 Testing of these compounds in the NCI 60-cell 
cancer assay revealed a selective cytotoxicity profile at that time unmatched in the 
NCI database, suggestive of a new mechanism of action.  Salicylihalamide A (1) was 
shown to be most cytotoxic against melanoma cancer types and displayed an overall 
mean GI50 of 15 nM with a sensitivity range of 1000 across the panel of cell lines. 
 While screening secondary metabolites of the zygomycete Mortierella 










1, (–)-salicylihalamide A: 17E


































5, lobatamide A: R = H, 25Z, E-oxime ether
6, lobatamide B: R = H, 25Z, Z-oxime ether
7, lobatamide C: R = H, 25E, E-oxime ether
8, lobatamide D: R = OH, 25Z, E-oxime ether
9, lobatamide E: R = OH, 25Z, Z-oxime ether
10, lobatamide F: R = OH, 25E, E-oxime ether
11, apicularen A: R = H








13, oximidine I: C12-C13 = "-epoxide, R = OH, 18Z
14, oximidine II: C12-C13 = Z-olefin, R = OH, 18Z





researchers from Pfizer discovered the CJ compounds, CJ-12,950 (3) and CJ-13,357 
(4).7 Increasing the production of LDL receptors leads to an increase in the cellular 
uptake of circulating LDL, thus decreasing the potential of freely circulating 
cholesterol to deposit on blood vessel walls.8 LDL, the “bad cholesterol”, is a 
contributing factor to a variety of diseases including atherosclerosis and coronary 
heart disease.  Compounds 3 and 4, however, did not affect cholesterol synthesis, 
tubulin polymerization, or lysosomal pH. 
 The Boyd group isolated lobatamides A and B (5 and 6) in 19979 and 
lobatamides C-F (7-10) in 199810 from tunicate Aplidium species of the southwest 
Pacific Ocean.  Following Boyd’s discovery in 1997, Suzumura et al. isolated YM-
75518 from the fermentation broth of Pseudomonas sp. Q38009.11 Later, this 
molecule was reassigned as lobatamide A.  The isolation of the molecule from two 
different species suggests that its biosynthesis may occur in related microorganisms 
living in the parent species or that the molecule is present in their diet.  Testing of 
compounds 5-8 in the NCI 60-cell human cancer assay revealed a differential 
cytotoxicity profile similar to salicylihalimide A10 as determined by a COMPARE 
analysis.12  The COMPARE analysis is an algorithm used to compare results from the 
NCI-60 cell assay between compounds to determine if the compounds share a similar 
mechanism of action.  Lobatamide A and salicylihalamide A were most active against 
melanoma and leukemia cancer types. 
 Apicularen A (11) and its N-acetyl-glucosamine glycoside apicularen B (12) 
were isolated in 1998 from myxobacteria of the Chondromyces genus by Kunze et 
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al.13 Interestingly, apicularen A was potently cytotoxic and displayed single digit nM 
IC50 values across 9 different cell lines but displayed no antibiotic activity, while 
apicularen B was modestly antibiotic and 1000-fold less cytotoxic than apicularen A.  
The biosynthesis of apicularen A was investigated through 13C-acetate feeding 
experiments.14 Based on incorporation of the carbon isotope, biosynthesis of 
apicularen was proposed to occur through a modular polyketide synthase containing a 
nonribosomal peptide synthetase. 
 Hayakawa and coworkers isolated the highly unsaturated benzolactone 
enamides oximidines I-III (13-15) from Pseudomonas strains.15-17 These molecules 
demonstrated selective cytotoxicity towards rat 3Y1 fibroblasts mutated with the src 
oncogene,18 ras oncogene,19 or adenovirus E1A20 compared to normal rat 3Y1 
fibroblasts.  Oximidines II and III, containing only one oxygen bonded to carbons 12, 
13, or 14, were generally at least twice as active as the doubly-oxygenated oximidine 
I in these assays.   
 In 2001, the Boyd laboratories at the NCI identified the cellular target for the 
benzolactone enamides.21 Screening oximidine II in the 60-cell panel gave a 
differential selectivity profile matching the previous salicylihalimide A and 
lobatamide A screening results, suggesting that these molecules share a similar 
mechanism of action.  Apicularen A was subsequently shown to share an identical 
screening profile.14,22 Database analyses from the 60-cell assay matched reactivity 
profiles to the known vacuolar-(H+)-adenosine triphosphatase (V-ATPase) inhibitors 
bafilomycin A1 (16, Figure 4)23-25 and concanamycin A (17, Figure 4).26-28 A 
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COMPARE analysis12 correlated the results between the benzolactone enamides and 
these V-ATPase inhibitors.21 Testing of the benzolactone enamides in various V-
ATPase assays confirmed their biological target.  Interestingly, this family of natural 
products inhibits only mammalian types of this eukaryotic enzyme.  Subsequent 
biological assessment of salicylihalamide A and lobatamide A showed they too were 
selective for rat mutated 3Y1 fibroblasts similar to oximidines I-III.  Additional 
biological information regarding the CJ compounds has not been reported beyond the 
initial isolation publication. 
 
1.2 Biological Significance of V-ATPases 
 The eukaryotic transport protein V-ATPase (Figure 2) is responsible for pH 
homeostasis in various intracellular organelles, such as the Golgi apparatus, 
endosomes29 and lysosomes.30,31 This pH control results in the regulation of cellular 
processes such as the degradation of proteins and other molecules, receptor-mediated 
endocytosis, and coupled transport of various small molecules.  V-ATPases have also 
been found on the plasma membrane of certain cells.32 These enzymes play crucial 
roles in renal acidification (renal intercalated cells in kidneys),33 bone resorption and 
degradation (osteoclasts),34 control of cytoplasmic pH (macrophages)31 and sperm 
maturation (clear cells in vas deferens and epidiymus).35 
 V-ATPases are ATP-dependent proton pumps and use energy released by 
ATP hydrolysis to shuttle protons from external sources into the organelle or cell.30,31 
They are comprised of two domains, a membrane-bound V0 domain and an 
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extramembranal V1 domain (Figure 2).  These domains can dissociate and re-
associate under certain conditions, but the underlying mechanisms of these processes 
are not completely understood.  The domains are formed by a number of subunits that 
serve specific enzymatic functions.  V0 consists of 6 subunits: a, c, c’, c″, d and e, of 
which only a, c, c″, d and e are found in mammalian cells.  Subunit a contains an 
arginine residue that is critical for proton influx.  Subunits c and c″ contain glutamate 
residues buried deep within these channel-shaped subunits that are responsible for 
harboring the proton to be transported across the membrane.  The exact stoichiometry 
of these subunits remains to be deduced, but most evidence supports a total of six c 
and c″ subunits and one a, d, and e subunit per enzyme as shown in Figure 2.  V1 
consists of eight subunits, A-H.  Subunits A and B serve as the ATP binding sites.  
These two subunits are present in a higher stoichiometry than the other subunits, 
similar to the subunits of V0.  The other subunits of V1 function either to rigidify the 
enzyme complex or to connect the two domains. 
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Figure 2. Structure of V-ATPase31 
 
 There are three known types of ATPases – P-ATPases, F-ATPases, and V-
ATPases.36 These enzymes transport ions through ATP-dependent processes.  P-
ATPases use ATP hydrolysis to fuel the transport of cations, such as Na+, K+ or Ca2+, 
across membranes and are widely distributed throughout the body.  F-ATPases and 
V-ATPases are structurally similar and transport protons across different membranes.  
They differ in location and how ATP is involved in the enzymatic activity.  F-
ATPases are found mostly in the mitochondria and are partly responsible for 
synthesizing ATP in the cell, hence the classification as an ATP-synthase.  V-
ATPases are found elsewhere in the cell and hydrolyze ATP to ADP as part of its 
catalytic mechanism. 
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 The V-ATPase proton pumps operate via a rotary mechanism as shown in 
Figure 3.31 A proton enters the enzyme from the cytoplasm first through the hemi-
channel subunit a (panel A).  The proton is then shuttled to the glutamate residues on 
subunits c and c” (panel B) where it resides until release into the organelle.  ATP 
hydrolysis on the interface of subunits A and B causes rotation of subunits c and c” 
relative to subunit a (panel C).  This rotation forces the realignment of the protein in 
such a way that the proton is shuttled from the glutamate residue back to subunit a, 
protonating the key arginine residue (panel D).  The proton is then released into the 
organelle to complete the catalytic cycle. 
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Figure 3. V-ATPase catalytic cycle31 
 
 Mammals express multiple isoforms of the V-ATPase subunits.  The 
incorporation of different subunit isoforms does not alter the enzymatic mechanism.  
However, different isoforms are expressed in different membranes, potentially 
allowing for selective drug targeting.  Two isoforms of subunit E are known, E1 and 
E2, but only E2 is expressed in the testis, creating a prospective opportunity for male 
contraceptive development.37 Malfunction of specific isoforms may contribute to 
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certain diseases.35 Mutation of the renal a (V0) or B (V1) subunit isoforms leads to 
distal renal tubule acidosis.38 Hyperactivity or hypoactivity of V-ATPases in 
osteoclast cells leads to osteoporosis or osteopetrosis, respectively.35  
 The V-ATPase system is important for normal human physiology but can be 
manipulated by various diseases.31,35 A basic cellular function of the V-ATPase 
system is to regulate the internalization of specific macromolecules through the 
endocytotic process.  Certain viruses, such as the influenza virus, and certain bacterial 
toxins, such as diphtheria and anthrax, use this pathway to enter healthy cells.   
The role of V-ATPases in cancer pathology is broad.  Of the six hallmarks of 
cancer,39 V-ATPase is involved in at least three – tissue invasiveness and metastasis, 
sustained angiogenesis and evasion of apoptosis.   
V-ATPases are more expressed on highly metastatic cancer cell surfaces than 
on the surface of less metastatic cells.32,38 The increased V-ATPase population serves 
two symbiotic functions.  Increased glycolysis rates inside the cancer cell lead to 
increased proton production.40 However, an alkaline cytoplasmic pH is necessary for 
cancer cell survival.41,42 Pumping of these extra protons into the extracellular space 
generates an acidic environment for certain secreted proteins, such as cathepsins, to 
become active.  These proteins are known to degrade the extracellular matrix 
surrounding cells, allowing metastasis to occur.  It is unclear if cathepsin activation is 
the only extracellular role for V-ATPase activity in tumor metastasis.  However, 
treatment of highly metastatic cells with V-ATPase inhibitors, such as the natural 
 34 
product bafilomycin38 or an indole compound,43 greatly attenuated the migration and 
invasion of these cells. 
 The recruitment of new vasculature, the process known as angiogenesis, is 
required for tumor expansion.  Direct access to the circulatory system also allows 
tumor metastasis to new sites in the body.44,45 Studies from the labs of Sennoune and 
Martinez-Zaguilan have shown that microvascular endothelial cells, cells 
instrumental in angiogenesis, overexpress V-ATPase enzymes on their plasma 
membrane similar to cancer cells.44,45 Thus, inhibiting migration of these endothelial 
cells to the growing tumor would prevent tumor expansion by cutting off its food and 
blood supply. 
 The mechanism by which V-ATPases cause apoptosis is not clearly defined 
and may involve more than one pathway.  It is known that cellular acidosis, 
potentially resulting from increased glycolysis, leads to apoptosis.46,47 Inhibition of V-
ATPases can also trigger apoptosis48 through both caspase-dependent49 and caspase-
independent50 pathways.  Higher than normal V-ATPase levels have been seen on 
certain cancer cell types and may resist drug-induced apoptosis due to the presence of 
a non-P-glycoprotein multi-drug efflux pump.36 It has been demonstrated that use of a 
V-ATPase inhibitor in combination with an anti-cancer agent increases cancer cell 
sensitivity towards chemotherapy,51,52 impacting cell viability at doses lower than the 
necessary dose for a single agent.  This result highlights the potential impact of V-
ATPase inhibitors on cancer chemotherapy. 
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 V-ATPases also play a role in the complex autophagy pathway in eukaryotic 
cells.  Autophagy is the intracellular degradation of proteins and organelles resulting 
from certain environmental stresses.53 Cancer cells that avoid apoptosis use the 
autophagy pathway to recycle mutated proteins and protect the cell from metabolic 
stress.54 The autophagy pathway can also destroy cancer cells.55 Certain types of 
cancers such as breast56 or prostate cancer57 undergo cell death not by apoptosis but 
by autophagy following radiation or chemotherapeutic treatment.55,58 In these studies, 
co-administration of the V-ATPase inhibitor bafilomycin (16) with temozolomide led 
to increased cell death compared to use of temozolomide alone.57 The exact role of 
autophagy in cancer cells is unknown, as inhibitors of autophagy are known to 
produce both cell death and cell growth.55 V-ATPase inhibitors could be used to gain 
a better understanding of these complex processes. 
 
1.3 V-ATPase Inhibitors – Investigation of Benzolactone Enamides  
 Although not all of the physiological consequences of V-ATPase modulation 
are understood, investigators have sought inhibitors of the enzyme.  V-ATPases 
influence a variety of disease states and selective inhibition could have an impact in 
many therapeutic areas.  Several synthetic compounds34 and natural products4,34,59,60 
have been discovered that bind selectively to V-ATPases.  These molecules bind in 
the ATP binding site34 or on various subunits.59 Despite therapeutic potential towards 
a number of diseases, V-ATPase inhibitors have been mainly investigated as anti-
osteoporosis or anti-cancer agents. 
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 The first selective V-ATPase inhibitors, the plecomacrolides 
concanamycin26,28 (17) and bafilomycin23,24 (16, Figure 4) were identified in 1988. 
Concanamycin A selectively targets V-ATPases, displaying 250,000-fold selectivity 
for V-ATPases vs. K+ P-ATPases, while bafilomycin A is 7,200-fold selective for V-
ATPases vs. K+ P-ATPases.25 Neither molecule is active against F-ATPases.  V-
ATPase mutagenic studies demonstrated that the plecomacrolides bind in subunit c on 
the V0 complex.61 Further photoaffinity labeling using a concanamycin analog 
confirmed this result.27,62 Analogs of bafilomycin A have been investigated for V-
ATPase inhibitory properties.63 Despite significant interest in these molecules, their in 
vivo toxicity has halted further development.  The plecomacrolides were instrumental 
in demonstrating that V-ATPases are relevant biological targets for the treatment of 
cancer and osteoporosis, spawning further research. 
 Since the discovery of the plecomacrolides, other macrolides have been 
isolated that display V-ATPase inhibitory properties.  The chondropsin class of 
macrolides (chondropsin B, 18, Figure 4) was tested in the NCI 60-cell panel in 
2003.64 These molecules displayed potent cytotoxicity, exhibiting a mean GI50 of 25.6 
nM across the panel.  Using a COMPARE correlation analysis, the chondropsins were 
identified as V-ATPase inhibitors and confirmed in subsequent biological assays.  
Archazolids A (19) and B (20) were isolated in 2003 from the culture broth of various 
myxobacteria species.65 Ensuing studies revealed that these molecules, similar to the 
plecomacrolides, bind to the c subunit on the membrane-bound V0 complex of V-
ATPases.66 Glycoside-containing archazolids C67 (21) and D68 (22) were isolated in 
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2007 and were shown to have attenuated biological properties compared to A (19) 
and B (20) (further analog development of the archazolids).69 The iejimalides (23 and 
24) were isolated in 2006 and exhibited mean log GI50’s between -6.67 and -6.11 
(correlating to 214 and 776 nM, respectively) across 39 different human cancer 
lines.70 Interestingly, a COMPARE analysis did not suggest a mechanism of action 
despite the known V-ATPase inhibitor profile.  However, testing of these molecules 
in V-ATPase assays by Kazami and coworkers demonstrated V-ATPase IC50 values 
between 71 and 95 nM and that the iejimalies were potent anti-osteoporotic 
compounds.71 The most recently isolated V-ATPase-targeting macrolide is 
palmerolide A (25), isolated from Antarctic tunicates.72 This enamide-containing 
macrolide, while not potently cytotoxic (µM IC50 values across different cancer 
lines), is active against V-ATPases with an IC50 value of 2 nM. 
 Small molecule synthesis groups at pharmaceutical companies have not 
ignored the promise of V-ATPase inhibition as a treatment for osteoporosis and 
cancer.  Astellas Pharma Inc. in Japan recently detailed their novel quinoline 
compound FR202126 (26, Figure 4) as a potential treatment for periodontitis.73 
Periodontitis is the inflammation and infection of the ligaments and bones that 
support the teeth.  This process is coupled with bone loss in the alveolar bone, similar 
to osteoporosis.  FR202126 displayed an IC50 of 99 nM in a proton transport assay 
using plasma membrane vesicles of murine osteoclasts.  Further murine in vivo 
testing demonstrated blockage of bone resorption in alveolar bones, generating a 
proof of concept.  A two-week murine toxicity test showed growth of a femoral bone 
 38 
following treatment with FR202126.  While the development of this compound was 
halted due to this side effect, it demonstrates that a selective V-ATPase inhibitor 
could be useful in vivo in treating bone loss.  Inspired by bafilomycin, a series of 
indolyl compounds (27) were investigated for their bone antiresorptive properties.74,75 
These compounds were selective for human osteoclast V-ATPases versus other 
human isoforms of the enzyme,75 displaying nanomolar potency against osteoclast V-
ATPases and in bone antiresorptive assays.  Another synthetic indolyl compound, 
NiK-12192 (28, Figure 4), has been reported to potentiate the cytotoxic effects of 
camptothecin in both in vitro and in vivo models.76 Further studies with this molecule 
displayed its ability to modulate the metastatic properties of lung carcinoma in vitro 
and in vivo.  When a nude mouse was implanted with a human lung carcinoma, the 
tumor’s metastasis was halted.43 However, the implanted tumor continued to grow 
inside the target organ, potentially highlighting the limits for V-ATPase inhibition as 
an anti-cancer target.  V-ATPase inhibitors may be useful anti-cancer agents when 
co-administered with other anti-cancer therapeutics, as previously discussed.  Another 
deduction from these results is that more potent, irreversible compounds are required 
to ascertain substantial anti-cancer effects from V-ATPase inhibitors. 
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Figure 4. Reported V-ATPase inhibitors 
 
 The benzolactone enamides are the only known V-ATPase inhibitors that 
selectively target mammalian enzyme types.4 The reasoning behind this eukaryotic 





















































19, archazolid A: R1 = Me, R2 = H, R3 = H
20, archazolid B: R1 = H, R2 = H, R3 = H
21, archazolid C: R1 = Me, R2 = !-D-glucopyranoside, R3 = H
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product family binds somewhere in the membrane-bound V0 region of the 
holoenzyme, similar to the plecomacrolides.77 However, competitive binding studies 
have shown that salicylihalamide does not bind to the same binding site as 
bafilomycin or concanamycin.27 The exact subunit targeted by the benzolactone 
enamides is still unknown despite their irreversible interaction with the enzyme.77 
 The De Brabander group proposed a mechanism for irreversible inhibition 
based on N-acyl-iminium ion chemistry (Figure 5).  Under acidic conditions, N-acyl 
enamides can form N-acyl-iminium ions.78 Following protonation of the olefin, a 
stabilized carbocation is generated.  This N-acyl iminium ion could then react with a 
variety of nucleophilic residues within the V-ATPase binding site.  This mechanism 
was supported by analog studies by the group that demonstrated the necessity of an 
N-acyl enamide for irreversible binding to the enzyme.77 Analogs lacking this 
functionality but containing a Michael-accepting hexadienyl side chain were not 
irreversible inhibitors.  
 To more thoroughly investigate this mode of action and to try to discover the 
residue responsible for covalent bond formation, the group synthesizied a 
radiolabeled salicylihalamide analog.77 Placement of the radiolabel on the enamide 
side chain and incubation with bovine brain V-ATPase surprisingly revealed only a 
small amount of radiolabeled protein despite high levels of proton pump inhibition, 
indicating that the side chain is most likely not covalently bound to the enzyme.  
These studies additionally could not deduce the subunit binding site or specific 
residue that bound the radiolabeled analog. 
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Figure 5. Proposed mechanism of inhibition by the enamide side chain77 
 
 Prior to the mechanism of action studies by De Brabander, his group 
synthesized a series of analogs to develop the structure-activity relationship (SAR) 
for the enamide side chain.  An easily synthesized enamide carbamate analog79 (entry 
7, Table 1) exhibited a similar biological profile compared to salicylihalamide A, with 
an IC50 of 1.6 nM against bovine brain V-ATPases and irreversible inhibition of the 
enzyme.  While saturation of the macrolactone olefin (entry 8) only marginally 
reduced the V-ATPase inhibitory properties of the molecule, reduction of the enamide 
double bond (entry 9) resulted in a 10-fold shift in the V-ATPase inhibition.80 This 
molecule also displayed reversible binding to the protein.  Attempts to model the 
proposed electrophilicity of the generated N-acyl iminium ion through development 
of α,β-unsaturated carbonyl compounds were moderately successful.  The α,β-
unsaturated ketone derivative (entry 3) displayed good V-ATPase inhibition but was a 
reversible inhibitor in various assays.  The enoate analog (entry 4) was much less 




























of the double bond or to the length of the side chain.  The group also probed the size 
of the lipophilic side chain binding pocket.  The saturated hexane side chain analog 
(entry 5) retained potent V-ATPase inhibition but was five-fold less active against the 
SK-MEL-5 melanoma cancer cell line compared to salicylihalamide A.  A 
phenylacetylene derivative (entry 6) was similarly potent to the saturated hexane side 
chain analog and showed irreversible inhibition, again displaying the necessity for an 
enamide moiety for covalent bonding to the protein.  While these analogs did not 
improve the anti-cancer properties of the natural product, the data suggests that 
covalent adduct formation is not necessary for successful V-ATPase inhibition by the 
benzolactone enamides. 
 Other analog studies probed the macrolactone core of salicylihalamide A.  The 
absolute stereochemistry of the molecule is important.  The unnatural enantiomer 
(entry 2, Table 1), (+)-salicylihalamide,80 displayed greatly attenuated V-ATPase 
inhibitory activity (270 nM) and was ineffective at inhibiting the growth of SK-MEL-
28 melanoma cancer cells at 20 µM.81 Eliminating the hydrogen donating ability of 
either the phenol (entry 1, Table 2) or the secondary alcohol (entry 2) dramatically 
reduced the biological properties of the molecule.  Smith and coworkers synthesized a 
modified macrolactone analog of the natural product, removing the alcohol and 
methyl groups (entry 4).82 This had a moderate effect on the GI50 values, reducing the 
potency of the molecules against various cancer lines 10-fold compared to 
salicylihalamide A (entry 6).  Reducing the C9-C10 macrolactone olefin (entry 5), 
allowing for more flexibility in the macrolactone, did not perturb the bioactivity of 
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the analog compared to the unsaturated analog (entry 4).  Following this work, the De 
Brabander group synthesized a series of macrolactone ether analogs83 lacking the 
methyl (entry 7) and hydroxyl (entry 8) groups appended to the core of 
salicylihalamide A.  The benzoate compound lacking the phenol moiety (entry 8) was 
inactive in various biological assays, highlighting the necessity for hydrogen bonding 
of the phenol for bioactivity.  The size requirement for the macrolactone is 
highlighted in entry 9.  Against different cancer cell lines from the NCI 60-cell assay, 
this truncated analog was about 1000-fold less active than the parent natural 
product.84 A fluorinated analog of salicylihalamide A (entry 10) has also been made 
in an attempt to use 19F NMR to elucidate the binding mode of the benzolactone 
enamides.85 With an IC50 of 2 nM, this molecule retained the potent anti-V-ATPase 
activity of the parent molecule.  Further studies with this molecule have not been 
published. 
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 The six known lobatamide molecules are structurally different in only three 
positions as shown in Figure 1.10 It is unknown how the C30 hydroxyl group, the 
C24-C25 olefin configuration, or the orientation of the methyl oxime ether 
differentiates the biological activity between this series of natural products as no 
bioactivity data has been reported for these isolated molecules.  To date, only 
lobatamide C (7) has been targeted for SAR development.86 The Porco group focused 
mainly on open chain analogs of the diester macrocycle 7 (Table 3).  They showed 
that open chain analogs lacking substitution at C7, such as entry 2, had no V-ATPase 
inhibitory properties at the concentrations tested.  However, substitution at this 
carbon with a methyl group (entry 3), iodine (entry 4) or prenyl group (entry 5) 
restored biological activity.87 In general, the IC50 values decrease with increasing 
bulkiness at C20.  The researchers attributed these results to the removal of the ester 
carbonyl from planarity with the benzene ring with the larger C20 substituents.  The 
crystal structure of the bromophenyl acetate of lobatamide C helps support this 
hypothesis.  In the crystal structure, the ester group lays 52° out of planarity with the 
aromatic ring.86 How this deviation from planarity moderates interaction with V-
ATPase is unknown.  Similar to the salicylihalamide analog exploration, reducing the 
ring size eliminated V-ATPase inhibitory properties (entry 6), while removing the 
substitution on the macrolactone core dramatically reduced its biological properties 
(entry 7).  The Porco group has also developed photoaffinity lobatamide molecules 
based upon their prenyl-substituted open chain analogs with the goal of identifying 
the protein binding site of the substrate.88 A benzophenone-substituted89 analog 29 
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retained some anti-V-ATPase activity with an IC50 of 100 nM (Figure 6). Further 
biological results employing these potentially useful probes have not been published. 
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Figure 6. Lobatamide benzophenone photoaffinity compound 2988 
 
 The crystal structure of apicularen A furthered the understanding of the 
geometrical conformation of the benzolactone enamides.  In the crystal structure of 
11, the ester carbonyl of apicularen A displayed a similar deviation from planarity as 
the lobatamide analog.14 The effect was more pronounced in apicularen A, as an 80° 
dihedral angle was observed between the ester carbonyl and the benzene ring.   
 Analog studies on apicularen A, similar to other benzolactone enamide SAR 
development campaigns, focused on the importance of the enamide side chain (Table 
4).90-92 Inverting the stereochemistry of either an olefin in the hexadienyl side chain 
(entry 2) or in the enamide olefin (entry 3) resulted in a 10- or 100-fold loss of 
potency, respectively.  As seen with salicylihalamide A analogs, substitution of the 
hexadienyl side chain with a bulkier phenyl group was tolerated provided that a 
geometrically slender group (here a trans olefin) separated the benzene ring from the 
amide (entries 4 and 5).  Methylation of the amide nitrogen dramatically decreased 
activity (entry 6), implicating the amide N-H in hydrogen bonding in the active site.  
Interestingly, substitution of the hexadienyl side chain found on the salicylihalamides 














oximidines greatly reduced the activity of the analog (entry 7).  Modification of the 
hydroxyl group on the tetrahydropyran (entries 8 and 9) had only a marginal effect on 
the biological activity.  However, inversion of this hydroxyl stereocenter resulted in a 
75-fold decrease in activity (not shown).90 Opening of the pyran ring (entry 10) 
generates a molecule similar in structure to salicylihalamide A.  However, this analog 
has greatly attenuated cytotoxic activity compared to the parent molecule, 




Table 4. Apicularen A analogs and biological activity  
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(*Compounds from reference 90 evaluated in SK-Mel-5 cells; reference 91 
    compounds evaluated in L929, Y1, KB-3-1, KB-VI cells; reference 92 
    compounds in 1A9 cells)
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 Cruentarens A and B (30 and 31, Figure 7), isolated in 2006, are structurally 
similar to the benzolactone enamides.93,94 Cruentaren A, containing a 12-membered 
macrolactone, is one of the most cytotoxic molecules isolated from myxobacteria, 
displaying an IC50 of 1.2 ng/mL (2 nM) against murine L929 fibroblast cells. As seen 
with salicylihalamide analogs, the truncated lactone version cruentaren B displayed 
dramatically decreased biological activity.94 Surprisingly, these molecules were found 
to inhibit F-ATPases, not V-ATPases as their structure suggests.95 Although F-
ATPases and V-ATPases are structurally similar, possessing lumen-exposed F1 and 
V1 domains and membrane-bound F0 and V0 domains, respectively, cruentaren A 
targets the F1 complex.  The benzolactone enamides target the V0 complex.77 
Figure 7. Cruentaren A and B 
  
 Four structural disparities could explain why these molecules interact with 
different cellular targets.  The amide side chain of cruentaren A is bulkier than the 
benzolactone enamide side chains, substituted with a methyl group at C24 and a 
hydroxyl group at C25.  There are three more carbons separating the amide from the 



















an allylic amide side chain, prohibiting covalent bonding to the F-ATPase enzyme 
through the N-acyl iminium ion chemistry hypothesized for the benzolactone 
enamides.  A crystal structure of cruentaren A supplied the final point of discrepancy 
between the molecules.  Crystal structures of apicularen A and the lobatamide analog 
demonstrated a non-planar relationship between the ester carbonyl bond and the 
phenyl ring.  However, the crystal structure of cruentaren A identified a hydrogen 
bond between the phenol hydrogen and the ester carbonyl oxygen, forming a six-
membered ring.  This intramolecular hydrogen bond generated co-planarity of the 
ester carbonyl and benzene ring.   
 Recent analog synthesis by the Maier laboratories has allowed insight into the 
SAR for the cruentaren molecule 30.96 Methylation of the phenol dramatically 
reduced the inhibitory properties against L929 murine fibroblast cells (Table 5, entry 
2).  Similar to the benzoylated salicylihalamide derivative (Table 2, entry 1), this 
change reduced the cytotoxicity 400-fold.  However, this molecule retained the F-
ATPase inhibitory properties of the parent molecule, displaying 42% inhibition at 0.1 
µM compared to 78% for cruentaren A at the same concentration.  This result implies 
that the side chain may be the biggest structural contributor for potent F-ATPase 
inhibtion.  Modification of the amide side chain to substituents demonstrated to retain 
biological activity for apicularen A (styrenyl, entry 3) or salicylihalamide A (pentyl, 
entry 4) drastically reduced the cytotoxicity of the analogs, displaying the necessity of 
hydrogen bonding in the side chain for bioactivity.  The group also investigated 
replacement of the allylic amide with the enamide functionality seen in the 
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benzolactone enamides.  These molecules (entries 5 and 6) displayed only 
micromolar cytotoxicity values.  Further, these enamide analogs did not display any 
V-ATPase inhibitory properties.  Based on the available data, it is unclear what 
contributes to the lack of activity of these enamide molecules. 
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 The oximidines, unlike their benzolactone enamide counterparts, have not 
been the subject of rigorous SAR investigation.  Oximidines II (14) and III (15) are 
generally twice as active as oximidine I (13) in various mutated rat 3Y1 cell lines 
(Table 6).15,17 The Porco group investigated the consequence of inverting the 
stereochemistry of both the enamide olefin and the epoxide on the V-ATPase 
inhibitory properties of oximidine III.97 Inverting the epoxide from α-oriented to β-
oriented had a minimal effect on the anti-V-ATPase properties (15 vs. 33 and 32 vs. 
34).  However, altering the stereochemistry of the enamide olefin from the native E-
configuration to the Z-configuration caused a 15- to 30-fold decrease in the inhibitory 
property of the molecule (15 vs. 32 and 33 vs. 34).  These results, coupled with 
Nicolaou’s studies of apicularen A (entry 3, Table 4)92 hint that the enamide olefin 



































































































































































































































































































































 Seeing an opportunity to expand the understanding of the SAR for the 
oximidines, we sought to develop an expedient route for their syntheses.  We decided 
to target oximidine II due to the potential chemical instability of the epoxide moieties 
in oximidines I and III.  Similar to previous SAR campaigns targeting the 
benzolactone enamides, we directed our attention at the enamide moiety.  However, 
unlike previous campaigns, our goal was to not only develop more potent analogs, but 
also to develop more metabolically stable analogs.  The acid-sensitive enamide 
moiety could be hydrolyzed in vivo to the corresponding aldehyde (Figure 8).  
Therefore, we chose to target an allylic amide homolog of oximidine II, inspired by 
the cruentaren molecule 30.  Following a successful synthesis of this analog, we 
planned to test oximidine II and the analog in various biological assays.  First, we 
would probe the anti-cancer activity of both compounds by testing against melanoma 
cancer cells.  If the analog displayed potency, we would investigate its mechanism of 
action by testing in both V-ATPase and F-ATPase inhibitory assays.  Pertinent to the 
development of this analog is its metabolic stability, particularly its acid sensitivity.  
Finally, we would examine the stability of both molecules across a pH range relevant 
to in vivo systems. 
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Figure 8. Predicted enamide in vivo hydrolysis and allylic amide stability 
 
1.4 Previous Synthetic Studies of the Oximidines 
 In general, the most challenging step in synthesizing macrocycle natural 
products is the macrocyclization event.  Typically, the loss of entropy from the open-
chain cyclization precursor provides the resistance to macrocyclization.98 An 
important fundamental discovery was the use of high-dilution conditions by Ziegler 
to help overcome the entropic barriers and prevent polymerization of the seco-cycle 
substrates.98-100 Several methodologies have been developed to aid organic chemists 
in forming large ring structures.98,101 Examples include ring-closing metathesis 
(RCM), palladium-mediated reactions (Heck, Suzuki-Miyaura, Stille, Tsuji-Trost 
allylation), Wittig/Horner-Wadsworth-Emmons (HWE)/Julia olefinations and 
macroaldolizations for C-C bond formation; macrolactonization (C-O bond 
formation) via Yamaguchi, Keck or Mitsunobu protocols;102 and macrolactamization 
(C-N bond formation) through the use of peptide coupling reagents.98 
Macrocyclization in the syntheses of the benzolactone enamides have utilitized many 




























 Scheufler and Maier published the first model study directed at the synthesis 
of the macrolactone of the oximidines in 2001.103 Their strategy used C-O bond 
formation to accomplish the macrocyclization.  Exposure of the seco-acid 35 to 
typical Yamaguchi macrolactonization conditions104 gave a 60:40 ratio of desired (36) 
to undesired (37) macrolactone products in 61% combined yield (Scheme 1).  This 
size ratio is not surprising given the thermodynamic and kinetic preference for 12-
membered ring formation vs. 11-membered ring formation.101,105 To perturb this 
competition, the chemists protected the C14 alcohol as its allylic ether, generating 
compound 38.  Exposure of this seco-acid to Yamaguchi conditions generated only a 
34% yield of the macrolactone product 39.  The authors did not detail the cause of the 
low yield.  Interestingly, exposure of the C15 allyl ether compound 40 to Yamaguchi 
conditions generated only 12% of the desired 11-membered ring (41).   
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Scheme 1. Yamaguchi macrocyclization by Scheufler and Maier 
 
 The model system developed by Coleman and Garg was the first to 
incorporate the nine consecutive sp2-hybridized carbon centers of oximidine II, 
exploring how a decrease in flexibility would affect the macrocyclization.106 
Exposure of the alkyne benzoate 42 to the Miura-modified Castro-Stephens 
conditions,107 utilizing a catalytic amount of CuI in the presence of phosphine ligands 
and a stoichiometric amount of base in N,N-dimethylformamide (DMF), gave 37% of 
the enyne product 43 (Scheme 2).  Macrolactone formation utilizing the Castro-
Stephens reaction had been achieved only once prior to this report.108 The related, 
palladium-mediated Sonogashira coupling reaction109 was ineffective at generating 
the desired product.  Addition of a Z-olefin to the alkyne chain (compound 44) had a 






















































molecule (45) was chemo- and stereoselectively reduced under Boland reduction 
conditions180 to give the macrocycle with the desired E,Z,Z-triene stereochemistry of 
oximidine II.  Attempts to execute the macrocyclization with the epoxide-containing 
backbone of oximidine I (46) were unsuccessful, potentially due to the lability of the 
propargylic epoxide.  Macrolactonization using the enyne (48) or diene (49) starting 
materials was successful only under Mitsunobu conditions, in contrast to Maier’s 
previous report with Yamaguchi’s protocol, and led to lower yields (26% for 50 and 
23% for 51, respectively) than the copper-mediated methodology.  This report 
demonstrated the feasibility of using metal-mediated processes in the key 
macrocyclization reaction. 
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 In 2003, Taylor and coworkers were able to form the epoxide-containing 
nucleus of oximidine I using HWE technology. 110 Anticipating the conversion of the 
epoxide of oximidine I to the alkene of oximidine II,111 this group targeted the 
epoxide macrolactone (52, Scheme 3) in their model study.  However, under a variety 
of basic conditions, high yields of the epoxide macrolactone 52 could not be realized 
from a HWE reaction of the phosponate seco-cycle (53).  The olefination cyclization 
was only successful when potassium bases, such as KHMDS or KOtBu, were used. 
 
Scheme 3. HWE macrocyclization by Harvey, Raw and Taylor 
 
 The total syntheses of the benzolactone enamides have not only been focused 
on macrocyclization strategies, but also the installation of the enamide side chain.  
Due to the potential chemical instability of this crucial functional group, it has 
typically been introduced near the end of a synthetic sequence.  Three main strategies 
have prevailed for enamide installation (Figure 9): nucleophilic trapping of an 
isocyanate resulting from a Curtius rearrangement (method A),80-82,90 Lewis acid-
mediated addition of an amide to an aldehyde followed by base-mediated elimination 
of the resultant hemi-aminal (method B),91,112,113 or copper-mediated coupling of an 














have proven applicable towards the synthesis of the oxime ether-containing side 
chains of the oximidines and lobatamides (method A,116,117 method B,91             
method C).86,87,97,118 
Figure 9. Methods of enamide side chain installation 
 
 Porco and Wang completed the first total synthesis of oximidine II in 2003.118 
They disconnected the molecule into three fragments: an amide (54), an aromatic 
Benzolactone
O


















Method A: Curtius rearrangement


















salicylate (55), and an aliphatic alcohol (56) (Figure 10).  Following their previous 
reports of enamide installation using copper thiophene carboxylate (CuTC, 57)119 as 
the catalyst for amide-vinyl iodide coupling,120 they planned to couple amide 54 and 
triene macrocycle 58 at the end of the synthesis.  The macrocycle would be formed 
using a RCM reaction of seco-cycle 59.  A base-mediated transesterification 
reaction121 between salicylate fragment 55 and aliphatic fragment 56 would generate 
the RCM substrate.   
Figure 10. Oximidine II retrosynthesis by Porco and Shen 
 
 Their asymmetric synthesis began with a Brown allylation reaction122 between 
aldehyde 60 and allyl methoxymethyl ether 61, generating the chiral product 62 in 
































aliphatic fragment 56, ready for the transesterification reaction.  Starting with the 
known aryl triflate 63,123 a Stille coupling formed the dienyl acetonide 55.  
Generation of the sodium alkoxide of 56 using sodium bis(trimethylsilyl)amide 
(NaHMDS) followed by addition of the acetonide generated a sodium phenolate that 
was silylated in situ, yielding seco-cycle 59.  The corresponding phenol compound 
(64) was also accessible by quenching the transesterification with water (not shown).   
 






































 Initial RCM studies employing Grubbs’ 1st generation catalyst led to complex 
mixtures of desired and oligomeric products.  Grubbs’ 2nd generation catalyst (65) 
was more discriminating.  Exposure of the TBS-protected compound 59 led to a 48% 
yield of the desired triene macrocycle following one recycle (Scheme 5).  However, 
the phenol compound 64 generated no monomeric macrocycle under similar RCM 
conditions – only oligimeric products resulted from the reaction.  Using Monte Carlo 
calculations on a model compound (not shown), the researchers demonstrated the 
importance of ester carbonyl-phenyl ring non-planarity for success in the RCM 
reaction.  The large TBS group forces this non-planarity and subsequently forces the 
two reactive dienes into close proximity for a favorable RCM macrocyclization.  This 
successful RCM reaction led to the E,Z,Z-triene stereochemistry of oximidine II.  For 
the phenol substrate, the carbonyl and aromatic ring are nearly planar allowing for a 
different orientation of the dienes relative to each other.  This orientation potentially 
leads to the formation of a hypothetically unstable E,E,Z-triene macrocycle that 
eventually oligimerizes.  Similar phenol protecting group effects have been 
demonstrated during syntheses of salicylihalamide A that utilize a RCM 
macrocyclization approach.114,124,125 This RCM strategy also proved useful in Porco’s 
synthesis of oximidine III.97 In the macrocyclization leading to the core structure of 
oximidine III, the allylic epoxide proved stable to the reaction conditions. 
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 Scheme 5. RCM macrocyclization by Porco and Shen 
 
 To prepare the substrate for installation of the enamide, the primary 4-
methoxybenzyl ether was cleaved and the resultant alcohol was oxidized with PDC to 
the aldehyde.  Stereoselective iodo-olefination under Stork-Zhao conditions,126 
employing the light sensitive iodomethyl(triphenyl)phosphonium iodide salt 
(IH2CPPh3I),127 generated the Z-vinyl iodide macrolactone 66.  Following protecting 
group interconversion, the macrolactone 67 was prepped for formation of the 
enamide.  Employing CuTC (57) as the copper source, N,N-dimethylethylene-diamine 
as the ligand and K2CO3 as the base in deoxygenated N,N-dimethylacetamide 
(DMA),120 the enamide was installed.  Removal of the silyl protecting groups with a 
































Scheme 6. Completion of oximidine II by Porco and Shen 
 
 Following the model system developed by Coleman and Garg, the Georg 
group developed a synthesis employing the Castro-Stephens reaction as the 
macrocyclization method.128 The retrosynthesis, displayed in Figure 11, shows a 
similar disconnection strategy compared to the Porco total synthesis.  The enamide 
bond would be established using Porco’s vinyl iodide-amide bond formation 
methodology.  The Castro-Stephens macrocyclization reaction would join C9 and 
C10 of compound 69, followed by a cis-selective reduction of the alkyne to the 
1) DDQ
2) PDC, 4Å mol. sieves
3) IH2CPPh3I, 
NaHMDS, HMPA
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corresponding alkene 68 to construct the E,Z,Z-triene stereochemistry of oximidine II.  
The final major disconnection in this synthesis is at the ester bond, joining together 
salicylate fragment 70 and enyne fragment 71 via an esterification reaction. 
Figure 11. Oximidine II retrosynthesis by Georg group 
 
 The synthesis of the aryl salicylate fragment 70 was accomplished in five 
steps (Scheme 7), generating the trisubstituted aromatic ring via a Diels-Alder 
cycloaddition and the requisite E-vinyl iodide via a Takai olefination.129 Using a 
chiral-pool strategy, the synthesis of the enyne aliphatic fragment began with L-
xylose (75).  In four steps,130 the sugar was transformed into the 2-deoxysugar 76.  
Protecting group interconversion transformed the acetonide 76 into primary alcohol 
compound 77 in five total steps.  Oxidation of the primary alcohol to the 








































dibromohomologation and stereoselective debromination yielded the Z-bromo olefin 
78 in 71% yield over the three steps.  Cleavage of the pivolate under reductive 
conditions, Sonogashira coupling with TMS-acetylene and removal of the alkyne 
protecting group readied the aliphatic fragment (71) for esterification with the 
aromatic fragment 70.  This esterification step proved difficult.  Under Yamaguchi 
conditions,104 the esterification reaction proceeded to give seco-cycle 69 in only 38% 
yield.  The low yield realized in this reaction could be attributed to both steric (di-
ortho-substituted acid substrate) and electronic (electron rich acid due to ortho-
methoxy group) issues with the acid 70. 
 








































































 Rigorous investigation of the crude reaction mixture following exposure of the 
seco-cycle 69 to the Castro-Stephens reaction conditions, as described by Coleman 
and Garg, revealed two unexpected products (Scheme 8).  In general, the Castro-
Stephens coupling is stereospecific, generating products that retain the double bond 
geometry of the starting material.133,134 However, in this case, the C8-C9 double bond 
isomerized during the reaction, generating the Z-dienyne product 79 in 31% yield.  A 
coupling constant of 3J = 12 Hz for the C8-C9 protons in the 1H NMR suggested a Z-
olefin geometry.  A strong NOE between the C8 and C9 protons further supported 
this hypothesis.  In Coleman’s model study, the C8-C9 proton coupling constants 
were 16 Hz, values consistent with an E-configured olefin.  Using Ramsey’s non-
relativistic approach135 and the B3LYP/6-311G(d,p) basis sets,136 computer 
calculations of the C8-C9 proton coupling constants were in agreement with the 
observed, experimental results.  To investigate why double bond inversion occurred, 
molecular mechanics and quantum chemical relative energies were calculated.  Table 
7 displays the results from these calculations using three different calculation 
methods: MMFF, DFT, MP2.  When the alkyne is present within the macrocycle, the 
C8-C9 Z-olefin (80) is thermodynamically favored versus the C8-C9 E-olefin (81) by 
11-16 kcal/mol.  However, upon stereoselective reduction of the macrocycle alkyne 
to the corresponding C10-C11 Z-alkene (81), this thermodynamic preference is 
reversed and the C8-C9 E-olefin geometry (46) is favored versus the C8-C9 Z-olefin 
81.  Using the results from the MMFF calculations, the Z-dienyne Castro-Stephens 
product 79 was shown to be favored by 15.3 kcal/mol versus the corresponding E-
 72 
olefin, again supporting the experimental outcome.  Considering the known 
stereospecificity of the Castro-Stephens reaction, the C8-C9 inversion most likely 
occurred after ring closure. 









































 The second unexpected product isolated from the crude mixture was the 
partially reduced triene macrocycle 68, albeit in a small, 3% yield (Scheme 8).  The 
reductant source was unclear given the reaction conditions – one equivalent of seco-
cycle 69, 0.10 equivalents CuI, 0.20 equivalents PPh3, 1.75 equivalents K2CO3 in 
0.005 M anhydrous DMF heated at 110 °C for 26 h – and was not investigated 
further.  The combined yield of the two functionalized products 68 and 79 (34%) was 
similar to that of Coleman and Garg’s model system (35%).   
 
Scheme 8. Castro-Stephens macrocyclization by Haack and Georg 
 
 An inherent advantage in utilizing a Pd-mediated macrocyclization in the 
synthesis of oximidine II is that each of the three olefin geometries of the triene 
would be established prior to cyclization.  This prefunctionalization would allow for 
stereospecific macrocycle formation with the triene in the correct geometry of 
oximidine II.  Pd-mediated couplings have demonstrated success when used as the 
macrocyclization event in other benzolactone enamide syntheses.137,138 Utilizing the 
























Miyuara coupling championed in his labs,139 Gary Molander and Florian Dehmel 
completed a formal total synthesis of oximidine II.140 
 Their synthetic strategy targeted a late stage intermediate of Porco’s total 
synthesis of oximidine II and specifically focused on the key macrocyclization event.  
Thus, they envisioned that intermediate 82 could be advanced to a total synthesis of 
oximidine II following Porco’s established methods (Figure 12).  Protecting group 
manipulations following macrocyclization via a modified Suzuki-Miyuara coupling 
of triene 83 would yield intermediate 82, constituting a formal total synthesis of the 
natural product.  Although previous macrocyclizations linked C9 and C10, this first 
generation approach attempted to join C7 and C8.  A transesterification reaction 
between dienynol 84 and the readily available salicylate fragment 85 followed by 
installation of the vinyl potassium trifluoroborate would ready the molecule 83 for 
Pd-mediated macrocyclization.  The chiral dienynol is available following a 




Figure 12. Oximidine II retrosynthesis by Molander and Dehmel 
 
 Beginning with cis-1,2-dichloroethylene (88), double Sonogashira coupling 
with silylated acetylenes followed by chemoselective hydrolysis of the TMS-
protected alkyne afforded ene-diyne 89 (Scheme 9).  Alkynylmagnesium or 
alkynyllithium reagents of 89 added to the chiral aldehyde 87141 failed to deliver 
acccepTable diastereoselectivities of the desired product 90.  However, application of 
Carreira’s Zn-mediated conditions, employing the chiral ligand (+)-N-
methylephedrine (NME),142 gave excellent diastereoselectivity (98:2 diastereomeric 
ratio (dr)) for the alkyne addition.  Protection of the secondary alcohol (90), regio- 
and chemoselective reduction of the doubly-alkylated alkyne under Lindlar 
conditions, and regioselective reductive opening of the acetal directed by the 
methoxymethyl (MOM) protecting group delivered the alcohol 91, ready for the 














































one step from the known phenol143) occurred following literature precedent.118 In 
three steps, the molecule 92 was prepared for selective hydroboration.  Despite their 
experimentation, the alkynyl molecule 92 was either unreactive towards various 
hydroborating reagents or decomposed when attempting to oxidize the hydroborated 
product to the corresponding boronic acid (93).   
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Scheme 9. First generation synthesis by Molander and Dehmel 
 
 A new retrosynthesis was then developed, avoiding the obstacles of 
hydroborating the polyene-yne system 77 (Figure 13).  Ring closure to form the C9-
C10 olefin linkage was then explored.  This strategy required only slight modification 
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organotrifluoroborate-acetonide 95 with the secondary alcohol 96 would afford the 
precursor (97) for the Suzuki-Miyuara coupling.  Using the Carreira protocol,142 the 
diol chirality would again be established through the diastereoselective addition of the 
alkyne 98 to the benzylidene acetal aldehyde 87.141   
Figure 13. Second-generation retrosynthesis by Molander and Dehmel 
 
 In four steps, the known acetonide triflate 63123 was converted to the requisite 
transesterification partner 95 (Scheme 10).  The synthesis of the aliphatic fragment 96 
began with the Zn-mediated addition of propargyl acetate (98) to the chiral aldehyde 
87.  This reaction proceeded with slightly diminished diastereoselectivity compared 




































straightforward and high yielding steps, the secondary alcohol 96 was prepped for the 
ensuing transesterification. 
 
Scheme 10. Synthesis of aromatic and aliphatic fragments by Molander and Dehmel 
 
 The synthesis again ran into a roadblock when attempting the 
transesterification reaction (Scheme 11).  The aryl acetonide 95 was added to the 
sodium alkoxide of 96, presumably forming intermediate 100.  This intermediate 
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unexpected exo-methylene product (101) formed.  Presumably, this reaction occurs 
following the base-induced elimination of HBr from the Z-vinyl bromide, revealing 
an enyne subunit that can undergo a carbometallation event.  Following protonation 
of the resultant palladium intermediate 102, the observed 11-membered macrocycle 
101 is formed.  Alternatively, the group attempted to perform a macrolactonization 
following a successful Suzuki-Miyuara coupling.  This route was also ineffective, 
presumably due to the developing ring strain when the sodium alkoxide attempted to 
add to the acetonide (103).   
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 Assuming a later installation of the organotrifluoroborate would allow for 
successful macrocyclization, the group again altered their synthetic course (Scheme 
12).  Under basic conditions, the alkynyl-acetonide 105 was coupled to the alcohol 
96.  A four-step protocol installed the requisite functionalized olefins, ready for Pd-
catalyzed coupling to form the C9-C10 bond.  This Suzuki-Miyuara coupling 
proceeded in a 42% yield, with the moderate yield realized again highlighting the 
difficulties associated with forming the strained triene core of oximidine II.  The 
reaction was successful when substrate 106 was heated to reflux in a THF/H2O 
mixture under high dilutions (1 mM) for 20 h in the presence of 10 mol % Pd(PPh3)4 
and five equivalents of  Cs2CO3.  Alteration of the concentration, Pd species, or 
solvent mixture led to reduced product formation.  During the course of the 
macrocyclization, the TBS-phenolic protecting group was removed.  To complete the 
formal total synthesis, this phenol compound 104 was re-silylated and the primary 
benzyl ether was removed by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to 
deliver the target compound 82.   
 83 
 
Scheme 12. Completion of the formal total synthesis of oximidine II by Molander 
and Dehmel 
 
1.5 Total Synthesis of Oximidine II 
 Our previous attempt at the total synthesis of oximidine II,128 employing the 
Castro-Stephens macrocyclization, left behind opportunities for further investigation.  
We embarked on a second-generation approach with the following goals in mind: 
1) Develop efficient routes to the aliphatic and aromatic fragments 
2) Improve the Castro-Stephens macrocyclization yield while investigating the 
reductive pathway leading to the in situ formation of the triene macrocycle 
















































4) Develop an efficient synthesis of an allylic amide homolog of oximidine II, 
inspired by cruentaren A (30), to probe the importance of the enamide bond 
on the bioactivity of oximidine II 
 The retrosynthesis of our second-generation synthesis targeting oximidine II is 
displayed in Figure 14.  The enamide bond would be installed using the Liebeskind 
catalyst, CuTC (57),119 following Porco’s protocol,118 joining the oxime amide 
fragment 54 and the bis-TBS macrocycle 67.  The oxime amide 54 could be 
synthesized in two steps from commercially available maleimide (107), reducing the 
number of steps required by Porco’s synthesis of the fragment.86 The Molander and 
Dehmel synthesis of the triene macrocycle140 demonstrated the necessity to join C9 
and C10 during the macrocyclization.  In their synthesis, attempting to link C7 and 
C8 in the ring-closure event was unsuccessful likely due to steric hindrance of the 
ortho ester group or to an overbearing amount of developing ring strain during the 
course of the reaction.  With this knowledge in hand, we envisioned following our 
previous work and joining C9 and C10 with a Castro-Stephens coupling followed by 
a cis-selective reduction to create the triene macrolactone core of oximidine II.  
Following literature precedence, a transesterification reaction between aromatic 
fragment 108 and the aliphatic enynol molecule 109 would form the ester bond. 
Elaboration of the known aryl triflate 63123 via a Heck coupling would enable ready 
access to the aromatic acetonide compound 108.  A stereoselective Peterson 
olefination between 1,3-bis-TIPS-propyne (110)144 and the enantioenriched aldehyde 
111 was envisioned to generate the enyne moiety of the aliphatic fragment 109.  
 85 
Protecting group and oxidation state manipulations of the known diol ester 112 (or 
other ester oxidation states of 112) would properly functionalize the aldehyde (111) 
prior to installation of the enyne.  Paramount to our synthetic strategy is the 
orthogonal protection of a tetrol intermediate, allowing selective exposure of each 
hydroxyl group at various points during the synthesis.  Further complicating the 
synthesis is the requirement of a MOM protecting group, or other small protecting 
group, on the alcohol at C14 to give high yields in the transesterification reaction.138 
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Figure 14. Our second-generation oximidine II retrosynthesis 
 
 The synthesis of the aryl fragment (108) began with acetonide formation of 
commercially available 2,6-dihydroxybenzoic acid (113) (Scheme 13).143 Triflation 
proceeded as previously described by Fürstner,123 readying the molecule (63) for 
Heck coupling with vinyl(trimethyl)silane.  Initially, Jeffery conditions,145 employing 
nBu4NOAc to act both as a phase-transfer reagent and to generate a more reactive 
palladium species, were explored to catalyze this coupling. These conditions led to 





























































NMR and mass spectroscopy) in addition to the desired product 115.  Further catalyst 
system refinement led to use of 10 mol % Pd(OAc)2, three equivalents of 
triethylamine (Et3N) in DMSO at room temperature to provide the desired product 
115.  A small amount (~5% by NMR) of desilylation occurred during this reaction, 
forming terminal alkene 117.  Ag salts are known to prevent this side reaction in 
Heck couplings with vinyl(trimethyl)silane,146 but were unsuccessful in preventing 
the deleterious side reaction in this case.  Iododesilylation following Kishi’s 
protocol147 led to formation of the vinyl iodide fragment 108 in 91% yield. 
 
































 The synthesis of the aliphatic piece began with protection of commercially 
available 1,3-propanediol (118) as its monosilyl ether (119).148 The primary alcohol 
119 was then oxidated to the corresponding aldehyde (120) by Dess-Martin 
periodinane (121a),131,132 homologated with a HWE reaction (121) and reduced with 
diisobutylaluminum hydride (DIBAL) to the E-allylic alcohol (122) following 
modification of the procedures of Baltas and coworkers (Scheme 14).149 A Sharpless 
asymmetric dihydroxylation (SAD) of the allylic alcohol with AD mix-α in the 
presence of sulfonamide (MeSO2NH2) gave an excellent yield of the desired 1,2,3-
triol 123.  Based upon studies by Sharpless150 and Kumar151 on asymmetric 
dihydroxylation reactions of long chain allylic alcohols similar to our substrate 122, 
we anticipated formation of the 2S,3S enantiomer 123 as drawn in Figure 15.  The 
mnemonic developed by Sharpless152 predicts the stereochemical outcome of this 
asymmetric reaction (Figure 15).  For our substrate, the hydroxymethylene group 
occupies the RL position and the silyloxyethylene group occupies the RM position, 
leading to the predicted diol stereochemistry.  The presence of MeSO2NH2 speeds up 
the catalytic turnover of the reaction by cleaving osmate esters formed during the 
catalytic cycle of the reaction.152   
 89 
Figure 15. Sharpless’s mnemonic device for asymmetric induction 
 
 The next challenge to conquer in the synthesis of the aliphatic piece was the 
selective formation of 1,3-benzylidene acetal 124 from the 1,2,3-triol 123.  Standard 
conditions for (p-methoxy)benzylidene acetal formation (p-methoxybenzaldehyde 
dimethyl acetal (PMB-dimethylacetal) with an acid catalyst)153 gave near quantitative 
conversion of the starting material to a mixture of products, presumably 1,2-acetal 
125, 2,3-acetal 126, and 1,3-acetal 124, as inferred from the multitude of spots seen 
on TLC.  A 1H NMR spectra of the crude reaction revealed at least four major peaks 
with chemical shifts between 5 and 6 parts per million (ppm) corresponding to both 
five- and six-membered acetal rings.  The relative stereochemistry of the major 
isomer generated by this reaction was confirmed by X-ray crystallography (Figure 
16).   Attempts to improve the ratio of 1,3-dioxane acetal 124 formation through 
variation of the acid, reaction time, temperature, solvent, or conversion to the 
corresponding tri-TMS variant following Noyori’s protocol154,155 led to diminished 
conversion of starting material or to complete decomposition of the starting material.  























ambient conditions.  Isomerization of the mixture occurred with benchtop storage 
after four to eight weeks, leading to a ratio of acetals similar to that of the crude 
reaction mixture as determined by 1H NMR.  The isomerized mixture could then be 
purified by column chromatography and subjected to the next synthetic step.  This 
recycling procedure could be repeated for up to six months following the initial acetal 
formation, after which time significant decomposition of the material occurred. 
Figure 16. Crystal structure of desired acetal 124 
 
 Immediately following chromatographic separation of the desired 1,3-
benzylidene acetal 124 from the product mixture, the material was subjected to MOM 
ether formation (127).  During this MOM protection step, some isomerization of the 
 91 
1,3-benzylidene acetal occurred, contributing to the 82% yield for this step.  This 
undesired regioisomeric material was easily removed by column chromatography.  
Regioselective reductive ring opening of acetal 127 with DIBAL generated the 
primary alcohol compound 128.156 While this route generated sufficient quantities to 
initially explore the formation of the enyne in subsequent steps, the prohibitive nature 
of the acetal protection step prompted us to revise our strategy for the synthesis of 





Scheme 14. Selective acetalization route towards the synthesis of alcohol 128 
 
 We were able to evade the troublesome acetal protection step by changing the 
reaction sequence (Scheme 15).  Using sodium hydride (NaH) as the base in the 
HWE reaction of aldehyde 120 gave high yields (<80%) on one to two mmol scale 







































39% of desired acetal
























mmol scale).   Following a recent report by Claridge et al.,157 methyl magnesium 
bromide (MeMgBr) was employed as the base to give the desired homologated ester 
121 in reproducible yields of 65% and high stereoselectivity (>40:1 E:Z).  A SAD 
occurred without event to generate the known ester diol 112 in high yields with an 
enantiomeric ratio (er) of 89:11 (reported er of 95:5).158 Not completely discouraged 
by our previous application of a benzylidene acetal protecting group, the diol was 
protected as its (p-methoxy)benzylidene acetal 129.  This acetal, similar to its 
predecessor 124, was not stable at room temperature. We briefly explored conditions 
to reductively open the acetal, regioselectively generating the C15 (oximidine II 
numbering) PMB-ether, prior to ester reduction.  This would then allow selective 
protection of the C14 alcohol as the MOM-ether.  Boranes, often in conjunction with 
Lewis acids, are known to perform reductive ring opening transformations.159 Also, 
boranes are generally unreactive towards esters at low temperatures.  However, at low 
temperatures BH3•SMe2 or BH3•THF did not effect the desired ring opening 
transformation.  Increasing the temperature or adding Lewis acids, such as AlCl3 or 
BF3•OEt2,160,161 led to decomposition of the starting material mostly through the 
deprotection of the acetal.  Other conditions employing hydrosilanes and AlCl3162 or 
sodium cyanoborohydride and hydrochloric acid163 were not explored because of the 
acid-sensitivity of the PMB-acetal 129.  A one-pot ester reduction/regioselective 
reductive acetal opening with DIBAL generated the diol 130.  While this work was 
ongoing, a similar sequence was developed by Brimble and coworkers.164 
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 Development of a three-step protection strategy was required to distinguish 
the primary and secondary alcohols.  Freshly distilled acetyl chloride (AcCl) and 2,6-
lutidine were necessary to achieve high levels of regioselectivity in the formation of 
secondary alcohol 131.  Use of acetic anhydride or less bulky bases, such as pyridine, 
was generally less selective for the primary alcohol and bis-acetylation was a 
common side reaction.  MOM protection of the secondary alcohol 132 followed by 
methanolysis of the acetate yielded the desired primary alcohol 130.  Oxidation of 
alcohol 128 with Dess-Martin periodinane (121a) followed to generate the aldehyde 
111, ready for installation of the critical enyne moiety. 
 




















































 The demonstrated stereoselectivity of Peterson olefinations convinced us to 
explore the methodology for creation of the Z-enyne (Table 8).144,165-168 Treatment of 
a 1,3-bis-silyl-propyne (110) with an alkyllithium species, such as n-butyllithium 
(nBuLi), converts the starting material to the corresponding lithiated species, a 
nucleophilic propargyl anion.   This lithiated species can be transmetalated with 
titanium169,170 or magnesium,171 leading to higher Z:E enyne ratios in certain instances 
upon treatment with an aldehyde or ketone.  Corey144 and Yamamoto171 have 
discussed the importance of bulkier 3-silyl groups on the stereoselectivity of this 
reaction.  In general, bulkier silyl groups such as TIPS or TBDPS at this position give 
higher stereoselectivities (Z:E enyne ratios). 
 Our search for optimal conditions for the synthesis of enyne 133 began with 
the addition of a cooled solution (-78 °C) of 1-lithio-1,3-bis-TIPS-propyne to a 
precooled solution (-78 °C) of the aldehyde (111) (Table 8, entry 1).  The overall 
yield for this reaction was low (35%) and generated a substantial amount (55% by 1H 
NMR) of side product 134 formed by elimination of p-methoxybenzyl alcohol from 
the starting material (confirmed by 1H and 13C NMR and mass spectroscopy).  
Eventually, it was discovered that a slow addition of the anion to the aldehyde at low 
temperatures reduced the production of the elimination product 134.  Even this 
procedural adjustment did not increase the yield or mass balance of the reaction, 
however.  In these initial attempts, 1,3-bis-TIPS-propyne (formed by treatment of 3-
lithio-1-TIPS-propyne with TIPS-OTf)144 was purified by column chromatography.  
Although the 1H NMR spectra of this columned product matched the reported spectra, 
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some impurity remained in the product leading to the diminished yields realized in 
the Peterson reaction.  Distillation of the 1,3-bis-TIPS-propyne following its 
formation led to dramatically increased yields (60-80%) in the Peterson olefination 
(entry 2).  Solvent effects were briefly explored.  Use of diethyl ether (Et2O) instead 
of tetrahydrofuran (THF) led to dramatically decreased reactivity.  In this reaction, 
only 50% of the starting material reacted even after prolonged reaction times at room 
temperature.  Presumably in THF, a solvent-ion pair (THF-Li) is formed and 
increases the nucleophilicity of the propargyl anion.  However, in Et2O, this effect is 
not present and the strength of the carbanion–Li bond hinders addition to the 
aldehyde.  Although the activity in Et2O is diminished, the stereoselectivity is greatly 
enhanced (entry 3).  Addition of hexamethylphosphoramide (HMPA) to the reaction, 
functioning to sequester the lithium cation and create a more reactive carbanion, led 
to almost exclusive formation of the E-enyne by crude 1H NMR (entry 4).  Based 
upon this result, the addition of other cation sequestering reagents, such as N,N,N’,N’-
tetramethylethylenediamine, was not further explored.  Variation of the counter ion 
had mixed results.  The overall yield was similar for each of the reactions and a 
reduced amount of eliminated product was generated when MgBr2•OEt2 (entry 5) or 
Ti(OiPr)4 (entry 6) were added to the reaction mixture.  The Mg salt favored 
formation of the E-enyne, contrary to Yamamoto’s previous report.171 Altering the 
quenching reagent (1N HCl, acetic acid (AcOH), aqueous NH4Cl) had no effect on 
the Z:E ratio (not shown in Table).  The best combination of yield and 
stereoselectivity resulted from a slow addition (1.5-2 h) of one equivalent of the 
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aldehyde to 1.8 equivalents of the anion generated from nBuLi at -78 °C (entry 2).  
Under these conditions, the reaction was complete within 30 min and gave a 5:1 Z:E 
ratio of unseparable enyne stereoisomers. 
Table 8. Optimization of Peterson olefination  
1 None THF 35 (0.8:1) 4:1 
2 None THF 80 (10:1) 5:1 
3 None Et2O 30 (1:2) >20:1 
4 HMPA THF 15 (2:1) 1:20 
5 MgBr2•OEt2 THF 34 (20:1) 1:10 
6 Ti(OiPr)4 THF 40 (10:1) 5:1 
 
 Selective removal of the alkynyl-TIPS protecting group with tetra-n-
butylammonium fluoride (TBAF) at 0 °C allowed for chromatographic separation of 
the previously unseparable Z- and E-enyne stereoisomer products (135, Scheme 16).  
Oxidative cleavage of the PMB ether with DDQ generated the Z-enynol 109 in 97% 












Entry Solvent % Yield (133:134)









group as the corresponding acetonide generates an electrophile that, when treated 
with an alkoxide nucleophile, drives the coupling reaction towards product formation 
due to the increase in entropy gained from the liberation of acetone from the 
acetonide.  The yields for this reaction were high provided that the alcohol 109 was 
dried by azeotroping with toluene or benzene prior to deprotonation with 
NaHMDS.118 To this sodium alkoxide solution was added a solution of the acetonide 
(108), generating a phenolate anion that could be quenched in situ with a variety of 
electrophiles.  For our total synthesis effort, we chose to use a methyl-protecting 
group because we hoped to remove both this aryl methyl ether and the MOM ether in 
one step later in the synthesis.  We initially tried methyl iodide as the phenolate anion 
quenching source but the reaction was slow and often did not go to completion.  
Dimethyl sulfate (Me2SO4) was more expedient and complete in performing the 





Scheme 16. Synthesis of seco-cycle 136 
 
 The biggest challenge of the synthesis was discovering and developing a more 
efficient macrocyclization approach based upon the Castro-Stephens coupling 
reaction.  Our previous studies achieved only a 34% total yield of the ring-closing 
reaction – 15% lower than the standard set by Porco with a RCM reaction.  In 
Molander’s synthesis, he demonstrated that ring-closure via a macrolactonization of 
the pre-formed triene 103 was unsuccessful in contrst to Maier’s previous work 
detailing a successful macrolactonization approach.103 Curious of the effect of 
dienyne incorporation compared to a triene system on this macrolactonization 










































Stephens conditions, generating the dienyne open chain molecule 137 in 42% yield 
(unoptimized) (Scheme 17).  Exposure of this molecule to NaH138 led only to 
decomposition products, consistent with Molander’s experimental results. 
 
Scheme 17. Base-induced transesterification attempt 
 
 We then began investigating modifications to the Castro-Stephens reaction to 
increase the yield of either the dienyne 139 or triene 140 macrocycles (Table 9).  
Under non-catalytic conditions using one equivalent of CuI, the reaction produced an 
18% yield of the dienyne 139 and an 8% yield of the reduced triene 140 (entry 1).  As 
demonstrated previously,128 the C8-C9 olefin inverted to the cis configuration during 
the course of the reaction.   Exposing the seco-cycle 136 to the catalyst conditions 
described by Coleman and used in our first generation synthesis, 26% of the dienyne 
139 was produced (entry 2).  This yield is similar to our previous result (31%) 

























little effect on the cyclization.  The reaction is successful in polar, coordinating 
solvents (entry 2 and 4), but not in non-polar solvents (entry 3).  We then investigated 
the role of the phosphine ligand in the outcome of the reaction.  Use of 2-(2‘,6‘-
dimethoxybiphenyl)dicyclohexylphosphine (S-Phos), a highly reactive Suzuki-
Miyuara catalyst,172 left the starting material untouched (entry 5).  Switching to PtBu3, 
a more bulky trialkylphosphine, generated a higher ratio of dienyne 139 to triene 140 
as seen in the crude 1H NMR, but was poor at converting the starting material to 
product.  A catalyst system developed by Venkataraman and coworkers,173 employing 
a bipyridine (bipy) ligand, gave similar results as the PPh3 system (entry 8).  
Interestingly, the pre-catalyst complex Cu(PPh3)3Br used to form Cu(bipy)PPh3Br 
showed only degradation products in the crude 1H NMR (entry 7).  Although only a 
small amount of starting material reacted by crude 1H NMR analysis, switching the 
base to KOtBu generated only the reduced product (entry 9).  The significance of this 
result will be highlighted by forthcoming studies. 
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Table 9. Castro-Stephens macrocyclization optimization  
1 CuI (1) PPh3 K2CO3 DMF 
139 = 18                        
140 = 8 
2 CuI (0.5) PPh3 K2CO3 DMF 26 
3 CuI (0.5) PPh3 K2CO3 Toluene NR 
4 CuI (0.5) PPh3 K2CO3 DMSO 24 
5 CuI (0.5) S-Phos K2CO3 DMF SM 
6 CuI (0.5) PtBu3 K2CO3 DMF 10:3:1 
7 Cu(PPh3)3Br (0.5)  K2CO3 DMSO Degradation 
8 Cu(bipy)PPh3Br (0.25)  K2CO3 DMF 24 
9 CuI (1) PPh3 KOtBu DMF 10:0:1 
 
 These initial studies suggested that higher-yielding conditions for this 
macrocyclization would not be easily found.  Therefore, we chose to develop a model 


























requisite Z-enyne, forming the bis-silylated product 141 in low yield.  The yield of 
this reaction could not be improved.  As all starting material was consumed during 
the reaction, it is likely that the instability of the alkyl aldehyde 120 contributes to this 
result.  Selective hydrolysis of the silyl ether (142),174 one-pot 
transesterification/phenolate quench (143), and alkynyl-TIPS removal generated the 
seco-cycle 144 ready for optimization studies.   
 
Scheme 18. Synthesis of model system for Castro-Stephens macrocyclization 
investigation 
 
 The results from this macrocyclization optimization study are displayed in 
Table 10.  As previously seen, the solvent plays a critical role in the outcome of the 
reaction.  When run in DMF (entry 1) or DMSO (entry 2), the Castro-Stephens 
coupling generated adequate yields of the dienyne macrocycle 145.  In less 


































(MeCN) (entry 4), or in a non-coordinating solvent (toluene, entry 5) no reaction 
occurred.  Switching to the bipy-supported complex (entry 6) had little effect on the 
yield of the macrocyclization, as did changing the ligand to a dialkyl-aryl phosphine, 
2-(di-tert-butyl)phosphino-2',4',6'-tri-isopropyl-biphenyl (DBPIB) (entry 7).  Addition 
of Et3N to the reaction completely halted activity (entries 8 and 9).   
Sheltering the Castro-Stephens reaction materials from light following a fast 
reaction workup and purification by chromatography allowed for the isolation of both 
the C8-C9 Z- and E-dienyne stereoisomers (145 and 146).  After eight h as a CDCl3 
solution stored at 4 °C, the E-dienyne (146, Figure 17) inverted to the corresponding 
Z-dienyne cycle (145), confirmed by 1H NMR.  These observations prove the 
stereospecificity of the Castro-Stephens reaction of 144. 


















* Performed at 90 °C 
Table 10. Castro-Stephens optimization with model system 144  
1 CuI PPh3 K2CO3 DMF 40 
2 CuI PPh3 K2CO3 DMSO 37 
3* CuI PPh3 K2CO3 NMP 
No Reaction 
(NR) 
4 CuI PPh3 K2CO3 MeCN NR 
5 CuI PPh3 K2CO3 Toluene NR 
6 Cu(bipy)PPh3Br  K2CO3 DMF 29 
7 CuI DBPIB,             iPrOH (2 equiv.) K2CO3 DMF 23 
8 CuI PPh3 Et3N DMF NR 
9 CuI Et3N Et3N DMF NR 
10 Cp2Zr(H)Cl 
Pd(PPh3)2Cl2,    
DIBAL  THF 147, X = H 
11 [CuH(PPh3)]6 
Pd(PPh3)2Cl2,    
DIBAL  Toluene Mixture 
12 [CuH(PPh3)]6   Toluene 148, X = I 
13 [CuH(PPh3)]6   DMF 148, X= I 
 
 With the oximidine system, we were able to isolate small amounts of the 
reduced, triene macrocycle (140) from the Castro-Stephens reaction (Table 9, entry 






















147, X = H
148, X = I
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by the idea of performing a one-pot macrocyclization/alkyne reduction reaction, we 
explored chemistry developed by Negishi.175-177 Treatment of the model system 144 
with Schwartz’s reagent (Cp2Zr(H)Cl) followed by a Pd-Al mixture generated a 
reduced, but un-cyclized product 147 (Table 10, entry 10).  Presumably, this product 
arises from hydrozirconation of the alkyne and a Pd-mediated deiodination.  
Changing the alkyne-reducing reagent to Stryker’s reagent ([CuH(PPh3)]6)178,179 
followed by treatment with the Negishi Pd-Al mixture generated an unidentifiable 
mixture of products by crude 1H NMR analysis (entry 11).  Use of only Stryker’s 
reagent in the catalyst system led only to reduction of the alkyne (148) (entries 12 and 
13). 
 Although we were unable to find conditions to dramatically increase the yield 
of the Castro-Stephens macrocyclization, we proceeded forward with our synthetic 
strategy that required chemo- and stereoselective reduction of the alkyne macrocycle 
145 to the corresponding cis-alkene macrocycle 149.  We also hoped that this 
reduction would also invert the C8-C9 cis-olefin to produce the thermodynamically 
more stable E,Z,Z triene configuration.  Again using the model system as practice, we 
investigated various reduction methods.  Coleman and Garg utilized a Boland 
reduction180 to execute this transformation.  Reduction of our alkyne macrocycle 145 
was inconsistent with these conditions, generating a yield of only of 16% (50% based 
on recovered starting material) (Scheme 19).  We explored other stereoselective 
alkyne-to-Z-alkene reduction methods, such as hydrogenation with the Lindlar 
catalyst, the Schwartz reagent, and samarium iodide-mediated reduction,104 but these 
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were also ineffective.  Low catalyst loading and running the reaction at room 
temperature in the Lindlar system gave no reaction, while increasing the catalyst 
loading and temperature resulted in degradation of the starting material (145).  
Understanding that the best model system is the actual system, the Boland and 
Lindlar reductions were performed on the dienyne macrocycle 139.  In this case, the 
model system proved to be true.  The oximidine macrocycle 139 was reduced by the 
Boland reduction conditions to the desired triene macrocycle 140, giving only 10% 
conversion to the product (Scheme 19).  This result was not repeatable.  Reduction 
attempts with the Lindlar catalyst were also futile.  This apparent roadblock presented 
an opportunity to explore the mechanism leading to the formation of the triene 
macrocycle 140 produced in the Castro-Stephens reaction. 
 























 Two potential reductive pathways for this transformation were investigated 
based upon both literature precedence and experimental observations.  Our initial idea 
was that some oxidation state of copper was propagating the reduction.  We had 
demonstrated the feasibility of Zn dust to reduce the alkyne to the alkene (Scheme 
19), so possibly Cu, although having a lower reduction potential compared to Zn, 
could induce the reduction under the right conditions.  Further, we noticed that the 
triene product was isolated in higher yields when CuI had been pre-activated by 
flame-drying under vacuum prior to utilization in the Castro-Stephens reaction.  This 
pre-activation process left a metallic coating on the flask, indicating the CuI was 
being partially disproportionated into Cu(0) and Cu(II) species.  CuI used directly 
from the vendor generated little or none of the reduction product in most cases.  
Application of CuI purified by precipitation with treatment of KI181 in the Castro-
Stephens reaction produced no reduction product 140.  We reasoned that Cu(0) was 
most likely the reductant source and began investigating the use of this metal.  
Addition of Cu wire or Cu powder to the reaction, with and without various Cu(II) 
salts, generated similar ratios of dienyne product 139 and triene product 140 as 
previously seen with the flame-dried CuI system.  The yields for these reactions were 
also comparable to previous results.  The addition of Zn dust to the Castro-Stephens 
reaction led only to partial degradation of the starting material. 
 An alternative pathway involves copper-hydride (Cu-H) reduction of the 
alkyne to the corresponding Z-alkene.  Cu-H species are well known to reduce 
alkynes to the corresponding cis-alkenes.179 Support for our hypothesis that a Cu-H 
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intermediate was responsible for the alkyne-to-alkene reduction arose from a previous 
result in which KOtBu was employed as the base in the Castro-Stephens reaction.  
Compared to K2CO3, use of this base generated a higher ratio of the triene 
macrocycle 140 to dienyne macrocycle 139 (Table 9).  Mixing KOtBu with Cu(I) 
salts generates Cu(OtBu), a complex used to make the Cu-H hexamer 
([CuH(PPh3)]6).182 In Stryker’s initial report, this Cu-H hexamer was made by mixing 
Cu(OtBu) with PPh3 under an atmosphere of hydrogen (H2).  In our system, DMF, the 
solvent of choice for the Castro-Stephens reaction, could decompose during the 
reaction to generate a hydride equivalent.  Although unprecedented with copper salts, 
DMF is known to act as a hydride source when treated with various metals (Pd,183 
Fe,184 and Rh185).  The triene product 140 was generated only when DMF was used as 
the solvent in the macrocyclization.  Although unclear if DMF could be the hydride 
source in our case, we explored other conditions known to generate the Cu-H species. 
 The first conditions explored emulated those of Stryker’s Cu-H formation 
paper.182 Stirring a DMF solution of CuI, PPh3 and KOtBu under an atmosphere of H2 
at 120 °C for 30 minutes followed by slow addition of a DMF solution of the seco-
cycle 136 generated the desired, triene macrocycle 140 in 31% yield (Table 11, entry 
1).  No dienyne (139) was observed in the 1H NMR spectra of the crude material.  
Further, this crude 1H NMR spectrum displayed a clean reaction product – no 
degradation or side products were seen.  Lowering the reaction temperature (entry 2) 
had a detrimental effect on the outcome of the reaction.  These observations are 
contrary to literature reports that question the thermal stability of Cu-H species.186 
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Seeking an easier reaction setup, the use of commercially available Stryker’s reagent 
was investigated.  Across a range of temperatures and in different solvents (entries 3-
6), use of this reagent to perform the reductive ring-closure generated a complex 
mixture of products by crude 1H NMR analysis.  Other conditions known to generate 
reactive Cu-H species also produced complex 1H NMR spectra (entries 7-9).  
Polymethylhydrosiloxane (PMHS) was investigated specifically due to its wide use in 
various literature preparations of Cu-H complexes.187 Therefore, we were surprised to 
see its ineffectiveness in our system.  Results from the application of the hydrosilane 
in model system reactions gave insight into its ineffectiveness (see below).  Alteration 
of the base (entry 10) also dramatically reduced the yield of triene formation, 
demonstrating the need to generate the Cu(OtBu) species, at least when H2 was used 
as the hydride source.  Formic acid (HCO2H) or formate salts are commonly used in 
transfer hydrogenation reactions with Pd catalysts.  Although unprecedented as the 
hydride source in Cu-H complex formation, addition of formic acid to the reaction 
mixture produced a 50% yield of only the desired triene macrocycle 140 (entry 11).  
No dienyne 139 was seen in the crude 1H NMR spectrum.  Key to success of the 
reductive macrocyclization was stirring the reagents together at 120 °C for 30 min 
prior to slow addition of the enyne seco-cycle 136 over one h.  The yield was further 
increased by increasing the CuI:PPh3 ratio from 1:2 to 1:3188 and using sodium 
formate (HCO2Na) (entry 12).  The 67% yield realized by these conditions is almost 
20% higher than the precedent set by Porco’s RCM macrocyclization approach.  
Simplification of the reaction setup by using commercially available copper (II) 
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formate hydrate (Cu(O2CH)2•H2O) (entry 13) with the addition of PPh3 generated the 
desired triene product by crude 1H NMR analysis.  However, crude 1H NMR analysis 
also displayed a variety of side products and these conditions were not explored 
further.  Another Cu(II) salt, Cu(OAc)2•H2O, was investigated because of its 
demonstrated ability to form Cu-H species.189,190 This salt was also successful in 
catalyzing the reductive ring closure, albeit in a slightly lower yield than CuI (entry 
14).   
 On reactions of less than 50 mg, CuI was reproducibly effective at catalyzing 
the reductive ring closure.  For unknown reasons, on larger scales CuI generated 
mixtures of the triene and dienyne macrocycles (140 and 139, respectively).  
Fortunately, Cu(OAc)2 catalyzed the reductive macrocyclization on all reaction 
scales.  Later investigations revealed that Cu(OAc)2 generates a catalyst with a rapid 
turnover rate.  The reductive macrocyclization was often complete within 15 minutes 
of substrate addition to the Cu(OAc)2 catalyst solution.  Further, the substrate could 
be added over a period of one to two minutes instead an hour as required for the CuI-
catalyzed reaction.  Other Cu(II) salts were not investigated. 
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Table 11. Optimization of reductive macrocyclization  
1 CuI KOtBu PPh3,  H2 (1 atm) 
DMF 120 31 
2 CuI KOtBu PPh3, H2 (1 atm) 
DMF 90 NR 
3 [CuH(PPh3)]6   DMF 90 mixture 
4 [CuH(PPh3)]6   Toluene 90 mixture 
5 [CuH(PPh3)]6   DMF 120 mixture 
6 [CuH(PPh3)]6   DMF 50 mixture 
7 CuCl NaOtBu PPh3,  H2 (1 atm) 
DMF 100 mixture 
8 CuCl NaOtBu PPh3, PMHS DMF 100 mixture 
9 CuCl NaOtBu PPh3, PMHS DMF 110 mixture 
10 CuI K2CO3 
PPh3,  
H2 (1 atm) 
DMF 120 some triene 
11 CuI K2CO3 HCO2H DMF 120 50 
12 CuI K2CO3 HCO2Na DMF 120 67 
13 Cu(O2CH)2  PPh3 DMF 120 triene 
14 Cu(OAc)2 K2CO3 HCO2Na DMF 120 55 
 
 Porco previously demonstrated the effect of the phenol protecting group on 
the yield of the RCM macrocyclization.118 The bulky TBS protecting group allowed 
the RCM reaction to occur, while lack of any phenol protecting group generated none 
of the desired macrocycle (Scheme 5).  We investigated the steric and electronic role 
of the phenol protecting group on the Cu-mediated reductive macrocyclization.  

















generated seco-cycles 150-153 (Table 12).  These substrates each produced the 
phenol triene macrocycle 154 when subjected to the reductive macrocyclization 
conditions.  The cyclization yields for the TBDPS- (entry 1), TBS- (entry 2) or 
hydroxyl (entry 4) seco-cycle reactions were approximately 60%, implying that 
cleavage of the silanes occurred prior to macrocyclization.  The acetate-protected 
compound 152 (entry 3), however, yielded 80% of the phenol triene 154, implying 
that electronics of the cyclization substrate may play an important role in this 
reaction. 
Table 12. Investigation of phenol protecting group on reductive macrocyclization  
1 TBDPSCl (150) 51 62 
2 TBSCl (151) 53 60 
3 AcCl (152) 65 80 
4 H2O (153) 65 57 
 
 A simplified model system was developed to explore other conditions known 
to generate Cu-H species.  Transesterification of the aryl acetonide 108 with 1-hexyn-
1-ol (155) produced the seco-cycle 156 (Scheme 20).  Exposure of the seco-cycle to 

































PPh3 (one equivalent), K2CO3 (1.5 equivalents), HCO2Na (four equivalents) 
generated the desired reduced macrocycle 157 in 38% yield.  The macrocycle was the 
only product of the reaction based upon crude 1H NMR analysis and it is unclear why 
the mass balance was low for the reaction.  Nonetheless, the success of this reaction 
demonstrated that an enyne functionality was not required for reductive 
macrocyclization and that this simplified model system could be used in further 
optimization and mechanistic investigations. 
Scheme 20. Reductive macrocyclization of alkyne model system 
 
 Besides phosphines, N-heterocyclic carbenes (NHC) have been used as 
ligands to support Cu-H species.187,189 In 2004, Sadighi and coworkers demonstrated 
the applicability of these ligands towards Cu-H generation.191 The researchers were 
able to hydrocuprate 1-hexyne using an NHC-Cu-H complex generated from NHC-
Cu(OtBu) and (EtO)3SiH.  Crystal structure analysis of this vinylcopper product 






















this intermediate that is likely involved in hydrogenation179 or reductive coupling192 
reactions involving Cu.  Use of this NHC-Cu-H catalyst in the reductive 
macrocyclization of the model system 155 only generated product 158 based on crude 
1H NMR analysis, resulting from reduction of the vinyl iodide and partial reduction of 
the alkyne (Scheme 21).  Use of hydrosilanes to generate the Cu-H species, whether 
from an NHC-Cu complex or from a mixture of CuI, PPh3 and base, generated this 
non-cyclized, reduced product 158.  Based on these results, use of formate as the 
hydride source generates a catalyst with attenuated reductive capability compared to 
Cu-H species derived from hydrosilanes.  This formate-derived Cu-H species is able 
to reduce only a highly strained alkynyl intermediate to the corresponding Z-olefin 
compound.  Further mechanistic implications of this cyclization reaction will be 
discussed in a forthcoming section. 
 
Scheme 21. Failed reductive macrocyclization with NHC-Cu-H complex 
 
 With a reliable synthesis of the triene macrocycle 140 in hand, we were able 
to complete the total synthesis of oximidine II (Scheme 23).  Removal of the primary 
silyl ether (159) followed by oxidation by Dess-Martin periodinane (121a) generated 










Wittig olefination with IH2CPPh3I127 installed the Z-vinyl iodide (161),126 required for 
late-stage amide coupling.  At this point we decided to change our protecting group 
strategy because of potential issues arising from trying to remove alkyl ethers in the 
presence of the methyl oxime ether at the end of the synthesis.   
 Initial attempts to remove both alkyl ethers in one step (i.e. from 161 to 162 
directly) with boron tribromide153 or boron trichloride (BCl3) were unsuccessful.  
Using either of these reagents generated an unidentifiable product as the major mass 
component.  Therefore, a two-step protocol was developed.  First, removal of the 
MOM-ether with carbon tetrabromide (CBr4) in warm iPrOH generated the secondary 
alcohol 163.  This mixture of reagents presumably generates a small amount of 
hydrobromic acid that facilitates the deprotection.193 The phenol (162) was exposed 
following treatment of the aryl methyl ether 163 with BCl3.  This unstable diol was 
immediately bis-TBS protected, readying the molecule for installation of the amide 
side chain.  With the formation of the bis-TBS ether 67, our synthesis intersected with 
Porco’s synthesis of oximidine II and allowed for both structure confirmation and 








25  = -151.2° (c = 0.49, CHCl3)).118 Further, this intermediate would serve as the 
point of divergence towards the synthesis of the allylic amide analog. 
 The oxime amide 54 was accessible in two steps from commercially available 
maleimide (107) following Coleman’s work (Scheme 22).115 Selective reduction of 
maleimide under Luche conditions delivered the corresponding hydroxypyrrolone 
164.  This masked aldehyde was condensed with methoxyammonium chloride 
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(MeONH3Cl) to generate the oxime amide 54.  This synthesis of amide 54 is one step 
shorter and 20% higher-yielding than Porco’s previous synthesis of the amide.86 
 
Scheme 22. Synthesis of oxime amide side chain 54 
 
 Besides Porco’s established conditions for enamide formation, we 
investigated conditions reported by Buchwald and Coleman.  Coupling of the amide 
54 to the Z-vinyl iodide 67 using Buchwald’s conditions (CuI, N,N’-
dimethylethylenediamine, K2CO3 in THF) returned only the starting materials.194 The 
conditions developed by Coleman and coworkers (CuTC (57), trans-N,N’-dimethyl-
1,2-cyclohexanediamine, K3PO4 in dioxane) generated some product by crude 1H 
NMR.115 However, attempts to push the reaction to completion by increasing the 
amount of amide 54, the amount of the catalyst system, or modifying the temperature 
were unsuccessful.  Following Porco’s two-step amide coupling/bis-silyl ether 
removal protocol, we synthesized oximidine II (14) in 19% yield over the final two 
steps (Scheme 23).  The 1H NMR and high-resolution mass spectrometry (HRMS) 




















Scheme 23. Completion of the total synthesis of oximidine II (14) 
 
1.6 Synthesis and Biological Activity of Oximidine II Analogs 
 The retrosynthesis for our allylic amide homolog 165 is displayed in Figure 
18.  We envisioned installation of the amide side chain via modification of the 



































































desired analog 165.  Specifically, the amide could be obtained by: conversion of the 
allylic alcohol to the allylic amine 167 followed by an amide coupling reaction, 
similar to Maier’s protocol for installing the allylic amide during his group’s total 
synthesis of cruentaren A;195 conversion of the allylic alcohol to a leaving group 
followed by SN2 displacement by the amide or an amide surrogate; or by Mitsunobu 
coupling of the allylic alcohol with maleimide196,197 followed by modification of the 
maleimide moiety into the desired oxime amide similar to our strategy for formation 
of amide 54 (Scheme 22).   
 























 The first task was formation of the allylic alcohol 166 from the vinyl iodide 67 
(Scheme 24).  We initially attempted to add the hydroxymethylene group by lithium-
iodine exchange followed by quenching the anion with paraformaldehyde (H2CO)n.  
However, the vinyl iodide moiety was prone to elimination.  Analysis of crude 
reaction mixtures by 1H NMR and HRMS revealed formation of the desired product 
166 in addition to the alkynyl molecules 168 and 169.  Variation of the lithium base 
(tBuLi or nBuLi), solvent or temperature did not avert the formation of these 
undesired alkynyl side products.  We then turned to a two-step protocol to install the 
hydroxymethyl group.  The vinyl iodide 67 was transformed into the cis-enoate 170 
by a Pd-catalyzed methoxycarbonylation reaction.  Careful control of reaction time 
was necessary to prevent base-catalyzed isomerization of the cis-enoate olefin.  Use 
of the bulkier amine base diisopropylethylamine (DIPEA) was also helpful in 
preventing this inversion.  Reduction to the Z-allylic alcohol 166 was achieved with 
slow addition of DIBAL to a solution of the ester 170.   
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 The next obstacle in the synthesis was conversion of the hydroxyl oxygen 
atom to a nitrogen atom.  We again employed a model system to tackle this challenge.  
Commercially available (Z)-4-(benzyloxy)but-2-en-1-ol (172) was used to investigate 
a variety of the oxygen-to-nitrogen interconversion ideas.  With an efficient synthesis 
of the oxime amide 54 in hand, we first explored conversion of allylic alcohol 172 to 
a leaving group followed by displacement with the anion of amide 171 (Scheme 25).  
While conversion of the alcohol (172) to a leaving group (LG = Br, OTs, OMs) (173) 
was facile, alkylation of the amide 54 was not.  Generation of the amide anion 171 by 
deprotonation with NaH198,199 or DIBAL200,201 followed by addition of the allylation 
substrate 173 did not yield any of the desired amide-alkylated product 174.  
 
Scheme 25. Failed allylation of oxime amide 54 
 
 We then investigated construction of the allylic amide via a Mitsunobu 
reaction of the allylic alcohol with maleimide.  Due to the relatively high pKa of 
maleimide (107), Mitsunobu reactions with this molecule are notoriously 
difficult.197,202 Using the procedure developed by Walker,196 the Mitsunobu reaction 
between allylic alcohol 166 and maleimide was unsuccessful (Scheme 26).  Variation 
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of solvent, time, temperature, maleimide or diethyl azodicarboxylate (DEAD)/PPh3 
equivalents failed to generate any product (175).   
 
Scheme 26. Initial failed Mitsunobu reaction with DEAD/PPh3 system 
 
 To further investigate this key reaction, we turned to the allylic alcohol model 
system for optimization studies (Scheme 27).  Using the DEAD/PPh3 activator 
system, the reaction inconsistently produced yields of compound 176 between 10-
40% even with modification of the phosphine, solvent, time, temperature, or reagent 
order of addition.  However, switching reagents system to 1,1’-(azodicarbonyl) 
dipiperidine/tri-n-butylphosphine (ADDP/PBu3)203 increased the yield, reliably 
generating 40-50% of the desired product 176.  Reduction of the maleimide moiety to 
the corresponding 5-hydroxypyrrolone (178) was straightforward.  Conversion to the 
corresponding allylic oxime amide 174 by condensing the pyrrolone with MeONH3Cl 
was not.  The base utilized in this reaction proved to be pivotal.  Using bases other 
than sodium bicarbonate (NaHCO3) produced a spectrum of products unidentifiable 
















Scheme 27. Formation of allylic amide 174 with model system 
 
 With methodology to install the allylic amide in hand, we turned to 
synthesizing the target analog 165 (Scheme 28).  We were disappointed to find that 
use of the ADDP/PBu3 system generated low yields (10-20%) of the desired allylic 
maleimide compound 175, resulting from low conversion of starting material even 
after increasing the equivalents of maleimide or activator reagents.  Returning to the 
original DEAD/PPh3 system, a slow addition of DEAD to a THF solution of 
malemide, PPh3, and the allylic alcohol gave a 62% yield of the Mitsunobu product 
175.  Reduction of the malemide to the corresponding 5-hydroxy-pyrrolone 178 by a 
Luche reduction occurred without incident.  Condensation of the pyrrolone 178 with 
MeNH3Cl was low yielding and gave a 3:1 ratio of E:Z oxime ether stereoisomers 
(179).  The major oxime ether stereoisomer configuration was assigned as trans based 
upon previous 1H NMR studies of the lobatamide oxime ethers.10 Lobatamides 




























NMR for the oxime C-H proton.  The Z-oxime ether lobatamides displayed a 
chemical shift of 8.3-8.4 ppm for this proton.  Finally, bis-TBS deprotection with a 
buffered solution of HF/Py. delivered the target allylic amide homolog of oximidine 
II (165).  Using the same deprotection conditions intermediates 170, 166, 175, and 
178 were desilylated to give compounds 180-183, increasing the amount of 
compounds available for biological testing (Scheme 29).  The maleimide diol 182 
















































































































 Prior to biological testing, LC/MS analysis of oximidine II (14), the allylic 
amide homolog 165 and molecules 180, 181 and 183 established purities between 
82% and 95% for the molecules.  Without further purification, the compounds were 
tested against melanoma cell lines SK-Mel-5 and SK-Mel-28.  Figures 19 and 20 
display the IC50 graphs for oximidine II (14) and the allylic amide analog 165, 
respectively, against SK-Mel-5 cancer cells.  Oximidine II realized an IC50 of 590 nM 
in this assay while the analog displayed only 40% inhibition at 100 µM.   Against the 
SK-Mel-28 cell line, known to be less sensitive towards the benzolactone enamides, 
oximidine II (Figure 19) and the analog 165 (Figure 20) were much less potent.  
Oximidine II displayed an IC50 of 100 µM while the analog was barely active, 
exhibiting only 10% inhibition at 100 µM.  The other compounds, 180, 181 and 183, 
were inactive against both cell lines (not shown).  As a control, Taxol® exhibited an 
IC50 value of 8.7 nM against the SK-Mel-5 cell line and 10% inhibition at 100 µM 




Figure 19. IC50 graphs for oximidine II (14), tested against SK-Mel-5 (top) and SK-
Mel-28 (bottom) melanoma cells 
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Figure 20. IC50 graphs for allylic amide analog (165), tested against SK-Mel-5 (top) 
and SK-Mel-28 (bottom) melanoma cells 
 
 These results reiterate the necessity of the enamide moiety for bioactivity of 
this natural product class against melanoma cancer cells.  Cruentaren A, containing 
the allylic amide moiety, has not been tested against either of these cell lines.  To gain 
a more thorough understanding of the relationship between the structure of the 
macrolactone and the presence of either an enamide or an allylic amide, we planned 
to test both oximidine II and our homolog 165 against the mouse L929 fibroblast cell 
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line.  Cruentaren A displays an IC50 of 1.2 ng/mL against this cell line.93 These 
biological assays are currently underway. 
 
1.7 Copper-mediated Reductive Ring-closure Mechanistic Investigation 
 The unprecedented nature of the copper-mediated reductive coupling reaction 
prompted mechanistic investigation.  We hoped that an in-depth understanding of the 
mechanism would lead to expansion of the scope of the technology, with a particular 
interest in developing intermolecular vinyl or aryl iodide-alkyne reductive couplings 
towards diene synthesis.  This reductive coupling reaction could become a powerful 
methodology in the toolbox of organic chemists.   
 Based upon previous studies, a Cu-H species was very likely responsible for 
the reduction of the alkyne to the alkene in the reaction.  However, we were unsure if 
this reduction proceeded by a radical or non-radical pathway.  Under the previously 
described reaction conditions (Cu(OAc)2, PPh3, K2CO3, HCO2Na in DMF at 120 °C 
for 30 min), the cyclized, reduced macrocycle 157 is produced in 38% yield (Scheme 
20).  To probe the intermediacy of radicals, the radical-sequestering reagents 
hydroquinone and DDQ were added to the macrocyclization reaction.204 Addition of 
either radical-mediating reagent had no noticeable effect on either the reaction rate or 
the reaction yield, suggesting that radicals were not likely produced during the course 
of the reaction. 
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 After ruling out the possibility of a radical-based mechanism, we focused on 
identifying the timing of the alkyne-to-alkene reduction, i.e. does the reduction occur 
prior to (path A) or after (path B) macrocyclization (Figure 21).   
Figure 21. Possible reductive cyclization mechanisms 
 
In order for path A to be active, the hydrocuprated intermediate 184 would 
undergo an Ullmann-like coupling reaction followed by a C10-C11 olefin inversion 
to generate the observed product 157.  We had observed reduction of the terminal 
alkyne to the corresponding terminal alkene (Scheme 21) when hydrosilanes were 
used as the hydride source in the reaction and believed that a vinylcopper species, 
generated from reduction of the alkyne, was the responsible intermediate.  This 
hypothesis was further supported by Sadighi’s crystal structure of the vinylcopper 
intermediate.191 To test the plausibility of this pathway, we exposed the methylated-
alkyne molecule 186 to the reductive cyclization conditions (Scheme 29).  However, 
this reaction generated none of the anticipated product 187.  No starting material was 
consumed during the course of the reaction.  The deuterated alkyne 188 also did not 



























bis-protonated macrocycle 157 resulted.  Although suggestive that path B was 
operational, the outcomes of these two experiments did not completely rule out the 
possibility of path A.  The reduction reaction could be specific for terminal alkynes, 
therefore making the methyl-alkyne 186 a poor substrate choice.  Considering the 
deutero-alkyne 188, a proton-deuteron exchange could occur in the reaction, leading 
to the observed result.  Copper acetylides result from the addition of a Cu(I) or Cu(II) 
salt to a solution of a terminal alkyne in the presence of a base.107 Under the reaction 
conditions employing the monohydrate of Cu(OAc)2 as the copper source, a kinetic 
quench of the copper acetylide 190 by water or another proton source could generate 
the protonated alkyne 156, followed by reduction and cyclization to yield the 
observed product 157 (Figure 22).   
 
























Figure 22. Potential deuterium-proton exchange pathway 
 
 Although no deuterium incorporation occurred when exposing 188 to the 
reductive cyclization conditions, we were able to incorporate deuterium by using 
DCO2Na instead of HCO2Na (Scheme 30).  Analysis of the product 1H NMR 
revealed that the deuterium was not regioselectively incorporated into the product as 
would be expected if path A were the mechanistic pathway.  Instead, a 9:1 ratio of 
deuterated products 190 and 191 resulted from the macrocyclization.  This 
regiochemical preference for deuterium incorporation implies that some steric or 
electronic force guides the reduction.  Deuterium labeling of the oximidine system 
with DCO2Na generated a 5:4 mixture of regioisomerically-deuterated products 
(192:193).  The reduction does not occur through a conjugate addition pathway due to 


























is presumably not co-planar with the aromatic ring based on the apicularen A crystal 
structure.  Based on this evidence, we concluded that path B was most likely the 
operating mechanism.   
 
Scheme 30. Deuterium incorporation during reductive cyclization 
 
 In mechanism B, a vinylcopper-macrocycle intermediate is generated that is 
quenched either during the reaction or during the reaction workup.  Because no bis-
dueterated product (194) was observed when DCO2Na was used, we deduced that 
formate was not the quenching source.  Quenching the reaction with D2O also gave 
no bis-deuterated product.  In Stryker’s paper detailing the reduction of alkynes to the 
corresponding cis-alkenes with Cu-H,179 he observed that the presence of five to 10 
equivalents of water in the reaction greatly increased yields compared to the complete 






































resulting from Cu-H addition across the triple bond.179 Further, adding more than five 
to 10 equivalents of water diminished the reactivity of the Cu-H species and 
prohibited conversion of the starting material to product.  Similar to Stryker’s 
observations, addition of 10 equivalents of D2O to the catalyst solution prohibited the 
reductive cyclization.  Addition of five equivalents of D2O, however, generated a 
different result.  Although 66% of the starting material (156) remained after two 
hours at 120 °C, 10-20% deuterium incorporation at C10 (191) was achieved when 
D2O was added to the catalyst system employing HCO2Na as the hydride source 
(Scheme 31).  The quenching proton, generating the remaining 80-90% of the product 
(157), could come from water hydrating the Cu(OAc)2 or from non-dry reagents or 
solvent.  We have not yet ruled out any of these possibilities. 
 
Scheme 31. Internal quench with D2O 
 
 The complete mechanism, based on current evidence, is displayed in Figure 
23.  Following Cu-acetylide generation (190), a Castro-Stephens coupling107 forms 
the C8-C9 E-dienyne macrocycle 196.  A moderate π-acid, Cu remains coordinated to 
the alkyne (196), stabilizing the intermediate and preventing the C8-C9 E to Z 
















Exposure of the Z-dienyne 139 to the reductive cyclization conditions generated none 
of the reduced triene product 140, hinting that the energetic barrier of C8-C9 Z- to E-
inversion is relatively high and that the reduction occurs due to ring-strain relief.  It is 
presently unclear if the reactive Castro-Stephens catalyst species contains the Cu-H 
species (i.e. L = H in 190) or if this species is generated somewhere along the 
catalytic cycle by loss of CO2 from formate (196 to 197).  In Figure 23, coordination 
of formate (196) followed by loss of CO2 yields the requisite Cu-H intermediate 197.  
1,2-Addition of the Cu-H results in reduction of the alkyne to the cis-alkenylcopper 
species (198) that is internally quenched by a proton (“H+”), yielding the desired 
product (157) and regenerating the active Cu species. 
Figure 23. Proposed mechanism for copper-mediated reductive cyclization 
 
 Attempts to perform intermolecular reductive coupling reactions have thus far 
been unsuccessful, generating only the Castro-Stephens enyne product.  Most likely, 




































macrocyclization examples.  Modifications to the catalyst system could lead to 
increasing the substrate scope for the reaction. 
 
1.8 Conclusions 
 The third total synthesis of the benzolactone enamide oximidine II was 
achieved in 1.1% overall yield in 22 linear steps from commercially available 1,3-
propanediol.  The key macrocyclization step in the synthesis was performed by an 
unprecedented copper-mediated reductive vinyl iodide-alkyne coupling reaction.  The 
67% yield realized by this reaction was 20% higher than previous methodologies 
utilized to form the triene core of oximidine II.  Based on current mechanistic 
evidence, this reductive macrocyclization is thought to occur as a consequence of 
ring-strain developed by stereospecific coupling of an E-vinyl iodide and an alkyne.   
 An allylic amide analog of oximidine II was synthesized to investigate the 
importance of the enamide side chain on biological activity of the benzolactone 
enamide natural product class.  Against melanoma cancer cells, oximidine II was 
bioactive while the allylic amide analog displayed marginal bioactivity.  
Benzolactone enamides are known to exert their biological activity through inhibition 
of the V-ATPase enzyme.  Further biological comparison of oximidine II and the 
allylic amide analog will determine if the allylic amide analog targets the V-ATPase 
enzyme or the F-ATPase enzyme – the biological target of cruentaren A, another 




The Search for New Antibiotics – New Inhibitors of the MurA Enzyme 
 
2.1 Background 
 Many types of bacteria depend on humans for survival.  Some of these 
prokaryotic microorganisms are symbiotic, such as Bacteroides thetaiotaomicron, 
functioning to digest polysaccharides inside the gastrointestinal tract, and some are 
harmful, such as the peptic ulcer-causing Helicobacter pylori.205 For bacteria to grow 
and thrive inside the body, they must be tolerant to a variety of physiological 
conditions.  Unchecked bacterial infections can form rapidly.  Mutations in bacterial 
genetic code occur partly because they replicate rapidly.  These mutations can lead to 
no observable change in bacterial function, bacterial death, or to a worse extreme – 
drug resistance.205 
 It is these drug-adapted and damage-causing bacteria that have kept medicinal 
chemists at work for nearly a century.206 Sulfonamides (sulfacetamide, 199, Figure 
24), the first antimicrobials, were widely used beginning in the 1930’s but are now 
generally used clinically for treating urinary tract infections (UTI’s).  This is due to 
the widespread development of resistance to the drug class.  World War II helped 
spread the use of penicillin antibiotics following their discovery by Alexander 
Fleming in 1929.  Initially, the original β-lactam drug Penicillin G (200) was 
successful at fighting mostly Gram-(+) bacteria.  However, resistance to the drug 
soon occurred, forcing medicinal chemists to develop successive generations of the 
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drug class.  Seeing that β-lactams would not be the end-all for antibiotic therapeutics, 
new classes with novel mechanisms of action were discovered and explored.  These 
antibiotic classes include the quinolones (ciprofloxacin, 201), tetracyclines (202), 
aminoglycosides (streptomycin, 203), macrolides (erythromycin A, 204) and 
oxazolidinones (linezolid, 205), among others (Figure 24).  Incurrence of resistance to 
antibiotic therapeutics by bacteria has led to the development of new agents by 
medicinal chemists. 
Figure 24. Examples of antibiotic therapeutics 
 
 Despite the extensive research in this area, there is again a growing need for 
new antibacterial targets and drugs.  It is estimated that 70% of all hospital infection-
causing bacteria are unaffected by at least one antibiotic and that about 90,000 people 
die each year in the U.S. from these “superbugs”.207 Even “drugs of last resort”, such 









































































Furthermore, a worldwide increase in the incidence of certain bacterial infections 
previously considered cured, such as tuberculosis, is being attributed to bacterial 
resistance. 
 Antibiotics target a variety of enzymes resulting in the inhibition of many 
cellular processes.  One of the most common processes targeted is biosynthesis of the 
cell wall, specifically construction of the peptidoglycan layer of the cell wall.  The 
cell wall is responsible for maintaining cellular shape, maintaining an internal 
osmotic pressure, and acting as a barrier for xenobiotics, among other roles.208 This 
approach is attractive for many reasons.  First, the cell wall and most of the enzymes 
responsible for its construction are necessary for bacterial survival.  Selective 
therapeutic targeting is easily achievable because the enzymes responsible for 
constructing the peptidoglycan layer are not found in mammals.  The peptidoglycan 
layer is comprised of a repeating linear N-acetylglucosamine (NAG) / N-
acetylmuramic acid (NAM) dimer functionalized with a pentapeptide chain (Figure 
25).209 The pentapeptide subunits serve to crosslink the glycan backbone, creating the 
3-D peptidoglycan polymer that provides structural rigidity to the cell wall (Figure 
26).208 
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Figure 25. Dimer of peptidoglycan layer209 
Figure 26.  Crosslinking of peptidoglycan layer208 
 
 Catalyzing the first commited step in peptidoglycan biosynthesis is the 
cytoplasmic enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA).210  
































































DA = diamino acid = NAM = NAG
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This enzyme is necessary for cell survival and not present in humans,211 therefore an 
attractive antibiotic target.  At steady state, MurA exists as two globular domains in 
an open conformation, shaped like a jellybean (Figure 27).212  Following UDP-N-
acetylglucosamine (UNAG, 207) binding, the two domains undergo a large structural 
change to form the closed, active state (Figure 28).213 During this conformational 
change, a loop region closes the interdomain section, similar to a lid.214 Upon binding 
of the second substrate, phosphoenolpyruvate (PEP, 206), the loop undergoes another 
structural change following an induced-fit mechanism – a key consideration for 
antibiotic development.213-215 The loop is also significant because it contains the 
Cys115 (E. coli numbering) residue that is important for successful product release.216 
Cys115 is also the target amino acid for the known MurA inhibitor fosfomycin.214 
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Figure 27. MurA in open state212
 144 
Figure 28. MurA with UNAG bound212 
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 Figure 29 displays the unusual mechanism of enolpyruvyl transfer from PEP 
(206) to UNAG (207) catalyzed by MurA.  This has been determined by both co-
crystallization and synthetic studies.217,218 The reaction proceeds via a typical 
mechanism for vinyl ether transfer.  First, protonation of the alkene of PEP generates 
an oxocarbenium ion 208.  The reactive hydroxyl group on UNAG attacks this 
intermediate to generate a tetrathedral intermediate 209.  Simultaneous collapse of the 
tetrahedral intermediate and release of inorganic phosphate (PO43-) generates the 
enolpyruvyl-UDP-N-acetylglucosamine (EP-UNAG, 210) product.  EP-UNAG is 
then released from the enzyme, relaxing the enzyme back to the open configuration. 
Figure 29. MurA-catalyzed conversion of UNAG to EP-UNAG (210) 
 
 5-Enolpyruvyl shikimate-3-phosphate synthase (EPSPS or AroA) is the only 
other member of the enolpyruvyl transferase family.219 This family is unusual as it 
utilizes PEP as an enolpyruvyl donor.  In all other known PEP-dependent reactions, 
its P-O bond is cleaved and a phosphoryl moiety is transferred to the substrate.  AroA 
is the sixth enzyme in the shikimate pathway – the pathway responsible for 












































 The development of inhibitors of these enzymes has led to a deeper 
understanding of the catalysis mechanism for MurA and AroA (Figure 30).  
Glyphosate (211), the active ingredient of the herbicide Roundup, is a potent and 
exclusive inhibitor of AroA.220 Discovered in 1969 by Hendlin and coworkers,221 
fosfomycin (212) inhibits MurA.  Fosfomycin is currently the only marketed inhibitor 
of MurA and is the active ingredient in Mourol.222 Interestingly, glyphosate and 
fosfomycin are mutually exclusive in inhibiting only AroA and MurA, respectively, 
although both enzymes proceed through a similar tetrahedral intermediate.  This is 
attributed to the differences in amino acids in the active site.217   
Figure 30. Inhibitors of the enolpyruvl transferase enzyme family 
 
 Fosfomycin, a phosphonate epoxide, forms a covalent adduct with the Cys115 
residue (numbering according to E. coli sequencing) in the active site via opening of 
the epoxide.214 The drug is specific for MurA with reported IC50 values of 0.40-12 
µM.223 Despite the reactive epoxide moiety, the molecule does not function as a 
group specific reagent in alkylating other nucleophilic amino acids in the body.  
Although the antibiotic is active against both Gram-(+) and Gram-(–) bacteria, the 







glyphosate 211 fosfomycin 212
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worldwide only in treating UTI’s.  It is also used in Japan as the drug of choice for 
treating Shiga-like toxin-producing E. coli.224  
 Similar to other antibiotic treatments, resistance is building against this MurA 
inhibitor through a variety of mechanisms.  Fosfomycin is actively transported across 
the bacterial cell wall.225,226 Bacterial genetic changes result in either decreased 
fosfomycin binding to the transporter proteins or to obstruction of drug uptake.  
Second, a fosfomycin-resistance protein, FosA, has recently been identified.  This 
enzyme uses glutathione as a nucleophile to open up the epoxide and form a covalent 
adduct to deactivate the drug.227-229 Lastly, is the mutation of the Cys115 residue to an 
aspartate amino acid leaves the enzyme catalytically active but renders fosfomycin 
inactive.230,231 
 
2.2 Generation of HTS-Inspired Library 
 The limited scope of fosfomycin and its incurrence of bacterial resistance 
coupled with a wealth of recently uncovered structural biology information about 
MurA from crystallographic studies has led to increased interest in MurA inhibitor 
exploration.  High-throughput screening (HTS) by various pharmaceutical companies 
has revealed several new structures with MurA inhibitory activity (Figure 31). 223,232-
234 Preincubation of the bacterial cells with UNAG prior to administering these lead 
candidates was necessary to achieve nanomolar IC50 values, suggesting that these 
compounds (213-218) bind to a UNAG-activated enzyme complex.  Unfortunately, 
development of the entire RWJ series (213-215) was halted due to unspecific 
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inhibition of DNA, RNA, protein and cell wall biosynthesis.223 Natural products have 
also been reported to inhibit the bacterial enzyme, most notably the sesquiterpene 
cnicin 216.235,236 X-ray crystallography revealed that this molecule works in an 
interesting manner, forming a covalent 1,3-adduct (219) with UNAG instead of the 
expected 1,4-adduct as the result of a typical Michael addition (Figure 32).235 The 
vicinal diol moiety is thought to imitate the phosphate moiety in the tetrahedral 
intermediate (220) of the MurA catalytic cycle, allowing the unusual adduct to form.  
Despite the recent activity targeting MurA, no lead candidate has emerged leaving an 
opportunity to discover and develop new inhibitors of the enzyme. 
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Figure 31.  Recently reported MurA inhibitors 
Figure 32. Unusual mechanism for cnicin binding 
 
 Our search for new MurA inhibitors began with an HTS campaign performed 
at the KU HTS facility.  A Lanzetta assay237 was used to identify possible lead 
structures in this screening campaign.  The Lanzetta assay uses color changes to 
quantify amounts of inorganic phosphate present in solution.  Therefore, a decrease in 














































































MurA catalytic pathway (Figure 29).  During this screening campaign, five different 
scaffolds (221-225) were identified with IC50 values of 2-41 µM (Figure 33).  The 
similarities between 221 and 224 – benzoic acids substituted with the isosteric 
heteroaromatics pyrrole or furan, respectively – prompted closer examination. 
Figure 33. MurA HTS hits 
 
 We followed up on the pyrrol-benzoic acid scaffold (compounds 226-228, 
Figure 34) for SAR development.  The relatively small number of compounds from 
this class present in the screening collection did not allow for an easily discernable 
SAR (Figure 34).  Furthermore, the lack of step-by-step functional group substitution 
on each of the rings prevented a clear correlation of functionality to activity.  
Carboxyl substitution, either on positions C3 or C4, appeared necessary although no 
C2-carboxylated ligands were examined.  It was unclear whether a carboxyl 
bioisostere, such as a nitro group, could be tolerated.  Some steric bulk was tolerated 



























225, IC50 = 4-11 µM
N




on the pyrrole ring at positions C1’ and C4’.  Other N-heteroaromatic compounds 
were not represented in the collection. 
Figure 34.  HTS compounds from lead series 1 
 
 Pyrrole-benzoic acids can be synthesized in a variety of ways (Figure 35).  
The first synthesis of substituted pyrroles appeared in 1884 from the independent labs 
of Paal and Knorr.238,239 Condensation of 1,4-diketone derivatives with amines in the 

































procedure was limited to the synthesis of 1,4-disubstituted pyrroles due to the 
instability of 1,4-dialdehydes under the harshly acidic reaction conditions.  In 1952, 
the lab of Clausen-Kaas developed the reagent 2,5-dimethoxytetrahydrofuran (229) as 
a surrogate for the labile succinaldehyde.240 This Clausen-Kaas modification of the 
Paal-Knorr pyrrole synthesis allows for formation of a variety of unsubstituted 
pyrroles via the acid-mediated condensation of primary amines and 2,5-
dimethoxytetrahydrofuran (route A).  This procedure is limited by the harsh reaction 
conditions necessary for product formation.   
 Quenching phenyl anions with carbon dioxide (CO2) produces benzoic acids.  
Regiospecific lithiation of substituted N-phenyl pyrroles can be achieved through 
variation of the lithiation conditions (route B).241 
 Copper and palladium are also known to mediate the coupling of amines to 
various halogenated or pseudohalogenated aryl or vinyl species (route C).242-244 The 
use of copper for this cross coupling reaction was first reported by Ullmann245in 1903 
then by Goldberg in 1906.246 The reaction was recently improved by the Buchwald 
labs through incorporation of diamine ligands into the reagent system,247 leading to 
lower catalyst loadings and broadening of the substrate scope.  Palladium is also an 
effective catalyst for pyrrole cross coupling.248-251 This Buchwald-Hartwig chemistry 
is attractive because the ligand can be optimized for specific substrates.  Copper is 
used in stoichiometric quantities to couple aryl and vinyl boronic acids to amines in 
the Chan-Lam coupling reaction (route D).252,253 A limitation of the metal mediated 
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reactions is that free carboxylic acids are not suitable substrates for the couplings, 
requiring an additional hydrolysis step to reveal the desired acid compound.  
Figure 35.  Pyrrole-benzoic acid synthetic strategies 
 
 We initially explored the lithiation-carboxylation route (route B, Table 13, 
entry 1).  However, we were unable to achieve the levels of regioselectivity required 
for the expedient synthesis of a library of pyrrole-benzoic acids and abandonded this 
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mediated protocols generated a complex mixture of products as seen in the crude 1H 
NMR’s and this strategy was also abandonded.  The Clausen-Kaas protocol was then 
employed (entries 3-6).240,254 This strategy allowed for rapid analog access due to the 
commercial availability of a variety of aniline derivatives and the simple one-step 
condensation procedure.  As yields were not important in this study, we set to 
establish a protocol that would provide clean compounds with minimal purification 
efforts.  Our first attempt utilized an uncatalyzed, direct condensation of the amino-
benzoic acid with 2,5-dimethoxytetrahydrofuran, adding 4Å molecular sieves to soak 
up methanol and drive the reaction equilibrium towards product formation.  While 
this procedure worked well for 4-chloro-aniline (230) (Table 13, entry 3), carboxyl 
substitution on the benzene ring (231) led to isolation of only starting materials and 
delivered no product (232) (entry 4).  We then turned to acid catalyzed variants of the 
reaction.  Following the precedent of Ottenheijm and coworkers,255 phosphorus 
pentoxide (P2O5) did provide the desired pyrrole product (233) by 1H NMR (entry 5), 
but multiple chromatographies could not deliver pure material.  We then turned to 
acetic acid as the catalyst.254 Indeed, refluxing the aniline 230 and tetrahydrofuran 
229 in glacial acetic acid for one h followed by column chromatography delivered the 
desired pyrrole (233) in 78% yield.  This technology was easily transferred to other 




Table 13. Optimization of pyrrole-benzoic acid formation 
 
 Using this standard protocol, a variety of substituted anilines and electrophiles 
were reacted to generate a 14-membered library for biological testing (Table 14).  The 
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yields are variable for these compounds (3–67%).  In general, the electron deficient 
anilines gave poorer yields of the condensation products (entry 2) compared to the 
more electron rich substrates (entry 8).  Also, sterically hindered anilines generated 
lower yields of the pyrroles (entries 1, 3 and 6).  Consumption of the starting material 
occurred in each reaction.  While decomposition of the starting materials cannot be 
ignored as a potential cause for the low yields realized, the most likely cause is 
decomposition of the pyrrole products.  Pyrroles are known to be unstable and can 
react with aldehyde substrates to undergo electrophilic aromatic substitution 
reactions, leading to polypyrrole compounds such as porphyrins.256 
 The analogs synthesized addressed a variety of issues generated by the HTS 
campaign.  The role of an electron-withdrawing group was probed, replacing the 
carboxyl group of 226 with a nitro group (238, entry 7).  The anionic character of the 
carboxyl group was also probed.  Methylation of the benzoic acid with 
trimethylsilyldiazomethane gave the corresponding methyl ester 239 (Scheme 32).  
Using a N-(3-dimethylaminopropyl)-N’-ethyldicarbodiimide hydrochloride (EDCI) 
coupling,257 the acid 226 was converted to the N,N’-dimethylamide 240 for testing 
(Scheme 32). Non-pyrrole N-substituted heterocycles were also synthesized following 
the acid-mediated protocol (entries 10-12).258 
 157 















100 °C, 2 h
Aniline + Electrophile Product                    Yield %
NH2
























































































Scheme 32.  Synthesis of ester and amide analogs 
 
 Despite the modifications to the lead scaffold, only the maleimide analog 265 
displayed significant MurA inhibitory properties when tested at 100 µM in the 
Lanzetta assay (Figure 36), at least initially.  The exact IC50 value was determined by 
varying the concentration of compound 265 in the Lanzetta assay, producing an IC50 
of about 25 µM (Figure 37).  The maleimide 265 displayed equipotency when 
compared to HTS lead compound 226.  This result, however, was discovered to be a 
false positive. 
 Maleimides are known to be good Michael acceptors and we hypothesized 
that the observed biological activity could result from this reactive moiety.  However, 
the purple color of the maleimide DMSO solution used in the biological assay 
suggested that decomposition of some component had occurred.  A multitude of 




















hypothesis.  Attempts to analytically identify compounds in the mixture were 
unsuccessful.  The maleimide compound 265 was synthesized again, 
spectroscopically confirmed as the desired structure, and tested in the Lanzetta assay.  
The biological activity displayed by the initial, decomposed compound was not 
reproduced by the newly synthesized maleimide 265.  Further, this new product 
proved to be stable to a variety of conditions present while as a DMSO solution 
awaiting biological testing, such as exposure to UV light or heat.   
 
Figure 36.  Relative MurA inhibitory activity for synthesized analogs 
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Figure 37.  Initial IC50 determined for compound 265 vs. 226 
 
 As our analog campaign failed to construct a quantifiable SAR, we assumed 
that these compounds possessed a flat SAR and halted further analog exploration.  
Still determined to find a new MurA inhibitor, structure-based drug design was then 
explored. 
 
2.3 Structure-Based / Fragment-Based Drug Design Approach 
 Hemoglobin was the first target for structure-based drug design.259 In 1975, 
Beddell et al. detailed their rational development of new binders of the iron-
containing protein based upon interactions seen in the X-ray crystal structure.  It is 




2,3-diphosphoglycerate and therefore most likely would not have been discovered 
following medicinal chemistry practices of that era. 
 As both X-ray crystallography and computational methodology became 
cheaper and easier to perform, the use of structure-based drug design grew.260 The 
basic premise of structure-based drug design is to use protein structural information, 
generally acquired from an X-ray crystal structure or NMR spectroscopy, to design 
molecules that form key binding interactions with the protein.  Commonly, this 
practice is coupled with computer modeling to speed the discovery process.  
Structure-based drug design has been successfully applied in the development of 
many drugs including the neuraminidase inhibitor Relenze®, an influenza 
treatment.261 
 A related drug design strategy, fragment-based drug design, has also grown 
rapidly in recent years due to technological advances.  A benefit of a fragment-based 
approach is that a relatively small amount of compounds need to be screened to find a 
hit compared with the standard HTS practice.262,263 The basic concept of fragment-
based drug design is to find small molecules, generally less than 250 Da in molecular 
weight, with high micromolar to millimolar activity against a specific biological 
target.264 These weak binders can then be elaborated upon in a ligand efficient 
manner265,266 to generate nM inhibitors of the target enzyme.267 To be considered 
“ligand efficient”, each non-hydrogen atom added to the scaffold should increase the 
free binding energy by approximately 1.5 kcal mol -1.  This generates a nM inhibitor 
from a 250 Da fragment with an initial Kd or IC50 value of 100 µM.266 The fragments 
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forming interactions with the target protein are identified by a variety of biophysical 
methods, such as high throughput X-ray crystallography, high-throughput NMR 
spectroscopy or isothermal calorimetry.  In addition to the cutting-edge technology 
required for a successful fragment-based screening program, this technique is limited 
towards proteins that can be easily purified in large quantities. 
 As there is a wealth of MurA structural information in the literature, we chose 
to utilize these two methods in the search for new MurA inhibitor scaffolds.  Crystal 
structures are solved with MurA in both the open and closed forms and with various 
ligands docked in each form.268 We envisioned that virtual screening of fragment 
libraries against the crystal structures would generate leads with µM binding 
affinities.  However, these weak binders would reveal chemical functionality 
pertinent for ligand-protein interactions to aid the discovery process.  Based on these 
modeling results, establishment of an SAR would lead to the design of more potent 
inhibitors.  Important to this structure-based drug design approach is confirmation of 
our modeling hits with follow-up testing in MurA inhibitory assays and, ultimately, 
co-crystallization with the enzyme. 
 In 2006, Klein and Bachelier reasoned that, while many crystal structures of 
MurA have been solved, only the closed form structures would be useful for in silico 
inhibitor development.268 In the open form, the enzyme’s loop region is flexible in 
solution.  Binding to this loop requires a large loss of entropic freedom from the 
enzyme, therefore requiring high affinity compounds for MurA inhibition.  Further, 
the positioning of the loop region in various crystal structures is influenced by several 
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crystal contacts.  This implies that the crystal structure conformation is likely not the 
conformation present in solution.  The authors also reasoned that targeting the loop is 
undesirable due to the observed lack of residue conservation.  For example, the 
C115D mutation is present in about 20% of known MurA enzymes.  Based on these 
hypotheses, we began our search by looking at the closed form of the enzyme, 
specifically the 1RYW crystal structure.216 
 We predicted that a successful MurA inhibitor would induce the open/closed 
conformational change similar to the native MurA substrates UNAG and PEP.  
Therefore, binding to the closed state was imperative.  MurA was co-crystallized with 
the reaction product EP-UNAG in the 1RYW crystal structure, forming an active site 
ready for ligand docking studies.  The 1RYW crystal structure contains a C115S 
mutation.  This mutation was not expected to be detrimental towards our in silico 
approach as the cysteine residue is required only for product release.216 Use of this 
structure may actually be beneficial towards MurA inhibitor development due to the 
known prevalence of mutation for this residue.  
 Our high-throughput virtual screening campaign began by generating a 
receptor model of the enzyme in the modeling program SYBYL.269 The reaction 
product EP-UNAG, the liberated phosphate molecule, and crystallographic waters 
were removed from the crystal structure.  Valence protons were added according to 
standard physiological conditions (pH = 7.4).  Gasteiger-Marsili formalism was used 
to assign partial atomic charges.270 We docked ligands using the Autodock 
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program271, requiring 10 poses per ligand.  The results were evaluated using default 
Lamarckian genetics algorithms search specifications. 
 Prior to beginning the screening campaign, we validated the receptor model 
by docking EP-UNAG into the receptor site.  This docking simulation generated EP-
UNAG poses comparable – less than 2.0Å root mean squared positional deviation – 
to the crystallographic EP-UNAG molecule.  According to the Autodock scoring 
function, this result corresponds to an exothermic -10 kcal mol-1 binding energy. 
 The ligands used in the virtual screen were extracted from the ChemNavigator 
iResearch Library collection, comprised of commercially available and synthetically 
feasible molecules.272 As this was a fragment-based screening approach, we used the 
UNITY program273 to mine only the molecules with molecular weight less than 150 
Da.  This size criterion allows for a small amount of structural complexity but plenty 
of room to evaluate and build larger molecules in line with the Lipinski rules.3 A total 
of 3,692 compounds fit this molecular weight criterion.  Using the Concord 
program,274 we then converted these compounds into 3D structures and assigned 
atomic charges again using the Gasteiger-Marsili formalism, ready for docking in the 
receptor model analogously to the EP-UNAG study.  This in silico screen revealed 
331 compounds with a predicted docking energy of greater than -8.0 kcal mol-1 and 
19 compounds with greater than -9.0 kcal mol-1 docking energy (Figure 38).  
Autodock estimated Ki values between 125 and 318 nM for these 19 compounds.   
 The 331 hit molecules displayed a variety of functionality.  At least one 
hydrogen-bonding element was required for activity.  Amines and amides were well 
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represented.  The 19 most potent inhibitors generally contained at least two hydrogen-
bonding functionalities. 
 As shown in Figure 38, the ligands expectedly clustered around the outside of 
the EP-UNAG-formed binding pocket.  UNAG is displayed in the center of the 
Figure as a reference.  The individual residues are not numbered in this Figure, but 
their labeling allows for some structural understanding.  In particular, a majority of 
the ligands bind near a tryptophan residue at the bottom of the Figure.  As this amino 
acid (Trp95) may be important for the open to closed conformational change, we 
visually dissected the 331 compounds and removed the compounds that did not bind 
within five angstroms of the W residue.  This left behind 255 compounds, 18 with 
greater than -9.0 kcal mol-1 binding energy, for further docking investigation. 
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Figure 38.  MurA docking results 
 
 The 255 compounds were then virtually screened in four different open 
conformation MurA crystal structures: 1EYN,275 1YBG,276 1EJC277 and 1EJD.277 A 
known MurA inhibitor, Aventis compound T6361 (compound 217), was co-
crystallized with the enzyme in crystal structure 1YBG and was removed using a 
similar protocol for EP-UNAG as above.  Similarly, the fluorescence probe 8-anilino-
1-naphthalene-sulfonate (ANS (226), Figure 39) was removed from crystal structure 
1EYN.  Method validation by virtual docking of these compounds into their 
respective crystal structures was difficult.  The Aventis inhibitor (217) did bind in the 
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correct active site compared to the 1YBG crystal structure, but in a different 
orientation.  Hydrogen bonding and π-π stacking interactions previously thought to be 
key for 217 binding to MurA based on the co-crystal structure were not present in the 
docking simulation.  ANS did not dock in the correct site altogether.  This result 
could be attributed to tightly-formed binding pocket of ANS in the crystal structure.  
We did not perform follow-up molecular dynamics simulations to relax the crystal in 
an attempt to promote ANS docking.   
Figure 39.  Structure of ANS 
 
 Using the Trp95 residue as the bullseye for compound docking, we again 
visually dissected the virtual screening results.  Crystal structures 1YBG and 1EYN 
docked a majority of the compounds, 133 and 255 respectively, within five angstroms 
of the Trp95 residue.  Without a co-crystallized molecule to define an active site, 
crystal structures 1EJC and 1EJD were more discriminate.  Only two compounds 
docked within 5Å of Trp95 in 1EJC and only three compounds fit this criterion in 
1EJD.    
 Comparing the hit fragments from the 1EJC and 1EJD docking studies with 





compounds that were successfully docked within five angstrons of Trp95 in two or 
more of the X-ray structures.  These molecules (267-270) are shown in Figure 40.  In 
general, the fragments contain a lipophilic side chain appended to a hydrogen bond 
donor in the center.  As none of these molecules were commercially available, a 
similar molecule N-(2-methylpropyl)-1-butanamide (271) was purchased and tested 
for MurA inhibitory activity.  Even at five mM concentrations, this molecule 
displayed no activity.  Further, it did not display activity when UNAG was added to 
the assay.  This compound did not appear as a hit in the initial 331 fragments and it is 
unclear whether this molecule was present in the initial 3,692 compounds virtually 
screened.   
Figure 40.  Virtual screen hits 267-270 and analog 271 tested for MurA inhibition 
 
2.4 Conclusions 
 The bacterial enzyme MurA was targeted for new antibiotic development.  A 
few inhibitors of the enzyme are known and only one, fosfomycin, is currently 
marketed as a therapeutic.  The limited applicability of fosfomycin coupled with a 
thorough understanding of the enzymatic role in bacteria presented an opportunity to 
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inhibitors with an HTS campaign that identified five scaffolds for further 
investigation.  The pyrrole-benzoic acid series was chosen for SAR development.  We 
synthesized 14 analogs using Clauson-Kaas methodology.  These analogs probed the 
role of the carboxylic acid and tolerance of other phenyl ring functionality.  Various 
N-heterocycles were also explored.  However, these analogs displayed no MurA 
inhibitory activity.  Subsequently, we turned to other investigatory tools to probe 
MurA.  Structure-based drug design using in silico screening of small molecules in 
various MurA X-ray structures identified four structurally similar molecules that 
could be used as starting points for further inhibitor discovery. 
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Chapter 3 
Synthesis and Initial Biological Evaluation of 2,3,7,8-Tetrachlorophenothiazine 
 
3.1 Background 
 Dioxins are environmental pollutants comprised of a polychlorinated aromatic 
structure, with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD (272)) being the one of 
the most potent congeners.  Formation of these toxic molecules occurs via various 
manufacturing processes, including chlorine bleaching of paper, via burning of solid 
waste, even resulting from volcanic eruptions and forest fires.278 These lethal 
chemicals enter the body mainly through the consumption of animal-based foods279 
but can also enter via inhalation of polluted air.  Highly chemically stable,280 their 
slow metabolism and excretion coupled with a highly lipophilic nature leads to the 
ready accumulation of dioxins in fat cells.  For example, TCDD has an elimination 
half-life of 7.8 years280 and a cLogP value of 7.05.  The calculated LD50 of six mg kg-
1 in humans makes TCDD especially dangerous281,282 yet widely studied because of 
its intriguing biological profile.  



















 Dioxins exert a range of biological activities dependent upon dose size.  At 
high doses, these compounds can be lethal by causing wasting syndrome283 or 
cancer.284 Medium dose effects include liver injury, immunosuppression,285 
debilitative reproductive effects,286 and reduced serum IGF-1 (insulin-like growth 
factor-1) levels.287 However, at low doses, TCDD has been shown to reduce age-
related tumor occurrence,284 reduce body weight288 and inhibit ovulation.289 A shift of 
body homeostasis could explain the biological activity differential in relation to 
potency.290 At low doses, dioxins could cause a slight fluctuation in body equilibrium.  
This flux forces the body to adapt by turning on or off certain pathways to eliminate 
the xenobiotic, affecting downstream biological pathways that lead to desirable 
therapeutic effects.  However, at high doses, the body could not recover from the 
influx of toxic xenobiotics and harmful side effects result.290 
 This broad range of biological effects has prompted various mechanism of 
action studies on dioxins.291-293 It is widely hypothesized that TCDD binds to the aryl 
hydrocarbon receptor (AhR) due to its planar geometry, exerting the observed 
biological effects through interaction with this receptor. The AhR is well known to 
bind planar molecules.  Indeed, TCDD is a strong AhR binder with a Ki of 0.54 
nM.294 However, recent evidence has challenged this hypothesis.295 Saturation of the 
rat AhR system by TCDD occurs at a dose of 0.2-0.3 µg/kg,296 but the LD50 is 10-50 
µg/kg for most rat variants,297 suggesting that binding to the AhR may occur but is 
not the ultimate source for dioxin toxicity.294 The AhR receptor can activate the p450 
enzyme CYP1A1.298,299 Activation of this enzyme could induce metabolism of 
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various carcinogens resulting in decreased cancer rates.284 Pharmaceutical companies 
view binding and activation of the CYP1A1 enzyme as disastrous for a prospective 
drug candidate because metabolites produced by this enzyme could be 
carcinogenic.300 However, case studies refute this school of thought.  The best 
example is a study published in 2005 by Rozman et al.301 A higher chlorinated dioxin, 
1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin, tested in rats was found to induce 
CYP1A1 but produced lower incidences of cancer compared to the control group.   
 Dioxins have been shown to decrease IGF-1 levels.287 IGF-1 is responsible for 
mediating a variety of body processes, such as stimulating mitosis, inhibiting 
apoptosis, stimulating glucose uptake and increasing protein biosynthesis.287 
Therefore, the reduction in body weight and inhibition of ovulation observed when 
TCDD is administered to female rats most likely results from reduced IGF-1 
levels.302,303 However, due to the wide range of bioactivity exerted by these 
molecules, it is possible that several mechanisms are responsible.  
 Given the therapeutic potential for a compound that could harvest the 
beneficial low-dose effects of dioxins while avoiding the harmful medium- and high-
dose effects, could a molecule be developed with these goals in mind?  Development 
of a TCDD analog, a tetra-chlorinated phenothiazine compound, served to probe this 
question.  Many factors made this bioisoelectronic approach desirable.  
Phenothiazines have been used as antihistaminic and antipsychotic drugs since the 
1930’s with the first antipsychotic phenothiazine, chlorpromazine (273, Figure 41), 
being approved by the FDA in 1954.281 While searching for novel antihistaminic and 
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antipsychotic therapeutics, researchers have carved out an extensive SAR for this 
class of compounds while demonstrating that these compounds generally possess 
accepTable absorption, distribution, metabolism, and excretion (ADME) properties – 
important for drug candidate development.281 The parent molecule of this class is a 
known anthelmintic compound,304 but analogs lacking substitution on the aniline 
nitrogen are generally unexplored due to the general lack of antihistaminic or 
antipsychotic activity.  Increased chlorine substitution on the phenothiazine ring 
system is also generally unexplored.  Another reason for choosing a phenothiazine as 
the basis for the analog is its non-planar butterfly molecular geometry.305 The 
dihedral angle, or fold angle, of these tricyclic molecules is defined as the angle 
between the bridging heteroatom and each of the phenyl rings.   Chlorpromazine 
displays a fold angle of 134°.305 Comparatively, the fold angle for TCDD is near 
180°.306 The non-planar geometrical orientation of phenothiazines should lead to 
decreased interaction with the AhR.  Hoping to meld the low-dose effects of dioxins 
with the ADME properties of phenothiazines, 2,3,7,8-tetrachlorophenothiazine 
(TCPT (274), Figure 41) was designed and synthesized. 
 
3.2 TCPT Synthesis 
 As phenothiazines have been known for many years, many methods exist for 
their synthesis (Figure 42).307,308 Each strategy relies upon the formation of a 
diphenyl-heteroatom (N or S) intermediate prior to phenothiazine ring closure.  No 
previous strategy consistently generates high yields (>50%) of the desired 
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heterocycle.  One of the harshest methods is the cyclization of diphenylamines in the 
presence of a sulfur reagent and a catalyst (method A).309 The triethyl phosphite-
mediated reductive cyclization of o-nitro-diphenylsulfides (method B), while 
generating decent yields of the desired product, is known to form rearranged products 
as side products.310 The requirement of a certain substitution pattern on the 
nitrophenyl ring of the diphenylsulfide starting material limits the Smiles 
rearrangement approach (method C).311 2-Azidodiphenylsulfide compounds undergo 
a rearrangement followed by loss of nitrogen gas under thermal conditions to afford 
phenothiazines (method D).308 Condensing thiozincate anilines with quinones 
substituted with a leaving group (LG) in the 2-position generates a cyclic imine 
intermediate that can then be reduced to generate the target tricyclic compounds 
(method E).308 The only proven transition metal catalyzed approach is the copper-
mediated Ullmann coupling (method F),312 also requiring high temperatures and 
generally resulting in low yields.  The application of many methodologies for 
phenothiazine synthesis suggests that a superior methodology has not yet been 
developed. 
 One previous synthesis of TCPT is reported in the literature in which 
unsubstituted phenothiazine is exposed to chlorine gas in the presence of a Friedel-
Crafts catalyst (D-X Li).313 Attempts to repeat this chemistry resulted only in the 
formation of 1,3,7,9-tetrachlorophenothiazine.314 A new route towards the synthesis 
of TCPT was subsequently designed.   
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Figure 42. Synthetic strategies for phenothiazine synthesis 
 
 The recently developed Buchwald-Hartwig coupling holds the potential as the 
superior technology for phenothiazine synthesis.249,251 This palladium-mediated 
carbon-heteroatom bond forming reaction has never been used in the synthesis of 
phenothiazines.  One limitation in the application of this strategy towards the 
synthesis of TCPT, as with any metal-catalyzed strategy, is the possibility for de-
chlorination at positions 2, 3, 7 or 8.  However, we reasoned that the Pd(0) species 







































either the sulfur or nitrogen atom, decreasing the probability of this deleterious side 
reaction.    
 Condensation of the commercially available 2,4,5-trichlorobenzenethiol (275) 
with 1,2-dichloro-4-fluoro-5-nitrobenzene (276) generated the diphenylsulfide 
compound (277) in 97% yield (Scheme 32).  Reduction of the nitro group with Fe 
filings in acetic acid (HOAc)315 yielded the aniline compound 278 prepped for the 
key cyclization step.  Before turning to the Buchwald-Hartwig reaction, we attempted 
to use the established Ullmann coupling technology312 to generate TCPT.  Refluxing 
diphenylsulfide 278, Cu powder, CuI, and Na2CO3 in DMF generated only 5% of the 
desired phenothiazine compound 274.  As all the starting material was consumed 
during the reaction, we reasoned that the product was being degraded by the reaction 
conditions leading to the observed low yields.  In an attempt to speed up the reaction 
and reduce the amount of degradation, we turned to microwave technology.  In fact, 
Ullmann couplings performed under microwave irradiation have been reported to 
decrease reaction time and increase yields.316 However, the Ullmann coupling of 278 
performed in the microwave returned only starting material.  Because of the 
confidence that long reaction times under harsh conditions degraded TCPT, we 
rationalized that a Buchwald-Hartwig coupling performed in the microwave would 
generate higher yields of TCPT. 
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Scheme 32.  Synthesis of TCPT 
 
 Due to the electronics and sterics of the cyclization substrate 278, specific 
parameters in a catalyst system were sought.  The strength of the aryl carbon-chloride 
bond generally makes the oxidative insertion of Pd(0) difficult.  However, based on 
studies performed by Buchwald and coworkers, we anticipated that the electron 
deficient nature of the trichlorosubstituted aryl ring would help to promote this step of 
the Pd catalytic cycle.251 The ortho-located thiobenzene group could sterically impede 
the Pd-insertion.  The Buchwald laboratories have also shown that substituents placed 
ortho to the desired reactive aryl C-halogen bond can be problematic.317 With these 
electronic and steric constraints in mind, a Pd-catalyst system using 2-
(dicyclohexylphosphino)-biphenyl (DCPB) as the ligand developed by Maes and 














































couple both activated and non-activated aryl chlorides, as well as sterically hindered 
aryl chlorides, under microwave irradiation.318,319 
 Table 15 summarizes the results for our Buchwald-Hartwig cyclization 
studies.  The reagents comprising the catalyst system were not altered during these 
studies.  We chose to focus on catalyst to substrate ratio, time, temperature, and 
solvent in the optimization of this reaction.  In a successful reaction employing a 10% 
catalyst loading ratio, 0.1 equivalents of Pd(OAc)2 and 0.2 equivalents of DCPB were 
dissolved in DMF and added to a DMF solution containing one equivalent of 
cyclization substrate 278 and 1.3 equivalents of NaOtBu.  The solution was flushed 
with argon for five minutes before heating.  Following microwave irradiation for two 
minutes at 200 °C, the starting material was completely consumed and TCPT was 
isolated in a 37% yield following column chromatography and recrystallization from 
CHCl3 (entry 3).  Reducing the reaction temperature and the amount of catalyst from 
10% to 1% (entries 1 and 2) gave no conversion to product, even after prolonged 
heating times.  Increasing the reaction time from two minutes led to decreased yields 
(entries 4 and 5), presumably due to degradation of the product as previously 
described.  The optimal solvent for the reaction was DMF.  Reactions in the less polar 
solvents dioxane and toluene failed to consume starting material.  To determine if 
microwave effects were responsible for the increased yields of TCPT, the reaction 
was performed using traditional oil bath heating (entry 6).  Following the addition and 
purging procedure previously described, diphenylsulfide 278 was heated at 150 °C 
for one h, a time and temperature corresponding to two minutes at 200 °C in the 
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microwave.  Despite the presence of starting material in the crude reaction as 
determined by TLC analysis, the reaction produced a 35% yield of TCPT following 
purification, demonstrating that no microwave effects were responsible for forming 
TCPT.   
Table 15. Optimization of reaction parameters for TCPT formation 
 
 Before TCPT could be tested in biological assays, an additional obstacle 
remained.  Degradation studies demonstrated that TCPT was light sensitive and 
unstable as a solid or as a solution in THF or acetone.  These facts help support our 
rationale behind the moderate yields realized in the cyclization reaction.  However, 
















Entry   Time(min.)            Temp (oC)         % Catalyst                         Yield
1              5                           150                     1                                No Reaction
2             10                          150                     1                                No Reaction
3              2                           200                    10                     37% after recrystallization
 
4              4                           200                    10                     27% after recrystallization
5              5                           200                    10                     26% after recrystallization
6             60                          150                    10                     35% after recrystallizationa
 a The reaction was run under normal reflux conditions.
278 274
 180 
3.3 Initial Biological Evaluation of TCPT 
 Prior to testing TCPT in in vitro and animal models, the crystal structure for 
TCPT was solved.  The crystal structure revealed a fold angle of 161.5° (Figure 43), 
hinting at the possibility for a decreased interaction with the AhR.  If there is a 
decreased interation with the AhR, downstream effects mediated by activation of the 
AhR, such as CYP1A1 induction, should also be reduced.   
Figure 43. Crystal structure of TCPT 
 
 TCPT was first evaluated in an ethoxyresorufin-O-deethylase (EROD) 
assay,320,321 an assay is commonly used to measure CYP1A1 activity.  As expected, 
TCDD induced CYP1A1 activity over time (Figure 44).  However, induction of the 
enzyme with TCPT decreased after 24 h with almost complete loss of activity after 72 
h.  This suggests that TCPT is metabolized to inactive compounds by hepatocytes.  
After 24 h, the ED50 for induction of EROD by TCDD was calculated to be 0.23 
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pg/well while TCPT was calculated at 85.1 pg/well – representing a 370-fold 
reduction in CYP1A1 induction potency for TCPT.  This loss in potency, however, 
was not completely mirrored by a loss in efficacy.  Maximal induction of EROD after 
24 h for TCDD was determined to be 637 pmol min-1 mg protein-1.  TCPT presented a 
maximum induction of 494 pmol min-1 mg protein-1 after 24 h, representing a 77.6% 
efficacy compared to TCDD. These findings show that the therapeutic window for 
CYP1A1 induction has been greatly broadened by TCPT compared with TCDD. 
Figure 44. In vitro EROD activity of TCDD (left, blue) and TCPT (right, green) 
 
 TCPT was evaluated in a radiolabel displacement assay to evaluate AhR 
binding.294 Displacement of 3H-TCDD by increasing concentrations of TCDD or 
TCPT determined the binding constant Ki.  The Ki’s for TCDD and TCPT were found 
to be 0.54 nM and 1.08 nM, respectively.294 Given the results of the EROD assay, 





































times higher than TCDD.  Methylcholanthrene is the only other compound known to 
display such a divergence between AhR binding and EROD activity.322 These results 
suggest that a more complicated mechanism exists between AhR binding and 
CYP1A1 induction.  Also, AhR binding may induce other enzymatic pathways 
leading to the demonstrated dioxin toxicity.  More investigation is necessary to 
address this issue.   
 As pharmacokinetics are an important aspect of drug development, TCPT was 
evaluated in rats and guinea pigs for distribution and elimination properties.  TCPT 
was administered to the animals via i.v. as an acetone solution.  Using classic curve 
feathering and a computational regression analysis following a two-compartment 
model analysis, TCPT was found to have a distribution half-life (t1/2) of 0.8 h and an 
elimination t1/2 of 5.4 h in rats (Figure 45).  In guinea pigs, these numbers were 0.4 h 
and 2.7 h, respectively (Figure 46).  The clinically used phenothiazine 273 has an 
elimination t1/2 of 9.1 h in similar rat strains,323 corresponding to a t1/2 of 30 h in 
humans.281 Correlating the known t1/2 of 273 in rats to TCPT’s determined t1/2 in rats 
suggests an elimination half-life of 18 h for humans.  This drastic decrease in t1/2 
cannot be attributed only to a decrease in the cLogP for TCPT compared to TCDD, as 
the cLogP’s vary by only 0.5 log units (7.05 for TCDD and 6.65 for TCPT).  The 
observed decrease achieves one of the goals for the design of TCPT – improved 
pharmacokinetics compared to TCDD. 
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Figure 45. Serum profile of TCPT in rats after i.v. administration 
 
 








 Achieving selectivity for the therapeutically beneficial low dose effects of 
dioxins over the harmful higher dose effects was explored with the development of 
TCPT.  The synthesis of this new phenothiazine compound was completed in a 31% 
overall yield over three steps utilizing a Buchwald-Hartwig coupling to perform the 
crucial ring-closing step.  This protocol had previously not been explored and should 
prove useful in future phenothiazine syntheses.  Initial biological evaluation of TCPT 
indicates that the compound has good pharmacokinetic properties.  While the analog 
was expected to bind substantially less to the AhR compared to TCDD due to its non-
linear molecular geometry, this hypothesis was proven incorrect in a competitive 
binding assay.  However, a dramatically lowered induction of EROD, suggesting 
lowered CYP1A1 activity, was seen for TCPT compared to TCDD.  This finding, 
coupled with the observed reduction in t1/2 for TCPT, suggests that the phenothiazine 
is being metabolized whereas TCDD generally is not.  These results prompt further 
biological investigation as TCPT is explored as both a tool to probe the source dioxin 




4.1 Materials and Methods 
 Melting points were determined using a melting point apparatus and are 
reported uncorrected.  Infrared (IR) spectra were recorded on an FT-IR instrument 
from thin films on NaCl plates.  Proton (1H) and carbon (13C) NMR experiments were 
recorded on either 400 or 500 MHz spectrometers as noted.  All chemical shifts are 
reported as parts per million (ppm) using the solvent residual peak as the internal 
standard.  Samples obtained in CDCl3 were referenced to 7.27 ppm for 1H and 77.0 
ppm for 13C.  Samples obtained in d6-DMSO were referenced to 2.50 ppm for 1H and 
39.5 ppm for 13C.  Coupling constants (J) are reported in Hz.  The multiplicities of the 
signals are assigned using the following abbreviations: s = singlet, d = doublet, t = 
triplet, q = quartet, qu = quintet, se = sextet, br = broad.  Optical rotations were 
recorded using a polarimeter at room temperature.  LRMS and HRMS were obtained 
using the electrospray ionization (ESI) technique. 
 Moisture sensitive reactions were run in flame-dried glassware under an 
atmosphere of nitrogen or argon unless otherwise specified.  THF, CH2Cl2, Et2O and 
toluene were dried and deoxygenated by passing the nitrogen-purged solvents through 
activated alumina columns on a solvent purification system.  DMF was similarly 
dried by passing through a column of activated 4Å molecular sieves.  5M HF/Py. 
solution was made by mixing HF/Py. (70% HF, 1 mL), Py. (2 mL), and THF (5 
mL).118 All other reagents and solvents were used as received from commercial 
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sources unless otherwise noted.  Reaction progress was monitored by thin layer 
chromatography (TLC, silica gel, 10 x 20 cm, 250 micron), visualizing with UV light 
(254 nm) and developing the plates with Hanessian’s stain (blue stain).  All 
compounds were purified by distillation or by column chromatography with 230-400 
mesh silica gel as described.  All compounds were concentrated using standard rotary 
evaporator and high-vacuum techniques. HPLC analysis was conducted on an HPLC 
system equipped with a photodiode array detector according to the conditions 
described.  UPLC-MS analysis was used to determine product purities prior to 
biological testing where noted. 
 
4.2 Biological Procedures 
Cytotoxicity Assay.  The human cancer cell lines SK-Mel-5 and SK-Mel-28 were 
obtained from the NCI and grown in normal RPMI 1640 culture medium containing 
10% fetal bovine serum.  The cells, in exponential-phase maintenance culture, were 
dissociated with 0.25% trypsin and harvested at 125xg for five min.  Trypsin was 
removed and the cells were resuspended in new culture medium.  The cell density 
was adjusted to 1 x 105 and dispensed in triplicate on 96-well plates in 50 µL 
volumes.  After incubation overnight at 37 °C under 5% CO2, 50 µL of culture 
medium containing various concentrations of the test compounds were added.  
Paclitaxel (Taxol®) and colchicine were used as positive controls.  After 48 h 
incubation, the relative cell viability in each well was determined by using the 
AlamarBlue Assay Kit.  Optical densities were then measured photometrically 
 187 
(excitation = 530 nm, emission = 590 nm) on the plate reader.  The IC50 of each 
compound was determined by fitting the relative viability of the cells to the drug 
concentration using a dose-response model. 
MurA Inhibition Assay.212 Inhibition studies were performed by assaying the 
activity of MurA in 100 µL of 50 mM HEPES (pH = 7.5) and two mM dithiothreitol 
at 20 °C when exposed to varying concentrations of the inhibitor by determining the 
amount of phosphate produced in the reaction using the Lanzetta reagent.  The 
Lanzetta reagent was prepared using plastic-ware according to the literature 
protocol.237 All assays were started with the addition of MurA to a solution containing 
one mM PEP, 0.025 – five mM UNAG and various concentrations of a DMSO 
solution of the inhibitor.  The enzyme, substrates and inhibitors were allowed to react 
for 3 min before addition of 800 µL of the Lanzetta reagent, which halted the 
reaction.  Color development was stopped after five min by the addition of 100 µL of 
34% (w/v) sodium citrate.  Changes in optical density were measured at 660 nm using 
a spectrometer.  The amount of phosphate produced in the reaction was determined 
by comparison to phosphate standards.  The relative activity was determined by 
comparing the optical density of the enzyme solution lacking inhibitor to solutions 
containing inhibitors.  Data evaluation was performed with SigmaPlot (SPSS Science, 




where ν is the initial velocity, Vmax is the maximum velocity, Vmin is the minimum 
velocity, [I] is the concentration of inhibitor and n is the hill slope. 
In Vitro Enzyme Induction.324 An in vitro ethoxyresorufin-O-deethylase (EROD) 
assay was conducted with H4IIEC/T3 rat hepatoma cells320,321 in 96-well plates 
according to standard procedures.325 Cells were plated at a density of about 10,000 
cells/well and cultured for 72 h prior to exposure.  TCPT was then added in 
concentrations of 0.25–256 pg/well (2.5–2560 ng/L). TCDD served as positive 
control in concentrations of 0.015–0.4 pg/well (0.15–4 ng/L). Plates were incubated 
at 37 °C and 7% CO2 for 24, 48, and 72 h. After incubation, media was discarded and 
hepatocytes were exposed to 7-ethoxyresorufin for 30 min. Subsequently, the 
generated resorufin was quantified by detecting fluorescence at 590 nm after 
excitation at 535 nm. Protein content was measured with the bicinchoninic acid 
protein assay and absorption was measured at 540 nm.326 Cytotoxicity was 
determined by the resazurine assay.  Data was processed using the Microsoft Excel 
Solver option, which was applied to yield a sigmoidal regression to a four-parameter 
equation. Each concentration was measured in quadruplicate and error bars depict the 
standard deviation. 
Serum Kinetic in Rats and Guinea Pigs after Intravenous Injection.  All animal 
studies were approved by the University of Kansas Medical Center Institutional 
Animal Care and Use Committee. Female Sprague-Dawley rats (228 – 264 g) and 







female Dunkin-Hartley guinea pigs (445 – 461 g) were purchased from Harlan, 
Indianapolis, Indiana, and Charles River Laboratories, Wilmington, Maine, 
respectively.  Animal numbers were two per species, based on inherently low 
interindividual variability regarding kinetics. In both species, the Vena jugularis was 
cannulated by the supplier. Animals were housed in a climate-controlled facility with 
12 h dark/light cycle and ad libidum access to feed and water. Rats were administered 
five mg/kg TCPT i.v. in freshly prepared acetone solution (1 mL acetone/kg), guinea 
pigs received 10 mg/kg TCPT i.v. in acetone (0.5 mL/kg). Blood samples were drawn 
in 500 mL volumes from both species at 0.25, 0.50, 1, 2, 4, 8, 16, and 24 h, and 36 h 
(guinea pigs only) after dosing and stored on ice. The sample volume withdrawn was 
replaced by saline injections. Coagulated blood samples were centrifuged at 9,000 g 
at 4 °C for 16 min, and serum stored at -80 °C until analysis.  
 Analytics were performed by reverse-phase HPLC, using a 655A-11 liquid 
chromatograph, L-5000 LC controller with D-6000 interface, L-3000 photo diode 
array detector, and the software D-6000 HPLC Manager version 2 (Merck-Hitachi, 
Darmstadt, Germany). The analytical column Nukleosil C18 5µ, 250 x 4.0 mm (VDS 
Optilab Chromatographie Technik GmbH, Berlin, Germany) was temperature-
controlled at 25 °C and protected by an upstream Security Guard C18 ODS 4 x 3 mm 
(Phenomenex, Aschaffenburg, Germany). All samples were prepared online using the 
alkyl-diol-silica (ADS) technology developed by Boos et al.327,328 The cartridge 
employed was LiChroCART 25-4 LiChrospher RP-4 ADS, generously provided by 
Prof. Dr. Boos, Klinikum Großhadern, Ludwig-Maximilians-Universität München, 
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Germany and protected by an upstream inline filter ADS (Merck KGaA, Darmstadt, 
Germany). Solvents for analytics (water and MeOH) were of HPLC grade (Fisher 
Scientific, Loughborough, Leicestershire, UK). Calibration was conducted with nine 
concentrations from 0.01–20 µg/mL TCPT in rat serum (R2 = 0.99) and five standards 
of 0.1–20 µg/mL in guinea pig serum (R2 = 0.99). Limit of quantification was set at 
0.05 µg/mL.  Curve regression was performed by manual curve feathering and 
computational regression according to one–compartment (Cp = C1e-k-1t), two-
compartment (Cp = C1e-k-1t  + C2e-k-2t), and three-compartment models (Cp = C1e-k-1t + 
C2e-k-2t+ C3e-k-3t) using Sigma Plot 4.0 (SPSS Inc., Chicago, Illinois), where Cp = 
concentration in plasma, C1,2,3 = concentrations in compartments, k-1,-2,-3 = 
compartmental rate constants, and t = time. 
 
4.3  Experimental Procedures 
4.3.1 Chapter 1 
 
5-Hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (116).  2,6-
Dihydroxybenzoic acid 113 (10.0 g, 64.9 mmol) and DMAP (0.396 g, 3.25 mmol) 
were dissolved in anhydrous DME (22.0 mL) in a three-neck flask equipped with an 





followed by dropwise addition of SOCl2 (6.60 mL, 90.8 mmol) from a plastic needle 
over a one h period, ensuring that the internal reaction temperature never rose higher 
than 30 °C.  After addition of the SOCl2, the reaction was stirred for one h then 
concentrated by blowing a stream of air into the flask.  The crude, red material was 
then subjected to flash column chromatography (hexanes/EtOAc, 100:0 – 85:15) to 
yield 9.03 g of an off-white solid (72%). TLC (hexane/EtOAc, 80:20): Rf = 0.60.  
Spectral data was identical to literature reported values:143 1H NMR (400 MHz, 
CDCl3) δ 10.34 (s, 1H), 7.41 (t, J = 8.2 Hz, 1H), 6.63 (dd, J = 8.2, 0.8 Hz, 1H), 6.44 
(dd, J = 8.2, 0.8 Hz, 1H), 1.75 (s, 6H). 
 
2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl Trifluoromethanesulfonate (63).  
The acetonide phenol 116 (865 mg, 4.45 mmol) was dissolved in CH2Cl2 (18.0 mL) 
and cooled to 0 °C.  To this solution was added Et3N (0.750 mL, 5.34 mmol) 
dropwise followed by a slow, dropwise addition of Tf2O (0.900 mL, 5.34 mmol).  
After stirring for 45 min, the volatiles were removed by rotary evaporation and the 
crude material was subjected to flash column chromatography (hexanes/EtOAc, 
80:20) to yield 1.29 g of a pale yellow solid (89%). TLC (hexane/EtOAc, 80:20): Rf = 





CDCl3) δ 7.65 (t, J = 8.2 Hz, 1H), 7.14 (dd, J = 8.2, 1.0 Hz, 1H), 7.02 (d, J = 8.2 Hz, 
1H), 1.75 (s, 6H). 
 
  (E)-2,2-Dimethyl-5-(2-(trimethylsilyl)vinyl)-4H-benzo[d][1,3]dioxin-4-one (115).  
To a DMSO (246 mL) solution of the aryl triflate 63 (8.02 g, 24.6 mmol) was added 
Pd(OAc)2 (0.55 g, 2.46 mmol), vinyl(trimethyl)silane (10.7 mL, 73.8 mmol), and 
triethylamine (10.3 mL, 73.8 mmol).  The mixture was heated at 55 °C for 2.5 h, then 
cooled to room temperature.  The reaction was diluted with water and extracted with 
50:50 hexanes/Et2O (3x).  The combined organic extracts were washed with brine, 
dried over MgSO4 and purified via flash column chromatography (hexanes/EtOAc, 
100:0 – 90:10) to provide 5.76 g of the desired compound as a white powder (85%). 
TLC (hexane/EtOAc, 80:20): Rf = 0.65; IR (thin film) υmax = 2999, 2955, 1739, 1603, 
1573, 1389, 1317, 1277,1248, 1204, 1044, 867, 842 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.93 (d, J = 19 Hz, 1H), 7.45 (dt, J = 8.0, 0.8 Hz, 1H), 7.31 (d, J = 8.0 Hz, 
1H), 6.86 (dd, J = 8.0, 0.8 Hz, 1H), 6.47 (d, J = 19 Hz, 1H), 1.71 (s, 6H), 0.19 (s, 
9H); 13C NMR (100 MHz, CDCl3) δ 160.2, 156.6, 143.3, 141.8, 135.0, 134.9, 121.3, 
116.3, 110.8, 105.2, 25.6, -1.3; HRMS (ESI+), m/z calcd for C15H21O3Si: 277.1260 






 (E)-5-(2-Iodovinyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (108).  The vinyl 
silane 115 (1.00 g, 3.62 mmol) was dissolved in anhydrous MeCN (36.2 mL) and the 
flask wrapped in aluminum foil to prevent light exposure.  N-Iodosuccinimide (4.00 
g, 18.1 mmol) was added in one portion and the reaction stirred for eight h at room 
temperature.  The reaction was diluted with a saturated solution of Na2SO3 and 
extracted with EtOAc (3x).  The combined organic extracts were washed with brine, 
dried over MgSO4 and purified via flash column chromatography (hexanes/EtOAc, 
100:0 – 90:10) to provide 1.09 g of the desired compound as a white powder (91%). 
TLC (hexane/EtOAc, 80:20): Rf = 0.50; IR (thin film) υmax = 3059, 2996, 1738, 1606, 
1571, 1477, 1319, 1268, 1230, 1211, 1047, 941, 818 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.45 (d, J = 15 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.12 (d, J = 7.8 Hz, 1H), 
6.92 (dd, J = 8.2, 0.7 Hz, 1H), 6.87 (d, J = 15 Hz, 1H), 1.72 (s, 6H); 13C NMR (100 
MHz, CDCl3) δ 160.0, 156.7, 143.1, 141.3, 135.4, 121.5, 117.2, 110.0, 105.5, 80.9, 
25.6; HRMS (ESI+), m/z calcd for C12H12O3I: 330.9831 (M+H); found, 330.9832; 







3-(tert-Butyldiphenylsilyloxy)propan-1-ol (119).  To a rapidly stirring suspension of 
NaH (2.14 g, 53.5 mmol, 60% suspension in mineral oil) in anhydrous THF (107 mL) 
at room temperature was slowly added 1,3-propanediol (118) (3.87 mL, 53.5 mmol).  
After stirring for approximately 45 min, during which time a substantial amount of 
white precipitate had formed, TBDPSCl (14.0 mL, 54.6 mmol) was slowly added.  
Vigorous stirring continued for two h, after which time the solution was poured into 
Et2O, washed with 10% K2CO3 solution, water and brine.  The ethereal layer was 
dried over MgSO4, concentrated and purified by flash column chromatography 
(Hexanes:EtOAc 100:0 – 70:30) to yield 15.8 g of the title compound (94%).  
Spectral data was identical to literature reported values:149 1H NMR (400 MHz, 
CDCl3) δ 7.68-7.66 (m, 4H), 7.46-7.38 (m, 6H), 3.87-3.83 (m, 4H), 2.36 (t, J = 5.6 
Hz, 1H), 1.81 (qu, J = 5.6 Hz, 2H), 1.05 (s, 9H). 
 
3-(tert-Butyldiphenylsilyloxy)propanal (120).  Alcohol 119 (4.70 g, 14.9 mmol) 
was dissolved in CH2Cl2 (140 mL) at room temperature and Dess-Martin periodinane 
(121a, prepared according to Ireland132) (9.50 g, 22.4 mmol) added in one portion.  
After 30 min of stirring, the reaction mixture was filtered through a plug of silica gel, 
eluted with hexanes/EtOAc (80:20) to give 4.4 g of the crude aldehyde (94%) that 




identical to literature reported values:149 1H NMR (400 MHz, CDCl3) δ 9.83 (t, J = 
2.3 Hz, 1H), 7.65-7.63 (m, 4H), 7.45-7.37 (m, 6H), 4.03 (t, J = 6.0 Hz, 2H), 2.60 (td, 
J = 6.0, 2.3 Hz, 2H), 1.05 (s, 9H). 
 
(E)-Ethyl 5-(tert-Butyldiphenylsilyloxy)pent-2-enoate (121).  To a room 
temperature solution of triethylphosphonoacetate (18.3mL, 91.2 mmol) in anhydrous 
THF (560 mL) was added MeMgBr (65.0 mL, 91.2 mmol, 1.4M in 3:1 toluene/THF) 
dropwise.  This mixture was stirred for 15 min, after which time a solution of 
aldehyde 120 (29.6 g, 94.7 mmol in 400 mL THF) was added dropwise over the 
course of 30 min. This mixture was heated at reflux for one h, then cooled to room 
temperature and quenched with an aqueous solution of NH4Cl.  The mixture was 
extracted with Et2O (3x).  The combined organic extracts were washed with brine, 
dried over MgSO4 and concentrated. Purification by flash column chromatography 
(hexanes/Et2O 100:0 – 95:5) yielded 24.0 g of the pure trans-ester (65%). Crude 
NMR revealed 40:1 E:Z enoate ratio.  Spectral data was identical to literature reported 
values:149 1H NMR (400 MHz, CDCl3) δ 7.71-7.64 (m, 4H), 7.45-7.35 (m, 6H), 6.98 
(td, J = 16, 7.2 Hz, 1H), 5.85 (d, J = 16 Hz, 1H), 4.18 (q, J = 7.2 Hz, 2H), 3.75 (q, J = 





(E)-5-(tert-Butyldiphenylsilyloxy)pent-2-en-1-ol (122). The ester 121 (13.7 g, 35.8 
mmol) was dissolved in anhydrous toluene (143 mL) and cooled to -60 °C.  DIBAL 
(80 mL, 80.0 mmol, 1M in hexanes) was added dropwise over 30 min, after which 
stirring continued for two h followed by warming to 0 °C and additional stirring for 
two h.  The reaction was quenched by the addition of EtOAc followed by water (32 
mL) with stirring for 15 min, 2N NaOH solution (32 mL) with stirring for 15 min, 
and water (8 mL) with stirring for 15 min.  The complexed aluminates were 
sequestered by the slow addition of solid MgSO4 (Caution: reaction is exothermic) 
with stirring for two h at room temperature.  The solids were filtered off and rinsed 
with EtOAc.  The crude material was subjected to flash column chromatography 
(hexanes/EtOAc, 80:20) to yield 11.2 g of the desired allylic alcohol 1 as a yellow oil 
(92%): TLC (hexanes/EtOAc, 80:20): Rf = 0.15; Spectral data was identical to 
literature reported values:149 1H NMR (400 MHz, CDCl3) δ 7.68-7.65 (m, 4H), 7.44-
7.35 (m, 6H), 5.67 (m, 2H), 4.09-4.05 (m, 2H), 3.71 (t, J = 6.4 Hz, 2H), 2.33-2.28 (m, 
2H), 1.29-1.15 (m, 1H), 1.05 (s, 9H). 
 
(2S,3S)-5-(tert-Butyldiphenylsilyloxy)pentane-1,2,3-triol (123).  AD mix-α (28.0 






volume) at room temperature. MeSO2NH2 (2.66 g, 22.4 mmol) was added in one 
portion and the resulting heterogeneous mixture was stirred until homogenous, after 
which time the solution was cooled to 0 °C.  The olefin 122 (7.62 g, 22.4 mmol) was 
dissolved in tBuOH (80 mL with two 10 mL flask rinses) and added to the reagent 
solution.  Water (100 mL) was then added and the solution stirred in the refrigerator 
(2-4 °C) for 24 h.  The reaction was quenched with solid sodium sulfite (28.0 g) and 
stirred for one h, after which time the reaction was extracted with EtOAc (3x).  The 
combined organic extracts were washed with brine, dried over MgSO4 and purified 
via flash column chromatography (hexanes/EtOAc, 70:30 – 50:50) to give 7.99 g of 





25  = +3.56 (c = 1.01, CHCl3); IR (thin film) υmax = 3360 (br), 2954, 2930. 
2887, 1632, 1427, 1321, 1138, 1111, 1090, 702 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.68-7.66 (m, 4H), 7.47-7.38 (m, 6H), 4.02-3.98 (m, 1H), 3.92-3.88 (m, 2H), 3.75-
3.73 (m, 2H), 3.69 (d, J = 2.8 Hz, 1H), 3.58-3.54 (m, 1H), 2.92 (d, J = 6.4 Hz, 1H), 
2.31 (t, J = 6.0 Hz, 1H), 1.99-1.90 (m, 1H), 1.71-1.65 (m, 1H), 1.06 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 135.5, 135.5, 130.0, 130.0, 127.9, 73.7, 72.9, 64.8, 63.0, 





dioxan-5-ol (124). Triol 123 (4.30 g, 11.6 mmol) was dissolved in MeCN (232 mL) 
and stirred at room temperature.  PPTS (1.40 g, 5.80 mmol) was added in one portion 
followed by p-methoxybenzyl-dimethyl acetal (2.00 mL, 13.9 mmol).  After stirring 
for 15 min, the reaction mixture was poured into water, extracted with Et2O (3x) and 
the combined organic extracts washed with brine, dried over MgSO4 and 
concentrated.  The product mixture was subjected to flash column chromatography 
(hexanes/EtOAc, 90:10 – 75:25) and only pure fractions containing the desired 
product were collected for use in the subsequent reaction, resulting in 1.20 g of the 
acetal as a colorless oil (21%).  The remaining mixed fractions were collected (3.02 g, 
74% total yield) allowed to remain on the benchtop for 2 weeks, and then subjected to 
flash column chromatography as before.  This recycling process could be repeated 
many times over the course of 6-12 months. A clear oil: IR (thin film) υmax 3437 (br), 
2957, 2930, 2856, 1614, 1518, 1427, 1385, 1250, 1111, 1086, 1034 cm-1; HRMS 










4-yl)ethoxy)diphenylsilane (127).   MOMCl (0.081 mL, 0.64 mmol) was added to a 
0 °C pre-cooled solution of the acetal 124 (52 mg, 0.11 mmol) in DIPEA (0.53 mL) 
and stirred overnight with gradual warming to room temperature.  After stirring for 15 
h, EtOAc was added to the solution and washed with water.  The aqueous layer was 
extracted with EtOAc (2x), and the combined organic extracts were washed with 
brine, dried over MgSO4 and subjected to flash column chromatography 
(hexanes/EtOAc 90:10 – 80:20) to give 52 mg of the title compound (91%) as a 




25  = +0.900 (c = 2.03, 
CHCl3); IR (thin film) υmax = 2957, 2932, 2887, 2856, 1616, 1518, 1427, 1250, 1151, 
1095, 1036, 702 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.68-7.63 (m, 4H), 7.42-7.37 
(m, 6H), 7.32-7.28 (m, 2H), 6.86 (d, J = 8.8 Hz, 2H), 5.51 (s, 1H), 4.82 (d, J = 7.0 
Hz, 1H), 4.67 (d, J = 7.0 Hz, 1H), 4.37 (dd, J = 12, 1.3 Hz, 1H), 4.25 (m, 1H), 3.97 
(d, J = 9.0 Hz, 1H), 3.96-3.90 (m, 1H), 3.81-3.78 (m, 1H), 3.80 (s, 3H), 3.40 (s, 4H), 
2.15-2.08 (m, 1H), 1.89-1.81 (m, 1H), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 






101.1, 95.4, 75.5, 70.4, 69.4, 59.4, 55.8, 55.3, 34.3, 26.9, 19.3; HRMS (ESI+), m/z 
calcd for C31H40O6SiNa: 559.2492 (M+Na); found, 559.2480. 
 
(2R,3S)-Ethyl 5-(tert-Butyldiphenylsilyloxy)-2,3-dihydroxypentanoate (112). AD 
mix-α (20.3 g) was suspended in a vigorously stirred water/tBuOH mixture (1:1, 80 
mL total volume) at room temperature. MeSO2NH2 (1.61 g, 16.9 mmol) was added in 
one portion and the resulting heterogeneous mixture was stirred until homogenous, 
after which time the solution was cooled to 0 °C.  The olefin 121 (6.48 g, 16.9 mmol) 
was dissolved in tBuOH (30.0 mL with two 8.00 mL flask rinses) and added to the 
reagent solution.  Water (40.0 mL) was then added and the solution stirred in the 
refrigerator (2-4 °C) for 15 h.  The reaction was quenched with solid sodium sulfite 
(20.3 g) and stirred for one h, after which time the reaction was extracted with EtOAc 
(3x).  The combined organic extracts were washed with brine, dried over MgSO4 and 
purified via flash column chromatography (hexanes/EtOAc, 80:20 – 70:30) to give 




25  = -10.8 (c = 1.09, CHCl3); IR (thin film) υmax = 3475 (br), 1737, 1428, 1212, 
1112, 1028, 703 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.68-7.66 (m, 4H), 7.44-7.37 
(m, 6H), 4.30 (q, J = 7.2 Hz, 2H), 4.29-4.24 (m, 1H), 4.08 (dd, J = 6.8, 2.0 Hz, 1H), 
3.93-3.83 (m, 2H), 3.12 (d, J = 6.8 Hz, 1H), 2.96 (d, 5.7 Hz, 1H), 2.04-1.95 (m, 1H), 





CDCl3) δ 173.4, 135.7, 135.7, 133.3, 133.1, 130.0, 130.0, 127.9, 73.7, 71.8, 62.4, 
62.1, 35.5, 27.0, 19.2, 14.3; HRMS (ESI+), m/z calcd for C23H33O5Si (M+H): 
417.2097; found, 417.2086; Chiral HPLC analysis (Diacel Chiracel OD (250 mm x 
4.6 mm), 5% iPrOH in hexanes, one mL/min, 254 nm, major isomer, tR = 14.9 min, 
minor isomer, tR = 12.2 min, e.r. = 89:11). 
 
 (4R,5S)-Ethyl 5-(2-(tert-Butyldiphenylsilyloxy)ethyl)-2-(4-methoxyphenyl)-1,3-
dioxolane-4-carboxylate (129). Diol ester 112 (14.1 g, 33.8 mmol) was dissolved in 
MeCN (169 mL) at room temperature.  To this solution was added PPTS (4.25 g, 16.9 
mmol) then p-methoxybenzyl-dimethyl acetal (13.0 mL, 77.8 mmol).  The mixture 
was stirred for 45 min, after which time the reaction was quenched with water and 
extracted with Et2O (3x).  The combined organic extracts were washed with brine, 
dried over MgSO4 and concentrated.  The crude material was partially purified via 
flash column chromatography (hexanes/EtOAc, 100:0 – 85:15).  The mixed fractions 
containing the desired acetal 129 and p-methoxybenzaldehyde were collected, re-
dissolved in CH2Cl2 and stirred with PS-TsNHNH2 until no p-methoxybenzaldehyde 
was detected by TLC analysis.  The polystyrene beads were removed by vacuum 








acetal ester was collected as a bright yellow oil (93%): TLC (hexanes/EtOAc, 70:30): 




25  = -7.4 (c = 0.89, CHCl3); IR (thin film) υmax = 1735, 1615, 1250, 
1112, 1034 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.68-7.65 (m, 4H), 7.50 (d, J = 7.6 
Hz, 1H), 7.42-7.35 (m, 7H), 6.92-6.88 (m, 2H), 5.95 (s, 1H), 4.63-4.61 (m, 0.5H), 
4.43-4.38 (m, 1.5H), 4.30-4.22 (m, 2H), 3.90-3.85 (m, 2H), 3.81 (s, 3H), 2.14-2.12 
(m, 0.5H), 2.05-1.99 (m, 1.5H), 1.32-1.27 (m, 3H), 1.04 (d, J = 3.6 Hz, 9H); 13C 
NMR (100 MHz, CDCl3) δ 171.1, 160.6, 135.5, 133.6, 133.5, 129.6, 128.5, 128.3, 
127.6, 113.7, 104.7, 104.2, 79.2, 78.6, 77.8, 77.1, 61.4, 60.2, 60.1, 55.3, 36.5, 35.8, 
26.8, 26.8, 19.2, 14.2, 14.2; HRMS (ESI+), m/z calcd for C31H39O6Si: 535.2516 
(M+H); found, 535.2502. 
 
(2S,3S)-5-(tert-Butyldiphenylsilyloxy)-3-(4-methoxybenzyloxy)pentane-1,2-diol 
(130).  The acetal ester 129 (6.20 g, 11.6 mmol) was dissolved in anhydrous CH2Cl2 
(116 mL) and cooled to -78 °C.  DIBAL (81 mL, 81.0 mmol, 1M in hexanes) was 
added dropwise over 30 min, after which stirring continued for three h followed by 
warming to 0 °C and additional stirring for two h.  The reaction was quenched by the 
addition of EtOAc followed by water (32 mL) with stirring for 15 min, 2N NaOH 
solution (32 mL) with stirring for 15 min, and water (8 mL) with stirring for 15 min.  
The complexed aluminates were sequestered by the slow addition of solid MgSO4 





solids were filtered off and rinsed with EtOAc.  The crude material was subjected to 
flash column chromatography (hexanes/EtOAc, 80:20 – 50:50) to yield 3.98 g of the 





= +22.7 (c = 1.05, CHCl3); IR (thin film) υmax = 3430 (br), 1612, 1248, 1111, 1023 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.67-7.64 (m, 4H), 7.45-7.36 (m, 6H), 7.17 (dd, 
J = 6.8, 2.0 Hz, 2H), 6.84 (dd, J = 6.8, 2.0 Hz, 2H), 4.55 (d, J = 11 Hz, 1H), 4.37 (d, J 
= 11 Hz, 1H), 3.79 (m, 5H), 3.70 (dd, J = 10, 6.0 Hz, 1H), 3.62 (br m, 3H), 2.75 (br, 
1H), 2.14 (br, 1H), 1.86 (m, 2H), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 159.4, 
135.6, 133.5, 133.4, 130.1, 129.8, 129.6, 127.7, 113.9, 72.9, 72.0, 64.1, 60.2, 55.3, 




Ethanoate (131).  The diol 130 (1.63 g, 3.29 mmol) was dissolved in freshly distilled 
2,6-lutidine (16.5 mL) and cooled to 0 °C.  Freshly distilled AcCl (0.258 mL, 3.62 
mmol) was added dropwise.  After 30 min, EtOAc and 1N HCl were added and the 
solution stirred for one h with warming to room temperature.  The organic layer was 
washed with 1N HCl solution (1x), then brine and dried over MgSO4.  The crude 
material was purified by flash column chromatography (hexanes/EtOAc, 90:10 – 









25  = +13.3 (c = 1.25, CHCl3); IR (thin film) 
υmax = 3467 (br), 1740, 1612, 1250, 1112, 1023 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.67-7.64 (m, 4H), 7.45-7.36 (m, 6H), 7.18 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.4 Hz, 
2H), 4.55 (d, J = 11 Hz, 1H), 4.42 (d, J = 11 Hz, 1H), 4.13 (d, J = 5.6 Hz, 2H), 3.83-
3.77 (m, 6H), 3.76-3.72 (m, 1H), 2.60 (d, J = 6.4 Hz, 1H), 2.05 (s, 3H), 1.94-1.79 (m, 
2H), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 171.0, 159.4, 135.6, 135.5, 133.4, 
130.1, 129.8, 129.6, 127.7, 113.9, 75.3, 72.3, 71.1, 65.7, 60.1, 55.3, 33.3, 26.9, 20.9, 
19.2; HRMS (ESI+), m/z calcd for C31H41O6Si: 537.2672 (M+H); found, 537.2665. 
 
(2S,3S)-5-(tert-Butyldiphenylsilyloxy)-3-(4-methoxybenzyloxy)-2-
(methoxymethoxy)pentyl Ethanoate (132).  The secondary alcohol 131 was 
dissolved in freshly distilled DIPEA and cooled to 0 °C.  MOMCl was added and the 
reaction stirred for 15 h with gradual warming to room temperature.  The reaction 
was diluted with water, extracted with EtOAc (3x).  The combined organic extracts 
were washed with brine, dried over MgSO4 and purified by flash column 
chromatography (hexanes/EtOAc, 80:20) to collect the title compound as a colorless 
oil (Note: in practice, the crude material was taken on to the acetate hydrolysis step 




25  = -17.2 





NMR (400 MHz, CDCl3) δ 7.67-7.63 (m, 4H), 7.44-7.34 (m, 6H), 7.18 (td, J = 8.4, 
2.0 Hz, 2H), 6.82 (td, J = 8.4, 2.0 Hz, 2H), 4.69 (dd, J = 16, 6.8 Hz, 2H), 4.51 (dd, J = 
29, 11 Hz, 2H), 4.29 (dd, J = 12, 3.6 Hz, 1H), 4.13 (dd, J = 12, 6.8 Hz, 1H), 3.94-3.86 
(m, 2H), 3.82-3.74 (m, 5H), 3.36 (s, 3H), 2.03 (s, 3H), 1.96-1.87 (m, 1H), 1.72-1.4(m, 
1H), 1.05 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 170.8, 159.2, 135.6, 133.7, 130.4, 
129.7, 129.6, 127.7, 127.7, 113.8, 96.7, 75.8, 74.5, 72.5, 64.0, 60.2, 55.7, 55.3, 32.9, 




(methoxymethoxy)pentan-1-ol (128).  To a solution of the protected tetrol 132 (1.48 
g, 2.55 mmol) in MeOH (26 mL) was added K2CO3 (3.5 g, 25.5 mmol) at room 
temperature.  The mixture was stirred for two h, diluted with water and extracted with 
EtOAc.  The combined organic extracts were washed with brine and dried over 
MgSO4 to yield 1.28 g (2.37 mmol) of the title compound as a colorless oil (93%).  
Alternatively: Acetonide 127 (788 mg, 1.47 mmol) was dissolved in 29 mL of CH2Cl2 
and cooled to -78 °C.  DIBAL (4.40 mL, 4.40 mmol, 1M in hexanes) was added 
dropwise over 30 min with vigorous stirring.  After one h, the solution was warmed to 
-40 °C and stirred at this temperature for six h.  EtOAc was then added to the reaction 





for 15 min, followed by addition of 2N NaOH solution (1.8 mL) with stirring for 15 
min, and finally addition of water (0.44 mL) with stirring for 15 min.  The complexed 
aluminates were sequestered by the slow addition of solid MgSO4 (Caution: reaction 
is exothermic) with stirring for at least two h at room temperature.  The solids were 
filtered off and rinsed with EtOAc.  The crude material was subjected to flash column 
chromatography (hexanes/EtOAc, 80:20 – 70:30) to yield 720 mg of the desired diol 




25  = -12.0 (c = 
1.00, CHCl3); IR (thin film) υmax = 3470 (br), 2955, 2932, 1612, 1514, 1248, 1109, 
1036, 702 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.67-7.63 (m, 4H), 7.43-7.35 (m, 6H), 
7.17 (dt, J = 8.4, 2.0 Hz, 2H), 6.82 (dt, J = 8.4, 2.0 Hz, 2H), 4.73 (d, J = 6.8 Hz, 1H), 
4.64 (d, J = 6.8 Hz, 1H), 4.48 (dt, J = 11, 5.2 Hz, 2H),3.85-3.80 (m, 1H), 3.78 (s, 3H), 
3.78-3.70 (m, 2H), 3.69-3.62 (m, 3H), 3.40 (s, 3H), 2.89 (br m, 1H), 1.92-1.85 (m, 
1H), 1.75-1.67 (m, 1H), 1.05 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 157.9, 134.2, 
132.3, 132.3, 128.9, 128.3, 126.3, 112.4, 96.0, 79.9, 74.3, 71.0, 61.4, 58.9, 54.4, 53.8, 




(methoxymethoxy)pentanal (111).  To a solution of the alcohol 128 (813 mg, 1.51 





room temperature.  The reaction was stirred for 20 min, diluted with EtOAc, washed 
with saturated NaHCO3 solution (2x), washed with brine, dried over MgSO4 and 
purified by flash column chromatography (hexanes/EtOAc, 80:20) to collect 715 mg 





25  = +1.60 (c = 1.20, CHCl3); IR (thin film) υmax = 2954, 2932, 2889, 2856, 
1734, 1612, 1514, 1248, 1111, 1038, 702 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.67 (s, 
1H), 7.65-7.62 (m, 4H), 7.45-7.36 (m, 6H), 7.16 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.4 
Hz, 2H), 4.72 (d, J = 6.8 Hz, 1H), 4.65(d, J = 6.8 Hz, 1H), 4.47 (s, 2H), 4.13-4.11 (br 
m, 1H), 3.97 (d, J = 4.0 Hz, 1H), 3.82-3.76 (m, 2H), 3.78 (s, 3H), 3.70 (se, J = 5.2 
Hz, 1H), 3.37 (s, 3H), 1.95-1.81 (m, 2H), 1.05 (s, 9H); 13C NMR (100 MHz, CDCl3) 
δ 202.7, 159.3, 135.6, 133.6, 133.5, 129.9, 129.7, 127.7, 113.8, 97.2, 83.1, 75.4, 72.5, 
60.0, 56.2, 55.3, 33.3, 26.9, 19.2; HRMS (ESI+), m/z calcd for C31H40O6SiK: 
575.2231 (M+K); found, 575.2249. 
 
Prop-1-yne-1,3-diylbis(triisopropylsilane) (110). 1-(triisopropyl)-1-propyne (6.10 
mL, 25.5 mmol) was dissolved in anhydrous THF (51 mL) and cooled to -20 °C.  
nBuLi (15.9 mL, 25.5 mmol, 1.6 M in hexanes) was added dropwise and stirring 
continued for 20-30 min, then the anion solution cooled to -78 °C.  Triisopropyl 
trifluoromethylsulfonate (7.16 mL, 26.7 mmol) was added dropwise and the solution 
stirred for one h at -78 °C followed by warming to room temperature with stirring for 




under reduced pressure (100 °C), collecting the distillate at 100 °C as a clear oil.  
Spectral data was identical to literature reported values:144 1H NMR (400 MHz, 
CDCl3) δ 1.59 (s, 2H), 1.19-1.11 (m, 6H), 1.10-0.84 (m, 36H); boiling point 130-135 
°C (reduced pressure). 
 
(5S,6S)-6-(4-Methoxybenzyloxy)-11,11-dimethyl-10,10-diphenyl-5-((Z)-4-
(triisopropylsilyl)but-1-en-3-ynyl)-2,4,9-trioxa-10-siladodecane (133).  Prop-1-
yne-1,3-diylbis(triisopropylsilane) 110 (444 mg, 1.26 mmol) was dissolved in 
anhydrous THF (10 mL) and cooled to -20 °C.  nBuLi (0.788 mL, 1.26 mmol, 1.6M 
in hexanes) was added dropwise over five min, stirred for 30 min, then cooled to -78 
°C.  The aldehyde 111 (390 mg, 0.727 mmol), as a solution in THF (7 mL), was 
added dropwise to the anion solution over 1.5 h.  After additional stirring for 30 min, 
the reaction was quenched at -78 °C with saturated NH4Cl solution and warmed to 
room temperature.  Following extraction with EtOAc (3x), washing of combined 
organic extracts with brine, and drying over MgSO4, the crude material was purified 
via flash column chromatography (hexanes/EtOAc, 100:0 – 90:10) to yield 352 mg of 
a yellow oil (68%).  The enyne product was isolated as an inseparable 5:1 Z:E olefin 
ratio, as determined by 1H NMR: TLC (hexanes/EtOAc, 80:20): Rf = 0.80; IR (thin 






(400 MHz, CDCl3) δ 7.59-7.56 (m, 4H), 7.36-7.27 (m, 6H), 7.09 (d, J = 8.6, 2H), 
6.71 (d, J = 8.6, 2H), 5.82 (dd, J = 11, 9.5 Hz, 1H), 5.70 (d, J = 11 Hz, 1H), 4.74 (dd, 
J = 9.2, 5.6 Hz, 1H), 4.64 (d, J = 6.4 Hz, 1H), 4.53 (d, J = 6.4 Hz, 1H), 4.38 (d, J = 11 
Hz, 1H) 3.73 (s, 3H), 3.72-3.65 (m, 4H) 3.27 (s, 3H), 1.89-1.79 (m, 1H), 1.68-1.61 
(m, 1H), 1.01 (s, 21H), 0.98 (s, 9H); HRMS (ESI+), m/z calcd for C43H62O5Si2Na: 
737.4033 (M+Na); found, 737.4014. 
 
 (5S,6S)-5-((Z)-But-1-en-3-ynyl)-6-(4-methoxybenzyloxy)-11,11-dimethyl-10,10-
diphenyl-2,4,9-trioxa-10-siladodecane (135).  The enyne 133 (1.21 g, 1.69 mmol), 
as a mixture of olefin isomers, was dissolved in anhydrous THF (17 mL) and cooled 
to 0 °C.  TBAF (1.72 mL, 1.72 mmol, 1M in THF) was added dropwise.  After 15 
min, the reaction quenched with silica gel and THF removed by rotary evaporation.  
Purification of the crude mixture via flash column chromatography (hexanes/Et2O, 
100:0 – 80:20) yielded 560 mg of pure Z-enyne as a yellow oil (59%, 47% over two 





25  = +35.4 (c = 1.70, CHCl3); IR (thin film) υmax = 3286, 2955, 2931, 
2887, 2858, 1613, 1514, 1248, 1111, 1035, 703 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.67-7.64 (m, 4H), 7.42-7.34 (m, 6H), 7.19 (dd, J = 6.8, 2.0 Hz, 2H), 6.80 (dd, J = 






(dd, J = 9.2, 5.2 Hz, 1H), 4.71-4.66 (m, 2H), 4.60 (d, 7.6 Hz, 1H), 4.47 (d, J = 11 Hz, 
1H, 3.89-3.84 (m, 1H), 3.83-3.72 (m, 5H), 3.36 (s, 3H), 3.09 (dd, J = 2.4, 0.8 Hz, 
1H), 1.94-1.85 (m, 1H), 1.76-1.68 (m, 1H), 1.05 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 159.1, 142.1, 135.6, 133.9, 133.9, 130.8, 129.7, 129.6, 127.7, 127.6, 113.7, 
112.2, 94.9, 82.9, 79.5, 77.3, 75.8, 73.3, 60.3, 55.7, 55.3, 33.9, 26.9, 19.2; HRMS 
(ESI+), m/z calcd for C34H42O5SiNa: 581.2699 (M+Na); found, 581.2699. 
 
(5S,6S)-5-((Z)-But-1-en-3-ynyl)-11,11-dimethyl-10,10-diphenyl-2,4,9-trioxa-10-
siladodecan-6-ol (109).  The enyne 135 (283 mg, 0.506 mmol) was dissolved in 
DCM (5.10 mL) and water (0.510 mL) and cooled to 0 °C.  DDQ (230 mg, 1.01 
mmol) was added in three aliquots over 20 min.  The solution was stirred for two h, 
diluted with EtOAc, washed with saturated NaHCO3 (3x), brine, dried over MgSO4 
and purified by flash column chromatography to collect 216 mg of the enynol 109 as 




25  = +39 (c = 0.83, 
CHCl3); IR (thin film) υmax = 3491 (br), 3288, 3071, 2931, 2858, 1606, 1589, 1472, 
1428, 1258, 1111, 1031 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.71-7.7.67 (m, 4H), 
7.46-7.37 (m, 6H), 5.98 (dd, J = 11, 9.6 Hz, 1H), 5.74 (dd, J = 11, 2.4 Hz, 1H), 4.74 
(d, J = 6.4 Hz, 1H), 4.64 (d, J = 6.4 Hz, 1H), 4.54 (dd, J = 9.2, 6.0 Hz, 1H), 3.98-3.90 






=3.6 Hz, 1H), 1.84-1.75 (m, 2H), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 141.7, 
135.6, 135.6, 133.5, 133.4, 129.7, 127.7, 112.7, 95.0, 83.1, 79.3, 77.9, 71.8, 61.8, 




siladodecan-6-yl 2-((E)-2-Iodovinyl)-6-methoxybenzoate (136).  The enyne 109 
(489 mg, 1.11 mmol) was azeotroped with toluene under reduced pressure, then 
diluted with anhydrous THF (12 mL) and cooled to 0 °C.  NaHMDS (1.17 mL, 1.17 
mmol, 1M in THF) was added dropwise and the mixture stirred at 0 °C for one h.  A 
THF solution (10 mL) of the vinyl iodide 108 (385 mg, 1.17 mmol) was added 
dropwise to the anion solution, with continued stirring for two h at 0 °C.  Me2SO4 
(0.42 mL, 4.44 mmol) was added to quench the resultant phenolate anion and the 
reaction was warmed to room temperature.  After three h of stirring, the reaction was 
quenched with water and extracted with EtOAc (3x).  The combined organic extracts 
were washed with brine, dried over MgSO4 and purified via flash column 
chromatography (hexanes/EtOAc, 95:5 – 80:20) to provide 713 mg of the desired 













1590, 1571, 1471, 1271, 1111, 1033, 703 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.72-
7.69 (m, 4H), 7.50 (d, J = 15 Hz, 1H), 7.42-7.32 (m, 6H), 7.28 (t, J = 8.0 Hz, 1H), 
6.99 (d, J = 8.0 Hz, 1H), 6.87 (d, J = 15 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 4.82 (dd, J 
= 8.8, 5.6 Hz, 1H), 4.73 (d, J = 4.0 Hz, 1H), 4.64 (d, J = 4 Hz, 1H), 3.95-3.83 (m, 
2H), 3.56 (s, 3H), 3.32 (s, 3H), 3.13 (dd, J = 2.4, 0.8 Hz, 1H), 2.07-2.01 (m, 2H), 1.07 
(s, 9H); 13C NMR (100 MHz, CDCl3) δ 166.8, 141.7, 141.0, 136.1, 135.7, 135.6, 
134.0, 130.4, 129.5, 127.6, 117.5, 113.4, 110.5, 94.7, 83.8, 80.2, 74.8, 73.1, 59.7, 
55.8, 55.5, 34.1, 26.8, 19.2; HRMS (ESI+), m/z calcd for C36H41O6SiINa: 747.1615 
(M+Na); found, 747.1607. 
 
(3S,4S,5Z,9Z)-3-(2-(tert-Butyldiphenylsilyloxy)ethyl)-14-methoxy-4-
(methoxymethoxy)-3,4-dihydro-1-oxabenzocyclododeca-5,9-dien-7-ynone (139).  
The enyne precycle 136 (27 mg, 0.037 mmol), PPh3 (20 mg, 0.075 mmol), and 
K2CO3 (8 mg, 0.056 mmol) were suspended in anhydrous DMF (1.00 mL).  CuI (7 
mg, 0.037 mmol) was then added to this solution and the solution was heated for four 
h at 120 °C.  After heating, the solution was cooled to room temperature, quenched 
by adding water, then extracted with Et2O (3x).  The combined organic layers were 
washed with brine and dried over MgSO4.  Purification of the crude material by flash 











25  = -70 (c = 0.60, CHCl3); IR (thin film) υmax = 1722, 
1575, 1472, 1434, 1278, 1106, 1071, 1037, 743, 697 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.72-7.67 (m, 4H), 7.42-7.28 (m, 7H), 6.85 (d, J = 12 Hz, 1H), 6.76 (d, J = 
8.0 Hz, 1H), 6.71 (d, J = 8.0 Hz, 1H), 6.06 (dd, J = 10, 8.0 Hz, 1H), 5.86 (d, 8.0 Hz, 
1H), 5.67 (br d, J = 10 Hz, 1H), 5.44 (ddd, J = 11, 4.5, 1.5 Hz, 1H), 5.30 (dd, J = 10, 
4.8 Hz, 1H), 4.74 (dd, J = 7.6, 6.4 Hz, 2H), 3.94-3.90 (m, 2H), 3.42 (s, 3H), 3.24 (s, 
3H), 2.32-2.24 (m, 1H), 1.91-1.82 (m, 1H), 1.05 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 167.4, 158.0, 142.2, 138.8, 137.0, 135.6, 133.9, 130.8, 129.5, 127.6, 122.4, 
121.5, 113.2, 111.1, 110.7, 95.7, 92.1, 91.5, 74.0, 73.0, 60.2, 55.7, 55.2, 31.0, 26.7, 
19.2; HRMS (ESI+), m/z calcd for C36H41O6Si: 597.2697 (M+H); found, 597.2659. 
 
(3S,4S,5Z,7Z,9E)-3-(2-(tert-Butyldiphenylsilyloxy)ethyl)-14-methoxy-4-
(methoxymethoxy)-3,4-dihydro-1H-benzo[c][1]oxacyclododecin-1-one (140).  
CuI (4.3 mg, 0.023 mmol), PPh3 (18 mg, 0.069 mmol), K2CO3 (14 mg, 0.10 mmol) 
and HCO2Na (15 mg, 0.22 mmol) were suspended in anhydrous DMF (7 mL) (Note: 
Cu(OAc)2 was used for reactions greater than 0.1 mmol scale).  This suspension was 
heated at 120 °C for 30 min, during which time a black precipate formed.  The cycle 
precursor 136 (45 mg, 0.062 mmol) was dissolved in DMF (7 mL) and added 







cooled to room temperature.  To the cooled reaction mixture was added Et2O and 
saturated NH4Cl solution.  This mixture was stirred for two h, whereupon a white 
precipitate formed. The aqueous layer was extracted with Et2O (2x), the combined 
organic layers were washed with brine and dried over MgSO4.  The crude material 
was purified by flash column chromatography (hexanes/EtOAc, 90:10 – 85:15) to 
yield 25 mg of the triene cycle as a bright yellow oil (67%).  Boland reduction 
conditions: Zn dust (466 mg, 7.12 mmol) was suspended in water and the mixture 
purged with N2 for 15 min.  Cu(OAc)2 (47 mg, 10% wt Zn) was added and the 
mixture stirred for 15 min.  AgNO3 (47 mg, 10% wt Zn) was then added, producing 
an exothermic reaction, and stirred for 30 min.  The solution was then filtered and the 
activated Zn was washed with water, MeOH, acetone and Et2O.  The Zn was quickly 
transferred to a water:MeOH solution (1:1 mixture, 2.8 mL total) of the dienyne 139 
(17 mg, 0.0285 mmol).  The reaction was heated at 40 °C for 12 h.  The solids were 
removed by filtration and rinsed with Et2O.  The ethereal layer was washed with 
water then brine and dried over MgSO4.  Crude 1H NMR of the resulting material 
displayed a 10% conversion of the starting material to the desired product 140: TLC 




25  = -118 (c = 0.520, CHCl3); IR (thin film) 
υmax = 3011, 2930, 2857, 1733, 1599, 1572, 1468, 1428, 1301, 1271, 1090, 1030, 
1000 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.72-7.69 (m, 4H), 7.41-7.33 (m, 6H), 7.23 
(t, J = 8.0 Hz, 1H), 7.00 (dd, J = 16, 12 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 6.70 (d, J = 
8.0 Hz, 1H), 6.65 (d, J = 16 Hz, 1H), 6.35 (t, J = 11 Hz, 1H), 6.16 (dd, J = 12, 3.9 Hz, 
1H), 5.91 (dd, J = 11, 3.5 Hz, 1H), 5.69 (t, J = 12 Hz, 1H), 5.55 (ddd, J = 12, 3.4, 1.6 
 215 
Hz, 1H), 4.56 (dd, J = 11, 3.4 Hz, 1H), 4.55 (dd, J =8.7, 6.5 Hz, 2H), 3.94-3.85 (m, 
2H), 3.40 (s, 3H), 3.36 (s, 3H), 2.35-2.27 (m, 1H), 2.10-2.01 (m, 1H), 1.07 (s, 9H); 
13C NMR (100 MHz, CDCl3) δ 168.3, 156.0, 135.6, 134.0, 133.0, 132.1, 130.8, 129.6, 
129.6, 127.7, 127.6, 127.4, 123.6, 120.4, 109.2, 93.3, 74.2, 68.4, 60.6, 55.4, 55.3, 




siladodecan-6-yl 2-(tert-butyldiphenylsilyloxy)-6-((E)-2-iodovinyl)benzoate (150). 
The enyne 109 (150 mg, 0.342 mmol) was azeotroped with toluene under reduced 
pressure, then diluted with anhydrous THF (1.00 mL) and cooled to 0 °C.  NaHMDS 
(0.349 mL, 0.349 mmol, 1M in THF) was added dropwise and the mixture stirred at 0 
°C for 1 h.  A THF solution (0.70 mL) of the vinyl iodide 108 (119 mg, 0.359 mmol) 
was added dropwise to the anion solution, with continued stirring for two h at 0 °C.  
Approximately 0.21 mL of this phenolate solution (0.043 mmol phenolate) was 
withdrawn via syringe and added to an empty flask.  With stirring, the phenolate 
anion was quenched with TBDPS-Cl (34.0 mg, 0.123 mmol), allowed to warm to 
room temperature over four h, after which time water was added and the mixture was 








dried over MgSO4 and purified via flash column chromatography (hexanes/EtOAc, 
95:5 – 80:20) to provide 21.0 mg of the desired compound as a pale yellow oil (51%): 
TLC (hexane/EtOAc, 80:20): Rf = 0.40; 1H NMR (400 MHz, CDCl3) δ 7.76-7.71 (m, 
8H), 7.52 (d, J = 14 Hz, 1H), 7.44-7.34 (m, 12H), 6.88-6.86 (m, 1H), 6.84 (dd, J = 
9.8, 7.7 Hz, 1H), 6.77 (d, J = 14 Hz, 1H), 6.35 (dd, J = 7.6, 1.4 Hz, 1H), 6.07 (dd, J = 
10, 9.6 Hz, 1H), 5.76 (dd, J = 11, 2.0 Hz, 1H), 5.54 (dt, J = 6.2, 4.0 Hz, 1H), 4.95 (dd, 
J = 7.0, 3.8 Hz, 1H), 4.71 (d, J = 6.8 Hz, 1H), 4.60 (d, J = 6.8 Hz, 1H), 3.96-3.84 (m, 
2H), 3.30 (s, 3H), 3.01 (d, J = 2.2 Hz, 1H), 2.24 (q, J = 6.4 Hz, 2H), 1.08 (s, 9H), 1.04 
(s, 9H); 13C NMR (100 MHz, CDCl3) δ 166.5, 152.6, 142.3, 141.1, 136.5, 135.7, 
135.6, 135.4, 135.4, 133.8, 133.6, 132.2, 131.9, 130.0, 129.7, 129.6, 127.9, 129.6, 
127.9, 127.9, 127.6, 124.0, 119.1, 118.0, 113.1, 94.7, 83.9, 79.8, 78.9, 74.7, 73.5, 
60.3, 55.9, 33.9, 26.9, 26.3, 19.4, 19.2; HRMS (ESI+), m/z calcd for C51H58IO6Si2: 
949.2817 (M+H); found, 949.2825. 
 
(5S,6S)-5-((Z)-But-1-en-3-ynyl)-11,11-dimethyl-10,10-diphenyl-2,4,9-trioxa-10-
siladodecan-6-yl 2-(tert-butyldimethylsilyloxy)-6-((E)-2-iodovinyl)benzoate (151). 
The enyne 109 (150 mg, 0.342 mmol) was azeotroped with toluene under reduced 
pressure, then diluted with anhydrous THF (1.00 mL) and cooled to 0 °C.  NaHMDS 








°C for one h.  A THF solution (0.70 mL) of the vinyl iodide 108 (119 mg, 0.359 
mmol) was added dropwise to the anion solution, with continued stirring for two h at 
0 °C.  Approximately 0.21 mL of this phenolate solution (0.043 mmol phenolate) was 
withdrawn via syringe and added to an empty flask.  With stirring, the phenolate 
anion was quenched with TBS-Cl (19.0 mg, 0.123 mmol), allowed to warm to room 
temperature over four h, after which time water was added and the mixture was 
extracted with EtOAc (3x).  The combined organic extracts were washed with brine, 
dried over MgSO4 and purified via flash column chromatography (hexanes/EtOAc, 
95:5 – 80:20) to provide 19.0 mg of the desired compound as a pale yellow oil (53%): 
TLC (hexane/EtOAc, 80:20): Rf = 0.50; 1H NMR (400 MHz, CDCl3) δ 7.72-7.70 (m, 
5H), 7.46 (d, J = 14 Hz, 1H), 7.43-7.37 (m, 7H), 7.19 (t, J = 8.0, 1H), 6.97 (d, J = 7.8 
Hz, 1H), 6.80 (d, J = 14 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 5.99 (ddd, J = 11, 9.0, 0.7 
Hz, 1H), 5.78 (dd, J = 11, 2.4 Hz, 1H), 5.46 (q, J = 5.7 Hz, 1H), 4.86 (dd, J = 9.0, 4.3 
Hz, 1H), 4.68 (d, J = 6.8 Hz, 1H), 4.57 (d, J = 6.8 Hz, 1H), 3.90 (m, 2H), 3.27 (s, 
3H), 3.02 (dd, J = 2.4, 0.8 Hz, 1H), 2.18-2.05 (m, 2H), 1.07 (s, 9H), 0.96 (s, 9H), 0.22 
(s, 3H), 0.22 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 166.6, 152.8, 142.2, 141.1, 
136.5, 135.7, 135.6, 134.8, 133.8, 133.6, 130.0, 129.6, 129.6, 127.7, 127.6, 124.8, 
118.9, 118.1, 113.1, 94.6, 83.8, 79.8, 78.9, 74.1, 73.6, 60.2, 55.8, 33.9, 26.8, 25.8, 





siladodecan-6-yl 2-(Ethanoyloxy)-6-((E)-2-iodovinyl)benzoate (152).  The enyne 
109 (150 mg, 0.342 mmol) was azeotroped with toluene under reduced pressure, then 
diluted with anhydrous THF (1.00 mL) and cooled to 0 °C.  NaHMDS (0.349 mL, 
0.349 mmol, 1M in THF) was added dropwise and the mixture stirred at 0 °C for one 
h.  A THF solution (0.70 mL) of the vinyl iodide 108 (119 mg, 0.359 mmol) was 
added dropwise to the anion solution, with continued stirring for two h at 0 °C.  
Approximately 0.21 mL of this phenolate solution (0.043 mmol phenolate) was 
withdrawn via syringe and added to an empty flask.  With stirring, the phenolate 
anion was quenched with freshly distilled AcCl (0.009 mL, 0.123 mmol), allowed to 
warm to room temperature over four h, after which time water was added and the 
mixture was extracted with EtOAc (3x).  The combined organic extracts were washed 
with brine, dried over MgSO4 and purified via flash column chromatography 
(hexanes/EtOAc, 95:5 – 80:20) to provide 21.0 mg of the desired compound as a pale 
yellow oil (65%): TLC (hexane/EtOAc, 80:20): Rf = 0.20; 1H NMR (400 MHz, 
CDCl3) δ 7.70-7.66 (m, 4H), 7.64 (d, J = 15 Hz, 1H), 7.42-7.33 (m, 7H), 7.28 (d, J = 
7.6 Hz, 1H), 7.09 (dd, J = 8.0, 0.8 Hz, 1H), 6.82 (d, J = 15 Hz, 1H), 5.97 (dd, J = 10, 








9.0, 5.2 Hz, 1H), 4.70 (d, J = 6.8 Hz, 1H), 4.61 (d, J = 6.8 Hz, 1H), 3.86-3.77 (m, 
2H), 3.30 (s, 3H), 3.09 (dd, J = 2.3, 0.7 Hz, 1H), 2.14 (s, 3H), 2.11-2.05 (m, 1H), 
2.01-1.94 (m, 1H), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 169.0, 164.5, 148.4, 
142.1, 140.8, 137.9, 135.6, 135.6, 133.6, 133.5, 130.8, 129.6, 127.7, 124.4, 123.8, 
122.9, 113.4, 94.7, 84.0, 80.5, 78.9, 74.5, 73.7, 59.8, 55.8, 33.8, 26.8, 20.8, 19.2; 
HRMS (ESI+), m/z calcd for C37H42IO7Si: 753.1744  (M+H); found, 753.1725. 
 
(5S,6S)-5-((Z)-But-1-en-3-ynyl)-11,11-dimethyl-10,10-diphenyl-2,4,9-trioxa-10-
siladodecan-6-yl 2-Hydroxy-6-((E)-2-iodovinyl)benzoate (153).  The enyne 109 
(150 mg, 0.342 mmol) was azeotroped with toluene under reduced pressure, then 
diluted with anhydrous THF (1.00 mL) and cooled to 0 °C.  NaHMDS (0.349 mL, 
0.349 mmol, 1M in THF) was added dropwise and the mixture stirred at 0 °C for one 
h.  A THF solution (0.70 mL) of the vinyl iodide 108 (119 mg, 0.359 mmol) was 
added dropwise to the anion solution, with continued stirring for two h at 0 °C.  
Approximately 0.21 mL of this phenolate solution (0.043 mmol phenolate) was 
withdrawn via syringe and added to an empty flask.  With stirring, the phenolate 
anion was quenched with water and allowed to warm to room temperature over four 
h, after which time the mixture was extracted with EtOAc (3x).  The combined 








column chromatography (hexanes/EtOAc, 95:5 – 80:20) to provide 17.0 mg of the 
desired compound as a pale yellow oil (65%): TLC (hexane/EtOAc, 80:20): Rf = 
0.85; 1H NMR (400 MHz, CDCl3) δ 11.47 (s, 1H), 7.86 (d, J = 15 Hz, 1H), 7.65-7.62 
(m, 2H), 7.57-7.55 (m, 2H), 7.38-7.32 (m, 4H), 7.30-7.26 (m, 1H), 7.23-7.19 (m, 2H), 
6.99 (dd, J = 8.4, 0.9 Hz, 1H), 6.75 (d, J = 7.4 Hz, 1H), 6.25 (d, J = 4.6 Hz, 1H), 5.97 
(dd, J = 10, 0.8 Hz, 1H), 5.76 (ddd, J = 11, 2.3, 0.6 Hz, 1H), 5.69-5.64 (m, 1H), 4.94 
(dd, J = 9.2, 5.6 Hz, 1H), 4.72 (d, J = 6.8 Hz, 1H), 4.66 (d, J = 6.8 Hz, 1H), 3.82-3.77 
(m, 1H), 3.69-3.63 (m, 1H), 3.35 (s, 3H), 2.99 (dd, J = 2.3, 0.7 Hz, 1H), 2.18-2.12 (m, 
1H), 2.02-1.95 (m, 1H), 1.02 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 170.1, 162.7, 
146.9, 141.5, 140.4, 135.5, 135.5, 134.6, 133.5, 133.2, 129.6, 129.5, 127.6, 127.5, 
120.1, 117.9, 113.6, 109.7, 95.0, 83.7, 78.8, 74.2, 73.5, 59.4, 55.9, 32.2, 26.8, 19.1; 
HRMS (ESI+), m/z calcd for C35H40IO6Si: 711.1639 (M+H); found, 711.1650. 
 
(3S,4S,5Z,7Z,9E)-3-(2-(tert-Butyldiphenylsilyloxy)ethyl)-14-hydroxy-4-
(methoxymethoxy)-3,4-dihydro-1H-benzo[c][1]oxacyclododecin-1-one (154).  CuI 
(1.4 mg, 0.0072 mmol), PPh3 (5.6 mg, 0.022 mmol), K2CO3 (5.0 mg, 0.036 mmol) 
and HCO2Na (6.5 mg, 0.096 mmol) were suspended in anhydrous DMF (2.8 mL).  
This suspension was heated at 120 °C for 30 min, during which time a black 







DMF (2.4 mL) and added dropwise over one h.  The reaction was stirred for an 
additional two h at 120 °C, then cooled to room temperature.  To the cooled reaction 
mixture was added Et2O and saturated NH4Cl solution.  This mixture was stirred for 
two h, whereupon a white precipitate formed. The aqueous layer was extracted with 
Et2O (2x), the combined organic layers were washed with brine and dried over 
MgSO4.  The crude material was purified by flash column chromatography 
(hexanes/EtOAc, 90:10 – 85:15) to yield 8.0 mg of the triene cycle as a bright yellow 
oil (57%): TLC (hexane/EtOAc, 80:20): Rf = 0.25; 1H NMR (400 MHz, CDCl3) δ 
7.71-7.68 (m, 4H), 7.42-7.36 (m, 9H), 7.25-7.19 (m, 2H), 6.75-6.71 (m, 3H), 6.66-
6.60 (m, 1H), 6.28 (t, J = 10 Hz, 1H), 6.20 (dd, J = 13, 3.2 Hz, 1H), 5.89 (dd, J = 11, 
3.4 Hz, 1H), 5.61 (t, J = 11 Hz, 1H), 5.57 (br, 1H), 4.60 (dd, J = 10, 3.2 Hz, 1H), 5.54 
(dd, J = 21, 6.6 Hz, 2H), 3.85 (br m, 2H), 3.34 (s, 3H), 2.29-2.19 (br, 1H), 2.00-1.93 
(m, 1H), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 170.0, 162.8, 146.8, 141.5, 
138.4, 135.5, 134.6, 133.4, 133.2, 129.5, 127.5, 120.1, 118.0, 115.6, 109.7, 101.7, 





dihydro-1H-benzo[c][1]oxacyclododecin-1-one (159). The triene cycle 140 (167 
mg, 0.279 mmol) was dissolved in anhydrous THF (1.40 mL) at room temperature.  
TBAF (0.300 mL, 0.300 mmol, 1M in THF) was added dropwise.  After 1.5 h, the 
reaction was quenched with silica gel and the THF was removed by rotary 
evaporation.  The crude mixture was purified via flash column chromatography 
(hexanes/EtOAc, 90:10 – 50:50) to collect 95 mg of 159 as an opaque oil (94%): TLC 




25  = -205 (c = 1.05, CHCl3); IR (thin film) 
υmax = 3448 (br), 2943, 2888, 1732, 1599, 1572, 1468, 1271, 1089, 1058, 1029 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.28 (t, J = 8.0 Hz, 1H), 7.00 (dd, J = 16, 12 Hz, 1H), 
6.83 (t, J = 8 Hz, 1H), 6.78 (d, J = 12 Hz, 1H), 6.37 (t, J = 11 Hz, 1H), 6.21 (dd, J = 
12, 3.6 Hz, 1H), 5.90 (dd, J = 11, 3.6 Hz, 1H), 5.72 (t, J = 11 Hz, 1H), 5.55 (dt, J = 
11, 3.2 Hz, 1H), 4.66 (dd, J = 11, 3.6 Hz, 1H), 4.58 (d, J = 6.0 Hz, 1H), 4.53 (d, J = 
6.0 Hz, 1H), 3.92-3.90 (br m, 2H), 3.85 (s, 3H), 3.38 (s, 3H), 2.39 (br t, J = 6.4 Hz, 
1H), 2.25-2.15 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 168.2, 155.7, 138.5, 133.3, 
132.7, 130.7, 129.9, 129.5, 127.8, 126.9, 123.3, 120.8, 109.4, 93.4, 76.7, 68.4, 61.3, 









benzo[c][1]oxacyclododecin-3-yl)ethanal (160).  To a solution of the alcohol 159 
(180 mg, 0.499 mmol) in DCM (5.00 mL) was added Dess-Martin periodinane (121a) 
(318 mg, 0.749 mmol) at room temperature.  The reaction was stirred for one h.  The 
solvent was removed by rotary evaporation and the crude material purified by flash 
column chromatography (hexanes/EtOAc, 80:20 – 70:30) to collect 154 mg of the 




25  = -199 (c = 0.400, CHCl3); IR (thin film) υmax = 2942, 2842, 1732, 1599, 1572, 
1469, 1438, 1271, 1251, 1090, 1057, 1027 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.77 
(t, J = 2.0 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H), 6.99 (dd, J = 16, 12 Hz, 1H), 6.81 (d, J = 
8.0 Hz, 1H), 6.79 (d, J = 8.0 Hz, 1H), 6.68 (d, J = 16 Hz, 1H), 6.38 (t, J = 11 Hz, 1H), 
6.24 (dd, J = 12, 4.0 Hz, 1H), 5.98 (dt, J = 9.6, 4.0 Hz, 1H), 5.90 (dd, J = 11, 3.2 Hz, 
1H), 5.59 (t, J = 11 Hz, 1H), 4.71 (dd, J = 10, 3.6 Hz, 1H), 4.57 (d, J = 6.4 Hz, 1H), 
4.52 ( d, J = 6.4 Hz, 1H), 3.80 (s, 3H), 3.38 (s, 3H), 3.00-2.88 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 199.5, 167.9, 156.1, 138.2, 133.3, 132.9, 131.0, 129.9, 129.8, 
127.4, 126.3, 123.1, 120.5, 109.6, 93.3, 71.8, 68.0, 55.8, 55.6, 42.1; HRMS (ESI+), 








dihydro-1H-benzo[c][1]oxacyclododecin-1-one (161).  Freshly prepared IH2CPPh3 
(35 mg, 0.0653 mmol) was suspended in THF (0.131 mL), cooled to 0 °C and 
protected from light.  NaHMDS (0.0650 mL, 0.0653 mmol, 1M in THF) was added 
dropwise, stirred for five min, and warmed to room temperature over 30 min.  HMPA 
(0.0170 mL, 0.0980 mmol) was added, the resulting solution stirred for five min at 
room temperature, then cooled to -78 °C.  The aldehyde 160 (13.0 mg, 0.0363 mmol) 
was dissolved in anhydrous DMF (0.182 mL) and added dropwise to the anion 
solution.  After 30 min of stirring at -78 °C, the solution was warmed to room 
temperature and stirred for 30 min, after which time the reaction was filtered through 
a plug of silica and eluted with hexanes/EtOAc (50:50).  Removal of the solvent 
followed by purification by flash column chromatography (hexanes/EtOAc 95:5 – 
90:10) yielded 14.0 mg of the desired vinyl iodide as a yellow oil (80%): TLC 




25  = -129 (c = 1.43, CHCl3); IR (thin film) 
υmax = 3008, 2942, 2887, 1733, 1599, 1572, 1468, 1438, 1300, 1271, 1251, 1153, 
1107, 1089, 1061, 1038 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.28 (t, J = 8.0 Hz, 1H), 
7.03 (dd, J = 16, 7.2 Hz, 1H), 6.82 (d, J = 2.4 Hz, 1H), 6.80 (d, J = 2.4 Hz, 1H), 6.67 






4.0 Hz, 1H), 5.73 (t, J = 11 Hz, 1H), 5.48 (dt, J = 11, 3.2 Hz, 1H), 4.64 (dd, J = 11, 
3.6 Hz, 1H), 4.57 (dd, J = 14, 6.4 Hz, 1H), 3.82 (s, 3H), 3.38 (s, 3H), 2.84-2.78 (m, 
1H), 2.69-2.61 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 168.3, 156.0, 138.1, 137.5, 
133.1, 132.6, 130.9, 129.7, 129.5, 127.6, 126.8, 123.4, 120.6, 109.5, 93.4, 84.2, 76.1, 




benzo[c][1]oxacyclododecin-1-one (163).  To a iPrOH (0.830 mL) solution of the 
vinyl iodide 161 (40.0 mg, 0.0830 mmol) was added CBr4 (110 mg, 0.332 mmol) in 
one portion.  The mixture was heated at 75 °C for two h, after which time the reaction 
was cooled to room temperature, the solvent removed by rotary evaporation, and the 
reaction mixture was purified by flash column chromatography (hexanes/EtOAc, 
90:10 – 80:20) to yield 35.0 mg the desired alcohol 163 as a colorless oil (96%): TLC 




25  = -107 (c = 0.720, CHCl3); IR (thin film) 
υmax = 3445 (br), 3007, 2924, 2850, 1731, 1599, 1572, 1468, 1271, 1107, 1088, 1061, 
1000 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.28 (t, J = 8.0 Hz, 1H), 7.02 (dd, J = 16, 
11 Hz, 1H), 6.83 (t, J = 2.0 Hz, 1H), 6.81 (t, J = 2.7 Hz, 1H), 6.67 (t, J = 16 Hz, 1H), 






(m, 2H), 5.44 (td, J = 11, 3.1 Hz, 1H), 4.75 (br d, J = 9.9 Hz, 1H), 3.82 (s, 3H), 2.89-
2.84 (m, 1H), 2.68-2.60 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 168.4, 156.0, 138.0, 
137.4, 133.1, 131.1, 130.9, 129.7, 129.5, 129.2, 127.5, 123.4, 120.6, 109.5, 84.3, 77.2, 




benzo[c][1]oxacyclododecin-1-one (162).  Alcohol 163 (98.0 mg, 0.224 mmol) was 
dissolved in anhydrous CH2Cl2 (22.0 mL) and cooled to -78 °C.  BCl3 (2.24 mL, 2.24 
mmol, 1M in CH2Cl2) was added dropwise and the reaction stirred for 10 min then 
warmed to room temperature.  The reaction was quenched with water then extracted 
with EtOAc (3x).  The combined organic extracts were washed with brine, dried over 
MgSO4 and purified by flash column chromatography (hexanes/EtOAc, 85:15 – 
75:25) to yield 89.0 mg of the desired diol as an unstable yellow oil (94%): TLC 
(hexanes/EtOAc, 70:30): Rf = 0.30; 1H NMR (400 MHz, CDCl3) δ 10.37 (s, 1H), 
7.30 (t, J = 8.0 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.80-6.70 (m, 3H), 6.37 (d, J = 7.6 
Hz, 2H), 6.21 (br, 2H), 6.07 (br d, J = 12 Hz, 1H), 5.79 (dd, J = 12, 4.7 Hz, 1H), 5.54 






NMR (100 MHz, CDCl3) δ; HRMS (ESI+), m/z calcd for C18H18O4I: 425.0250 
(M+H); found, 425.0259. 
 
(3S,4S,5Z,7Z,9E)-4,14-Bis(tert-butyldimethylsilyloxy)-3-((Z)-3-iodoallyl)-3,4-
dihydro-1H-benzo[c][1]oxacyclododecin-1-one (67).  The diol 162 (89.0 mg, 0.210 
mmol) was dissolved in CH2Cl2 (2.00 mL), followed by the addition of Py. (0.120 
mL, 1.47 mmol) and cooled to 0 °C.  TBS-OTf (0.335 mL, 1.47 mmol) was added 
dropwise and the reaction was allowed to warm to room temperature during the 
course of 15 h.  EtOAc was added and the organic mixture was washed with saturated 
NaHCO3 solution.  The aqueous layer was re-extracted with EtOAc (2x), the organic 
extracts combined, washed with brine, dried over MgSO4 and purified by flash 
column chromatography (hexanes/EtOAc, 100:0 – 95:5) to yield 110 mg of the title 




25  = -




25  = -171 (c = 2.00, CHCl3)); IR (thin film) υmax = 
3010, 2929, 2885, 2857, 1732, 1599, 1571, 1463, 1361, 1251, 1100, 1062, 1000 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.17 (t, J = 8.0 Hz, 1H), 7.05 (dd, J = 16, 11 Hz, 1H), 
6.79 (d, J = 6.6 Hz, 1H), 6.74 (d, J = 8.0 Hz, 1H), 6.64 (d, J = 16 Hz, 1H), 6.47 (dt, J 






4.1 Hz, 1H), 5.79 (t, J = 11 Hz, 1H), 5.21 (dt, J = 9.3, 3.5 Hz, 1H), 4.63 (dd, J = 10, 
3.1 Hz, 1H), 2.95-2.88 (m, 1H), 2.63-2.55 (m, 1H), 0.98 (s, 9H), 0.90 (s, 9H), 0.22 (s, 
3H), 0.19 (s, 3H), 0.11 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 168.3, 
152.3, 138.0, 132.4, 130.7, 130.7, 129.7, 129.3, 128.6, 128.0, 126.4, 121.2, 117.9, 
83.8, 78.4, 66.5, 33.8, 25.8, 25.8, 18.4, 17.9, -4.1, -4.1, -4.5, -4.9; HRMS (ESI+), m/z 
calcd for C30H46O4Si2: 653.1979 (M+H); found, 653.1963. 
 
5-Hydroxy-1H-pyrrol-2(5H)-one (164).  Maleimide (107) (1.00 g, 10.3 mmol) and 
CeCl3•7H2O (2.50 g, 10.3 mmol) were dissolved in anhydrous MeOH (129 mL) and 
cooled to 0 °C.  To this solution was added NaBH4 (0.390 g, 10.3 mmol) with 
vigorous stirring.  Upon consumption of the starting material (one to two h), the 
reaction mixture was diluted with MeOH and the solvent removed by rotary 
evaporation.  This process was repeated twice, then the resulting material was loaded 
onto silica gel and purified by column chromatography (CH2Cl2/MeOH, 90:10) to 
yield 805 mg of the desired compound as a white solid (79%).  TLC (CH2Cl2/MeOH, 
90:10): Rf = 0.20; IR (thin film) υmax = 3293 (br), 1682, 1400, 1291, 1081 cm-1; 1H 
NMR (400 MHz, d6-Acetone) δ 7.51 (br, 1H), 7.00 (td, J = 6.0, 1.6 Hz, 1H), 5.97 (td, 
J = 6.0, 1.6 Hz, 1H), 5.62 (d, J = 8.0 Hz, 1H), 5.05 (d, J = 8.8 Hz, 1H); 13C NMR (100 







(2Z,4E)-4-(Methoxyimino)but-2-enamide (54).  The pyrrolone 164 (160 mg, 1.60 
mmol), MeONH3Cl (1.21 g, 14.5 mmol), and Et3N (2.04 mL, 14.5 mmol) were 
dissolved in anhydrous MeOH (32 mL).  After heating at 70 °C for three h, the 
volatiles were removed by rotary evaporation.  The crude mixture was dissolved in 
EtOAc and washed once with brine.  The organic layer was dried over MgSO4 and 
purified by flash column chromatography (hexanes/EtOAc, 30:70 – 20:80) to yield 
143 mg of the desired amide as an off-white solid (70%).  TLC (EtOAc, 100): Rf = 
0.45; IR (thin film) υmax = 3400 (br), 1667, 1437, 1340, 1044 cm-1; 1H NMR (400 
MHz, CDCl3) δ 8.97 (d, J = 10 Hz, 1H), 6.51 (dd, J = 12, 10 Hz, 1H), 5.97 (d, J = 12 
Hz, 1H), 3.92 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 167.3, 148.4, 134.0, 127.3, 




(14).  Oxime amide 54 (22 mg, 0.172 mmol), CuTC (57) (14 mg, 0.0730 mmol), and 












protocol.118 The flask was flushed rigorously with N2.  To the flask was added DMA 
(freshly distilled from BaO) (0.115 mL).  The solution was vacuum degassed (house 
vacuum pressure) for 30 min.  To this suspension was then added N,N’-dimethyl-
ethylenediamine (13 mg, 0.016 mL, 0.146 mmol) and the mixture was stirred for one 
h at room temperature.  The vinyl iodide 67 (28 mg, 0.0430 mmol) was the dissolved 
in DMA (0.086 mL) and added at once to the catalyst solution.  After heating the 
solution for 16 h at 50 °C, it was cooled to room temperature and EDTA (107 mg, 
0.365 mmol) was added and stirred for 10 min.  Saturated NH4Cl solution was then 
added to the quenched reaction and stirred for 30 min.  The aqueous layer was 
extracted with EtOAc (3x), the organic extracts combined, washed with brine and 
dried over MgSO4.   
To a crude enamide/THF (0.43 mL) solution was added 5M HF/Py. (0.263 mL).  The 
reaction was stirred at room temperature until TLC showed consumption of starting 
material, about seven h, after which time the reaction was quenched with the addition 
of pH 7 buffer and stirred for two h.  The aqueous layer was extracted with EtOAc 
(3x), the organic extracts combined, washed with brine, dried over MgSO4 and 
purified by prep TLC (hexanes/EtOAc, 40:60) to yield 3.5 mg of an off-white powder 
(19% from vinyl iodide 67): 1H NMR (400 MHz, CDCl3) δ 10.77 (s, 1H), 9.04 (d, J = 
10.3 Hz, 1H), 8.38 (d, J = 10.0 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 6.97-6.86 (m, 3H), 
6.76 (d, J = 6.4 Hz, 1H), 6.77-6.70 (m, 1H), 6.52 (t, J = 11.0 Hz, 1H), 6.42 (t, J = 
10.0 Hz, 1H), 6.31 (d, J = 11.0 Hz, 1H), 6.11 (d, J = 12.5 Hz, 1H), 5.93 (d, J = 11.5 
Hz, 1H), 5.74 (dd, J = 12.5, 3.4 Hz, 1H), 5.30 (dd, J = 10.5, 4.6 Hz, 1H), 4.85 (qu, J = 
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8.6 Hz, 1H), 4.35 (d, J = 9.7 Hz, 1H), 3.95 (s, 3H), 3.20 (d, J = 11.0 Hz, 1H), 2.67-
2.58 (m, 1H), 2.33-2.26 (m, 1H);  HRMS (ESI+), m/z calcd for  C23H25N2O6: 
425.1713 (M+H); found, 425.1707.  UPLC-MS analysis revealed 91.5% purity prior 
to biological testing. 
 
(Z)-tert-Butyldiphenyl(6-(triisopropylsilyl)hex-3-en-5-ynyloxy)silane (141).  Prop-
1-yne-1,3-diylbis(triisopropylsilane) (110) (5.30 g, 15.05 mmol) was dissolved in 
anhydrous THF (125 mL) and cooled to -20 °C.  nBuLi (9.40 mL, 15.05 mmol, 1.6M 
in hexanes) was added dropwise over 10 min, stirred for 30 min, then cooled to -78 
°C.  The aldehyde 120 (3.92 g, 12.55 mmol), as a solution in THF (125 mL), was 
added dropwise to the anion solution over 30 min.  After additional stirring for five h, 
the reaction was allowed to warm to room temperature and stirred for an additional 10 
h.  The reaction was then quenched with saturated NH4Cl solution.  Following 
extraction with EtOAc (3x), washing of combined organic extracts with brine, and 
drying over MgSO4, the crude material was purified via flash column 
chromatography (hexanes/CH2Cl2, 100:0 – 95:5) to yield 1.659 g of the pure Z-enyne 
as a yellow oil (22%): TLC (hexanes/EtOAc, 80:20): Rf = 0.80; 1H NMR (400 MHz, 
CDCl3) δ 7.59-7.56 (m, 4H), 7.36-7.27 (m, 6H), 6.05 (td, J = 11, 7.2 Hz, 1H), 5.59 (d, 





(Z)-6-(Triisopropylsilyl)hex-3-en-5-yn-1-ol (142). The silyl ether 141 (1.66 g, 3.38 
mmol) was dissolved in anhydrous THF (3 mL) at room temperature.  To this 
solution was added 0.4 mL of a 5% NaOH solution (13.5 mmol NaOH) in absolute 
ethanol, then the solution was heated at 55 °C for 12 h.  After heating, the solution 
was cooled to room temperature, dissolved in EtOAc and washed with saturated 
NaHCO3 solution.  The aqueous phase was reextracted with EtOAc and the combined 
organic extracts were washed with brine and dried over MgSO4.  The crude material 
was purified via flash column chromatography (hexanes/EtOAc, 95:5 – 85-15) to 
yield 333 mg of the pure Z-alkenol as a yellow oil (39%): TLC (hexanes/EtOAc, 
80:20): Rf = 0.25; 1H NMR (400 MHz, CDCl3) δ 6.01 (td, J = 11, 7.4 Hz, 1H), 5.67 
(td, J = 11, 1.2 Hz, 1H), 3.75 (t, 6.4 Hz, 2H), 2.63 (dq, J = 6.4, 1.2 Hz, 2H), 1.34 (br, 
1H), 1.09 (s, 21H); 13C NMR (100 MHz, CDCl3) δ 140.4, 112.2, 103.3, 95.9, 61.9, 
33.9, 18.6, 11.3. 
 
(Z)-6-(Triisopropylsilyl)hex-3-en-5-ynyl 2-((E)-2-Iodovinyl)-6-methoxybenzoate 








reduced pressure, then diluted with anhydrous THF (0.340 mL) and cooled to 0 °C.  
NaHMDS (0.135 mL, 0.135 mmol, 1M in THF) was added dropwise and the mixture 
stirred at 0 °C for one h.  A THF solution (0.200 mL) of the vinyl iodide 108 (47.0 
mg, 0.142 mmol) was added dropwise to the anion solution, with continued stirring 
for four h at 0 °C.  Me2SO4 (0.051 mL, 0.540 mmol) was added to quench the 
resultant phenolate anion and the reaction was warmed to room temperature.  After 
three h of stirring, the reaction was quenched with water and extracted with EtOAc 
(3x).  The combined organic extracts were washed with brine, dried over MgSO4 and 
purified via flash column chromatography (hexanes/EtOAc, 95:5 – 90:10) to provide 
52.0 mg of the desired compound as a pale yellow oil (72%), along with a small 
amount of the alcohol (3.00 mg) (79% based on recovered starting material): TLC 
(hexane/EtOAc, 80:20): Rf = 0.55; 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 15 Hz, 
1H), 7.32 (t, J = 8.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 6.87 (d, J = 8.0 Hz, 1H), 6.86 
(d, J = 15 Hz, 1H), 6.05 (td, J = 11, 7.0 Hz, 1H), 5.70 (dd, J = 11, 1.2 Hz, 1H), 4.43 
(t, J = 7.2 Hz, 2H), 3.82 (s, 3H), 2.83-2.78 (m, 2H), 1.07 (s, 21H); 13C NMR (100 
MHz, CDCl3) δ 167.4, 156.6, 141.7, 139.4, 136.4, 130.6, 117.9, 112.4, 110.8, 103.1, 
80.2, 64.3, 56.0, 29.8, 18.6, 11.3. 
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(Z)-Hex-3-en-5-ynyl 2-((E)-2-Iodovinyl)-6-methoxybenzoate (144).  The enyne 
143 (86.0 mg, 0.160 mmol), as a mixture of olefin isomers, was dissolved in 
anhydrous THF (1.60 mL) and cooled to 0 °C.  TBAF (0.168 mL mL, 0.168 mmol, 
1M in THF) was added dropwise.  After 15 min, the reaction was quenched with the 
addition of silica gel, then the THF was removed by rotary evaporation and the crude 
mixture subjected to purification via flash column chromatography (hexanes/Et2O, 
100:0 – 80:20) to collect 58.0 mg of a 4:3 Z:E mixture of olefin isomers, as 
determined by 1H NMR, as a yellow oil (95%): TLC (hexanes/Et2O, 70:30): Rf = 
0.20 for Z-enyne, 0.23 for E-enyne; IR (thin film) υmax = 3293, 2917, 1727, 1602, 
1591, 1571, 1471, 1270, 1117, 1068 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 
15 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 6.87 (d, J = 8.0 Hz, 
1H), 6.86 (d, J = 15 Hz, 1H), 6.11 (td, J = 11, 7.0 Hz, 1H), 5.70 (m, 1H), 4.44 (t, J = 
6.4 Hz, 2H), 3.83 (s, 3H), 3.14 (d, J = 2.0 Hz, 1H), 2.80 (dq, J = 14, 1.2 Hz, 2H); 13C 
NMR (100 MHz, CDCl3) δ 167.3, 156.6, 141.7, 140.6, 136.5, 130.7, 121.8, 117.8, 








CuI (5.0 mg, 0.026 mmol), PPh3 (14 mg, 0.053 mmol) and K2CO3 (22 mg, 0.16 
mmol) were suspended in anhydrous DMSO (20 mL).  This suspension was heated at 
120 °C for 30 min.  The cycle precursor 144 (40 mg, 0.105 mmol) was dissolved in 
DMSO (15 mL) and added dropwise over one h.  The reaction was stirred for an 
additional 1.5 h at 120 °C, then cooled to room temperature.  To the cooled reaction 
mixture was added Et2O and water.  The aqueous layer was extracted with Et2O (2x), 
the combined organic layers were washed with brine and dried over MgSO4.  The 
crude material was purified by flash column chromatography (hexanes/EtOAc, 100:0 
– 85:15) to yield 10 mg of the Z,Z-dienyne cycle as a yellow oil and 12 mg of the 
starting material (37%, 53% based on recovered starting material): TLC 
(hexane/EtOAc, 80:20): Rf = 0.25; 1H NMR (400 MHz, CDCl3) δ 7.33 (t, J = 8.0 Hz, 
1H), 6.87 (d, J = 8.0 Hz, 1H), 6.82-6.79 (m, 2H), 6.11 (td, J = 11, 6.8 Hz, 1H), 5.88 
(d, J = 12 Hz, 1H), 5.66 (t, J = 11 Hz, 1H), 3.82 (s, 3H), methylene protons not 
detected; 13C NMR (100 MHz, CDCl3) δ 168.3, 157.9, 139.6, 137.9, 136.5, 132.1, 
130.6, 128.6, 122.6, 112.4, 111.4, 92.9, 89.4, 64.2, 56.3, 29.7; HRMS (ESI+), m/z 







(5Z,9E)-14-Methoxy-3,4-dihydro-1-oxabenzocyclododeca-5,9-dien-7-ynone (146).  
Following the procedure for the preparation of compound 145, a fast workup and 
column allowed the isolation and spectroscopic identification of the title E,Z-enyne 
cycle 146.  TLC (hexane/EtOAc, 80:20): Rf = 0.25; IR (thin film) υmax =  cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.76 (d, J = 16 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H), 7.23 (d, 
J = 8.0 Hz, 1H), 6.97 (d, J = 8.0 Hz, 1H), 6.30 (d, J = 16 Hz, 1H), 5.68-5.57 (m, 2H), 
3.87 (s, 3H), methylene protons not detected. 
 
(E)-Hex-5-ynyl 2-(2-Iodovinyl)-6-methoxybenzoate (156).  5-Hexyn-1-ol (155) 
(50.0 mg, 0.510 mmol) was dissolved in anhydrous THF (1.40 mL) and cooled to 0 
°C.  NaHMDS (0.540 mL, 0.540 mmol, 1M in THF) was added dropwise and the 
mixture stirred at 0 °C for one h.  A THF solution (0.640 mL) of the vinyl iodide 108 
(163 mg, 0.490 mmol) was added dropwise to the anion solution, with continued 
stirring for two h at 0 °C.  Me2SO4 (0.193 mL, 2.04 mmol) was added to quench the 
resultant phenolate anion and the reaction was warmed to room temperature.  After 
three h of stirring, the reaction was quenched with water and extracted with EtOAc 







purified via flash column chromatography (hexanes/EtOAc, 95:5 – 88:12) to provide 
152 mg of the desired compound as a colorless oil (85%): TLC (hexane/EtOAc, 
80:20): Rf = 0.35; 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 15 Hz, 1H), 7.32 (t, J = 
8.0 Hz, 1H), 7.00 (d, J = 7.9 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 6.86 (d, J = 15 Hz, 
1H), 4.39 (t, J = 6.3 Hz, 2H), 3.84 (s, 3H), 2.28 (dt, J = 6.0, 2.7 Hz, 2H), 1.97 (t, J = 
2.7 Hz, 1H), 1.92-1.85 (m, 2H), 1.74-1.66 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 
167.4, 156.5, 141.7, 136.4, 130.5, 117.9, 110.7, 83.9, 80.2, 68.8, 65.0, 56.0, 27.7, 




(157).  Cu(OAc)2 (6.4 mg, 0.035 mmol), PPh3 (28 mg, 0.106 mmol), K2CO3 (22 mg, 
0.159 mmol) and HCO2Na (29 mg, 0.424 mmol) were suspended in anhydrous DMF 
(11 mL).  This suspension was heated at 110 °C for 30 min, during which time the 
solution turned from colorless to gold.  The cycle precursor 156 (39 mg, 0.102 mmol) 
was dissolved in DMF (10 mL) and added dropwise over one h.  The reaction was 
stirred for an additional two h at 110 °C, then cooled to room temperature.  To the 
cooled reaction mixture was added Et2O and saturated NH4Cl solution.  This mixture 




extracted with Et2O (2x), the combined organic layers were washed with brine and 
dried over MgSO4.  The crude material was purified by flash column chromatography 
(hexanes/EtOAc, 95:5 – 90:10) to yield 10 mg of the diene cycle as a yellow oil 
(38%): TLC (hexane/EtOAc, 80:20): Rf = 0.30; 1H NMR (400 MHz, CDCl3) δ 7.29 
(t, J = 8.0 Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 6.86 (m, 3H), 6.53 (d, J = 16 Hz, 1H), 
6.15 (t, J = 9.6 Hz, 1H), 5.65 (td, J = 11, 7.4 Hz, 1H), 4.51 (t, J = 5.0 Hz, 1H), 3.85 (s, 
3H), 2.36 (q, J = 7.3 Hz, 2H), 1.83 (qu, J = 5.0 Hz, 1H), 1.71 (qu, J = 6.5 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 168.6, 156.7, 137.7, 132.8, 130.9, 130.3, 130.1, 128.5, 
128.3, 120.5, 109.7, 66.0, 56.0, 27.3, 26.2, 26.0; HRMS (ESI+), m/z calcd for 
C16H19O3: 259.1334 (M+H); found, 259.1332. 
 
(Z)-Methyl 4-((3S,4S,5Z,7Z,9E)-4,14-Bis(tert-butyldimethylsilyloxy)-1-oxo-3,4-
dihydro-1H-benzo[c][1]oxacyclododecin-3-yl)but-2-enoate (170).  A flask 
containing Pd(PPh3)4 (71 mg, 0.661 mmol) was flushed with CO (1 atm).  To this 
flask was added DIPEA (0.044 mL, 0.245 mmol) and anhydrous MeOH (4.90 mL) at 
room temperature and the flask was flushed with CO again.  A THF solution of vinyl 
iodide 67 (160 mg, 0.245 mmol in 1.23 mL THF) was added and the reaction stirred 







Celite and the Celite layer was eluted with Et2O until the eluent was colorless.  The 
crude material was purified by flash column chromatography (hexanes/Et2O, 100:0 – 
95:5) to collect 122 mg of the desired ester as a yellow oil (85%): TLC 




25  = -148 (c = 0.600, CHCl3); IR (thin film) υmax 
= 2972, 2861, 1732, 1648, 1561, 1152, 1056, 963 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.17 (t, J = 8.0 Hz, 1H), 7.06 (ddd, J = 16, 10, 0.5 Hz, 1H), 6.79 (d, J = 7.4 Hz, 1H), 
6.75 (d, J = 8.1 Hz, 1H), 6.64 (d, J = 16 Hz, 1H), 6.46 (ddd, J = 12, 7.7, 5.6 Hz, 1H), 
6.34 (t, J = 11 Hz, 1H), 5.97 (dd, J = 12, 4.1 Hz, 1H), 5.89-5.85 (m, 2H), 5.82 (t, J = 
12 Hz, 1H), 5.24 (td, J = 9.1, 4.0 Hz, 1H), 4.64 (dd, J = 10, 3.2 Hz, 1H), 3.74 (s, 3H), 
3.63-3.55 (m, 1H), 3.09-3.00 (m, 1H), 0.98 (s, 9H), 0.88 (s, 9H), 0.22 (s, 3H), 0.20 (s, 
3H), 0.09 (s, 3H), 0.01 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 168.4, 166.6, 152.3, 
146.3, 138.0, 132.4, 130.8, 130.6, 129.7, 129.3, 128.5, 128.0, 126.4, 121.2, 120.4, 
117.8, 78.9, 66.5, 51.1, 29.7, 27.9, 25.8, 25.7, 18.4, 17.9, -4.1, -4.5, -5.0; HRMS 





(166).  Ester 170 (9.5 mg, 0.016 mmol) was dissolved in anhydrous CH2Cl2 (0.160 
mL) and cooled to -78 °C.  To this cooled solution was added DIBAL (0.037 mL, 
0.037 mmol, 1M solution in CH2Cl2) dropwise (*Note: very slow addition of DIBAL 
is required to prevent side reactions).  After 1.5 h of reacting, the cooling bath was 
removed, the reaction quenched with EtOAc and Rochelle’s salt solution was added.  
The mixture was warmed to room temperature and stirred for two h, or until both 
aqueous and organic layers were clear.  The aqueous layer was extracted with EtOAc 
(3x), and the organic extracts combined, washed with brine and dried over MgSO4.  
Purification via flash column chromatography (hexanes/EtOAc, 95:5 – 85:15) yielded 
8 mg of pure allylic alcohol 166 as a colorless oil (90%): TLC (hexanes/EtOAc, 




25  = -94.5 (c = 1.32, CHCl3); IR (thin film) υmax = 3430 (br), 
2959, 1729, 1256, 745 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.17 (t, J = 8.0 Hz, 1H), 
7.05 (dd, J = 16, 11 Hz, 1H), 6.80 (d, J = 7.6 Hz, 1H), 6.76 (d, J = 8.2 Hz, 1H), 6.63 
(d, J = 16 Hz, 1H), 6.34 (t, J = 11 Hz, 1H), 5.97 (dd, J = 12, 4.0 Hz, 1H), 5.87 (dd, J 






Hz, 1H), 4.32-4.28 (m, 1H), 4.16-4.10 (m, 1H), 2.79-2.74 (m, 1H), 2.63-2.56 (m, 1H), 
1.63 (br, 1H), 0.99 (s, 9H), 0.86 (s, 9H), 0.19 (s, 3H), 0.17 (s, 3H), 0.10 (s, 3H), 0.01 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 168.4, 152.0, 138.8, 132.2, 131.3, 130.7, 
130.6, 129.7, 129.3, 128.7, 128.5, 127.9, 126.7, 121.6, 118.5, 79.6, 66.4, 58.5, 25.9, 
18.4, 17.9, -4.0, -4.4, -4.5, -4.9; HRMS (ESI), m/z calcd for C31H48NaO5Si2: 579.2938 




(175).  Allylic alcohol 166 (27 mg, 0.048 mmol), maleimide (107) (5 mg, 0.053 
mmol) and PPh3 (23 mg, 0.086 mmol) were dissolved in anhydrous THF (0.480 mL) 
and cooled to 0 °C.  A solution of DEAD (0.039 mL, 0.086 mmol, 40% w/w solution 
in toluene) was added dropwise, watching the initial yellow color dissipate before an 
additional drop was added.  The reaction was stirred for 15 min, then the volatiles 
were removed by rotary evaporation.  Purification of the crude material by flash 
column chromatography (hexanes/CH2Cl2, 80:20 – 30:70, then hexanes/EtOAc, 








the allylic alcohol 166 (62%, 67% based on recovered starting material): TLC 




25  = -111 (c = 0.310, CHCl3); IR (thin film) 
υmax = 1729, 1155 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.16 (t, J = 8.0 Hz, 1H), 7.06 
(dd, J = 16, 11 Hz, 1H), 6.79 (d, J = 7.7 Hz, 1H), 6.74 (d, J = 8.0 Hz, 1H), 6.63 (d, J 
= 16 Hz, 1H), 6.59 (s, 2H), 6.34 (t, J = 11 Hz, 1H), 6.00 (dd, J = 12, 4.0 Hz, 1H), 5.87 
(dd, J = 11, 4.1 Hz, 1H), 5.85 (t, J = 12 Hz, 1H), 5.81-5.76 (m, 1H), 5.56-5.50 (m, 
1H), 5.14 (td, J =10, 3.0 Hz, 1H), 4.63 (dd, J = 10, 3.0 Hz, 1H), 4.24 (dd, J = 15, 7.1 
Hz, 1H), 4.13 (dd, J = 15, 7.1 Hz, 1H), 2.97-2.91 (m, 1H), 2.76-2.68 (m, 1H), 0.97 (s, 
9H), 0.89 (s, 9H), 0.19 (s, 3H), 0.18 (s, 3H), 0.11 (s, 3H), 0.02 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 170.2, 168.4, 152.4, 137.8, 134.0, 132.2, 130.8, 130.7, 130.7, 129.7, 
129.2, 128.3, 128.0, 126.6, 125.2, 121.2, 118.1, 79.6, 66.6, 34.5, 25.8, 25.8, 18.4, 
17.9, -4.1, -4.2, -4.5, -4.9; HRMS (ESI), m/z calcd for C35H50NO6Si2: 636.3177 












mg, 0.0236 mmol) were suspended in MeOH (0.100 mL) and cooled to 0 °C.  NaBH4 
(0.9 mg, 0.0236 mmol) was added in one portion and the reaction stirred for 30 min.  
The reaction was diluted with MeOH (5 mL) and the volatiles removed by rotary 
evaporation.  This process was repeated two more times, then the crude material was 
purified by flash column chromatography (hexanes/EtOAc, 90:10 – 50:50) to yield 13 
mg of a dark yellow oil (86%), determined by 1H NMR and LC/MS to be a 55:45 
ratio of diastereomers.  These diastereomers were not separated and the mixture used 




25  = -61 (c = 
0.25, CHCl3); IR (thin film) υmax = 3337 (br), 1732, 1690, 1596, 1455, 1253, 1168, 





2-enamide (179).  Hydroxy-pyrrolone 178 (13 mg, 0.020 mmol), NaHCO3 (17 mg, 
0.203 mmol), and MeONH3Cl (17 mg, 0.203 mmol) were suspended in MeOH (0.200 









the solvent was removed by rotary evaporation and the crude material purified by 
flash column chromatography (hexanes/EtOAc, 90:10 – 50:50) to yield 4.5 mg of the 
desired oxime amide 179 as a colorless oil (a 3:1 ratio of E:Z oxime ether 
stereoisomers by 1H NMR) and 5 mg of the starting material (34%, 54% based on 
recovered starting material): TLC (hexanes/EtOAc, 70:30): Rf = 0.65; IR (thin film) 
υmax = 3308 (br), 1733, 1674, 1569, 1539, 1049, 700 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.96 (dd, J = 10, 0.8 Hz, 1H), 7.23-7.18 (m, 1H), 7.02 (dd, J = 16, 11 Hz, 
1H), 6.85 (dd, J = 7.7, 3.6 Hz, 1H), 6.77 (d, J = 8.5 Hz, 1H), 6.63 (d, J = 16 Hz, 1H), 
6.34 (t, J = 11 Hz, 1H), 6.21 (dd, J = 12, 10 Hz, 1H), 5.98 (dd, J = 12, 4.1 Hz, 1H), 
5.88 (dd, J = 11, 4.2 Hz, 1H), 5.84 (br, 1H), 5.79-5.72 (m, 1H), 5.75 (t, J = 11 Hz, 
1H), 5.71-5.64 (m, 1H), 5.46 (dt, J = 11, 0.8 Hz, 1H), 5.12-5.08 (m, 1H), 4.63 (dd, J = 
10, 3.0 Hz, 1H), 4.09-3.99 (m, 1H), 3.93-3.85 (m, 1H), 3.91 (s, 3H), 2.71-2.68 (m, 
2H), 0.98 (s, 9H), 0.89 (s, 9H), 0.17 (s, 3H), 0.15 (s, 3H), 0.10 (s, 3H), 0.01 (s, 3H); 
Minor Z-oxime ether isomer peaks: 8.42 (dd, J = 9.6, 0.9 Hz, 1H), 3.94 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 168.2, 164.7, 151.9, 147.8, 138.2, 133.2, 132.2, 131.3, 
130.7, 130.5, 129.5, 128.7, 128.1, 127.5, 125.5, 122.1, 118.7, 79.5, 66.3, 62.1, 35.9, 
25.9, 25.7, 18.4, 17.9, -4.0, -4.4, -4.5, -4.9; HRMS (ESI), m/z calcd for 






(165).  To a THF solution (0.009 mL) of bis-TBS oxime ether 179 (6 mg, 0.009 
mmol) at room temperature was added 0.055 mL of 5M HF/Py. solution.  The 
reaction was stirred for 24 h, then quenched with pH 7 buffer.  The aqueous layer was 
extracted with EtOAc (3x), the organic extracts washed with brine and dried over 
MgSO4.  Purification of the crude material by flash column chromatography 
(hexanes/EtOAc, 80:20 – 40:60) gave 3.5 mg of a tan solid (89%): TLC 
(hexanes/EtOAc, 50:50): Rf = 0.10; 1H NMR (400 MHz, CDCl3) δ 10.48 (br, 1H), 
8.99 (dd, J = 10, 0.6 Hz, 1H), 7.32 (br, 1H), 6.90 (d, J = 7.9 Hz, 1H), 6.78-6.76 (m, 
3H), 6.40 (t, J = 11 Hz, 2H), 6.30 (br, 1H), 6.08 (d, J = 13 Hz, 1H), 5.93 (br, 1H), 
5.79 (br, 1H), 5.75 (d, J = 7.5 Hz, 1H), 5.65-5.61 (m, 1H), 5.58 (br, 1H), 5.47 (br, 
1H), 4.40 (br, 1H), 3.93 (s, 3H), 3.87 (br, 1H), 3.02 (br, 1H), 2.67 (br, 1H), 2.51 (br, 
1H), 1.29 (br, 1H); HRMS (ESI), m/z calcd for C24H27N2O6: 439.1869 (M+H); found, 












benzo[c][1]oxacyclododecin-3-yl)but-2-enoate (180).  To a THF solution (0.220 
mL) of bis-TBS ester 170 (13 mg, 0.022 mmol) at room temperature was added 0.135 
mL of 5M HF/Py. solution.  The reaction was stirred for 24 h, then quenched with pH 
7 buffer.  The aqueous layer was extracted with EtOAc (3x), the organic extracts 
washed with brine and dried over MgSO4.  Purification of the crude material by flash 
column chromatography (hexanes/EtOAc, 80:20 – 50:50) gave 7 mg of a colorless oil 
(89%): TLC (hexanes/EtOAc, 60:40): Rf = 0.10; 1H NMR (400 MHz, CDCl3) δ 10.30 
(br, 1H), 7.30 (t, J = 8.0 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.77-6.71 (br m, 3H), 6.38 
(br, 1H), 6.22 (br, 1H), 6.07 (br d, J = 12 Hz, 1H), 5.87 (d, J = 11 Hz, 1H), 5.81 (dd, J 
= 12, 4.9 Hz, 1H), 5.59 (br, 1H), 4.42 (br, 1H), 3.68 (s, 3H), 3.26 (br, 1H), 3.10-3.04 
(m, 1H), 2.88 (br, 1H), 1.28 (br, 1H);  HRMS (ESI), m/z calcd for C20H21O6: 357.1338 










benzo[c][1]oxacyclododecin-1-one (181).  To a THF solution (0.230 mL) of bis-TBS 
Z-allylic alcohol 166 (13 mg, 0.023 mmol) at room temperature was added 0.143 mL 
of 5M HF/Pyr. solution.  The reaction was stirred for 24 h, then quenched with pH 7 
buffer.  The aqueous layer was extracted with EtOAc (3x), the organic extracts 
washed with brine and dried over MgSO4.  Purification of the crude material by flash 
column chromatography (hexanes/EtOAc, 50:50 – 30:70) gave 6 mg of a white solid 
(80%): TLC (hexanes/EtOAc, 40:60): Rf = 0.15; 1H NMR (400 MHz, d6-DMSO) δ 
9.34 (s, 1H), 7.16 (t, J = 7.9 Hz, 1H), 6.92 (dd, J = 16, 12 Hz, 1H), 6.75 (d, J = 8.0 
Hz, 1H), 6.70 (s, 1H), 6.68 (t, J = 8.4 Hz, 1H), 6.35 (t, J = 11 Hz, 1H), 5.96 (ddd, J = 
17, 11, 4.2 Hz, 2H), 5.79 (t, J = 11 Hz, 1H), 5.61-5.49 (m, 2H), 5.31 (d, J = 4.6 Hz, 
1H), 5.04 (td, J = 12, 2.0 Hz, 1H), 4.58 (t, J = 5.2 Hz, 1H), 4.36 (td, J =10, 4.0 Hz, 
1H), 4.10-3.98 (m, 2H), 2.73 (m, 1H), 2.39-2.31 (m, 1H), 1.27 (br, 1H); 13C NMR 
(100 MHz, d6-DMSO) δ 168.2, 153.8, 137.4, 132.5, 132.1, 130.7, 129.8, 129.6, 
129.5, 128.5, 128.4, 125.8, 121.8, 118.6, 114.1, 79.0, 64.5, 57.0, 24.9; HRMS (ESI), 
m/z calcd for C19H21O5: 329.1389 (M+H); found, 329.1393;  UPLC-MS analysis 









(183).  To a THF solution (0.141 mL) of bis-TBS hydroxy-pyrrole 178 (9 mg, 0.0141 
mmol) at room temperature was added 0.0.086 mL of 5M HF/Py. solution.  The 
reaction was stirred for 24 h, then quenched with pH 7 buffer.  The aqueous layer was 
extracted with EtOAc (3x), the organic extracts washed with brine and dried over 
MgSO4.  Purification of the crude material by flash column chromatography 
(hexanes/EtOAc, 70:30 – 0:100) gave 4 mg of a tan solid (69%): TLC 
(hexanes/EtOAc, 40:60): Rf = 0.04; 1H NMR (400 MHz, d6-DMSO) δ 9.93 (d, J = 12 
Hz, 1H), 7.16 (t, J = 7.9 Hz, 1H), 7.01 (d, J = 6.0 Hz, 1H), 6.98-6.90 (m, 1H), 6.76 
(dd, J = 8.0, 5.0 Hz, 1H), 6.70 (s, 1H), 6.68 (t, J = 7.0 Hz, 1H), 6.36 (t, J = 11 Hz, 
1H), 6.19 (dd, J = 9.1, 6.5 Hz, 1H), 6.09 (dd, J = 7.8, 6.0 Hz, 1H), 5.97 (ddd, J = 15, 
11, 4.0 Hz, 2H), 5.81 (t, J = 11 Hz, 1H), 5.67-5.61 (m, 1H), 5.51-5.45 (m, 1H), 5.36-
5.32 (m, 2H), 5.08 (td, J = 9.3, 5.0 Hz, 1H), 4.38 (td, J = 10, 3.8 Hz, 1H), 4.12-4.07 
(m, 1H), 3.81 (dd, J = 15, 7.8 Hz, 1H), 2.86-2.78 (m, 1H), 2.58-2.50 (m, 1H); 13C 








129.6, 129.5, 128.6, 128.5, 128.4, 127.1, 121.8, 118.7, 114.2, 82.0, 81.9, 64.6, 35.4, 
24.7, 20.8; HRMS (ESI), m/z calcd for C23H24NO6: 410.1604 (M+H); found, 
410.1591;  UPLC-MS analysis revealed 85.5% purity prior to biological testing. 
 
4.3.2 Chapter 2 
 
2-Chloro-3-(1H-pyrrol-1-yl)benzoic Acid (242).  3-Amino-2-chloro-benzoic acid 
241 (50 mg, 0.291 mmol) was dissolved in HOAc (0.090 mL).  To this solution was 
added 2,5-dimethoxytetrahydrofuran (229) (40 mg, 0.040 mL, 0.306 mmol) and the 
mixture heated to reflux for two h.  The solution was then cooled to room temperature 
and the volatiles removed under reduced pressure.  The resultant material was 
dissolved in Et2O, filtered through filter paper, and purified by flash column 
chromatography (hexanes/EtOAc, 50:50 – 40:60) to yield 9 mg of a white solid 
(14%): TLC (hexanes/EtOAc, 25:75): Rf = 0.60; 1H NMR (400 MHz, d6-DMSO) δ 
13.66 (br, 1H), 7.66 (br d, J = 6.7 Hz, 1H), 7.50-7.47 (m, 2H), 6.99 (t, J = 2.2 Hz, 
2H), 6.25 (t, J = 2.2 Hz, 2H); HRMS (ESI-), m/z calcd for C11H7ClNO2: 220.0171 






2-Chloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic Acid (245).  4-Amino-2-chloro-
benzoic acid (243) (100 mg, 0.583 mmol) was dissolved in HOAc (0.175 mL).  To 
this solution was added 2,5-hexanedione (244) (70 mg, 0.072 mL, 0.612 mmol) and 
the mixture heated to reflux for two h.  The solution was then cooled to room 
temperature and the volatiles removed under reduced pressure.  The resultant material 
was dissolved in Et2O, filtered through filter paper, and purified by flash column 
chromatography (hexanes/EtOAc, 50:50 – 40:60) to yield 4 mg of a white solid (3%):  
TLC (hexanes/EtOAc, 25:75): Rf = 0.50; 1H NMR (400 MHz, d6-DMSO) δ 13.58 (br, 
1H), 7.89 (d, J = 8.2 Hz, 1H), 7.52 (d, J = 2.0 Hz, 1H), 7.34 (dd, J = 8.2, 2.0 Hz, 1H), 
5.84 (s, 2H), 2.00 (s, 6H); 13C NMR (100 MHz, d6-DMSO) δ 166.3, 141.3, 132.1, 
131.4, 129.7, 127.7, 126.8, 106.8, 12.8; HRMS (ESI-), m/z calcd for C13H11ClNO2: 
248.0484 (M-H); found, 248.0488. 
 
3-Hydroxy-4-(1H-pyrrol-1-yl)benzoic Acid (247). 4-Amino-3-hydroxy-benzoic 








solution was added 2,5-dimethoxytetrahydrofuran (229) (91 mg, 0.089 mL, 0.686 
mmol) and the mixture heated to reflux for two h.  The solution was then cooled to 
room temperature and the volatiles removed under reduced pressure.  The resultant 
material was dissolved in Et2O, filtered through filter paper, and purified by flash 
column chromatography (hexanes/EtOAc, 50:50 – 40:60) to yield 10 mg of a brown 
solid (8%): TLC (hexanes/EtOAc, 25:75): Rf = 0.45; 1H NMR (400 MHz, d6-DMSO) 
δ 12.88 (br, 1H), 10.37 (br, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.44 (d, J = 1.8 Hz, 1H), 
7.4 (s, 1H), 7.36 (dt, J = 7.6, 1.2 Hz, 1H), 7.21 (t, J = 2.2 Hz, 2H), 6.21 (t, J = 2.2 Hz, 
2H). 
 
2-Hydroxy-4-(1H-pyrrol-1-yl)benzoic Acid (249).  4-Amino-2-hydroxy-benzoic 
acid (248) (100 mg, 0.653 mmol) was dissolved in HOAc (0.200 mL).  To this 
solution was added 2,5-dimethoxytetrahydrofuran (229) (91 mg, 0.089 mL, 0.686 
mmol) and the mixture heated to reflux for two h.  The solution was then cooled to 
room temperature and the volatiles removed under reduced pressure.  The resultant 
material was dissolved in Et2O, filtered through filter paper, and purified by flash 
column chromatography (hexanes/EtOAc, 50:50 – 40:60) to yield 89 mg of a white 
solid (67%): TLC (hexanes/EtOAc, 25:75): Rf = 0.60; 1H NMR (400 MHz, d6-





2H), 7.21 (d, J = 2.2 Hz, 1H), 7.18 (dd, J = 8.5, 2.2 Hz, 1H), 6.30 (t, J = 2.2 Hz, 2H); 
13C NMR (100 MHz, d6-DMSO) δ 171.6, 162.6, 145.2, 131.9, 119.1, 111.5, 109.7, 
109.4, 106.2; HRMS (ESI-), m/z calcd for C11H8NO3: 202.0510 (M-H); found, 
202.0506. 
 
2-Chloro-4-(1H-pyrrol-1-yl)benzoic Acid (251).  4-Amino-2-chloro-benzoic acid 
(250)(100 mg, 0.583 mmol) was dissolved in HOAc (0.175 mL).  To this solution 
was added 2,5-dimethoxytetrahydrofuran (229) (81 mg, 0.079 mL, 0.612 mmol) and 
the mixture heated to reflux for two h.  The solution was then cooled to room 
temperature and the volatiles removed under reduced pressure.  The resultant material 
was dissolved in Et2O, filtered through filter paper, and purified by flash column 
chromatography (hexanes/EtOAc, 50:50 – 40:60) to yield 12 mg of a white solid 
(9%): TLC (hexanes/EtOAc, 25:75): Rf = 0.60; 1H NMR (400 MHz, d6-DMSO) δ 
13.31 (br, 1H), 7.89 (d, J = 8.6 Hz, 1H), 7.84 (d, J = 2.2 Hz, 1H), 7.67 (dd, J = 8.6, 
2.2 Hz, 1H), 7.55 (t, J = 2.2 Hz, 2H), 6.32 (t, J = 2.2 Hz, 2H); 13C NMR (100 MHz, 
d6-DMSO) δ 165.9, 142.5, 133.7, 132.7, 120.3, 119.2, 116.9, 111.6; HRMS (ESI-), 






3-Nitro-4-(1H-pyrrol-1-yl)benzoic Acid (253).  4-Amino-3-nitro-benzoic acid (252) 
(100 mg, 0.549 mmol) was dissolved in HOAc (0.165 mL).  To this solution was 
added 2,5-dimethoxytetrahydrofuran (229) (76 mg, 0.075 mL, 0.575 mmol) and the 
mixture heated to reflux for two h.  The solution was then cooled to room temperature 
and the volatiles removed under reduced pressure.  The resultant material was 
dissolved in Et2O, filtered through filter paper, and purified by flash column 
chromatography (hexanes/EtOAc, 50:50 – 20:80) to yield 3 mg of a gold solid (2%): 
TLC (hexanes/EtOAc, 25:75): Rf = 0.20; 1H NMR (500 MHz, d6-DMSO) δ 13.79 (br, 
1H), 8.50 (d, J = 2.2 Hz, 1H), 8.31 (dd, J = 8.4, 2.2 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 
7.05 (t, J = 2.0 Hz, 2H), 6.39 (t, J = 2.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 
165.0, 143.8, 135.7, 134.1, 128.7, 128.0, 121.3, 111.5. 
 
1-(4-Chloro-3-nitrophenyl)-1H-pyrrole (238).  4-Chloro-3-nitroaniline (254) (100 
mg, 0.579 mmol) was dissolved in HOAc (0.174 mL).  To this solution was added 








heated to reflux for two h.  The solution was then cooled to room temperature and the 
volatiles removed under reduced pressure.  The resultant material was dissolved in 
Et2O, filtered through filter paper, and purified by flash column chromatography 
(hexanes/EtOAc, 50:50 – 20:80) to yield 39 mg of a yellow solid (30%): TLC 
(hexanes/EtOAc, 25:75): Rf = 0.65; 1H NMR (400 MHz, d6-DMSO) δ 8.33 (d, 1H, J 
= 2.7 Hz), 7.95 (dd, J = 8.9, 2.7 Hz, 1H), 7.81 (d, J = 8.9 Hz, 1H), 7.53 (t, J = 2.3 Hz, 
2H), 6.33 (t, J = 2.3 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 148.5, 139.3, 132.5, 
123.3, 120.0, 119.3, 115.2, 111.7. 
 
4-(1H-Pyrrol-1-yl)phenol (256).  4-Amino-phenol (255) (100 mg, 0.916 mmol) was 
dissolved in HOAc (0.300 mL).  To this solution was added 2,5-
dimethoxytetrahydrofuran (229) (127 mg, 0.125 mL, 0.962 mmol) and the mixture 
heated to reflux for two h.  The solution was then cooled to room temperature and the 
volatiles removed under reduced pressure.  The resultant material was dissolved in 
Et2O, filtered through filter paper, and purified by flash column chromatography 
(hexanes/EtOAc, 50:50 – 40:60) to yield 70 mg of a white solid (48%): TLC 
(hexanes/EtOAc, 25:75): Rf = 0.85; 1H NMR (400 MHz, d6-DMSO) δ 9.48 (s, 1H), 




2.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 155.2, 132.3, 121.2, 119.1, 115.9, 109.6; 
LRMS (ES+), m/z calcd for C10H10NO: 160.1 (M+H); found, 160.1. 
 
2-(3-(1H-Pyrrol-1-yl)phenyl)acetic Acid (258).  3-Aminophenylacetic acid (257) 
(100 mg, 0.662 mmol) was dissolved in HOAc (0.200 mL).  To this solution was 
added 2,5-dimethoxytetrahydrofuran (229) (92 mg, 0.090 mL, 0.695 mmol) and the 
mixture heated to reflux for two h.  The solution was then cooled to room temperature 
and the volatiles removed under reduced pressure.  The resultant material was 
dissolved in Et2O, filtered through filter paper, and purified by flash column 
chromatography (hexanes/EtOAc, 50:50 – 40:60) to yield 27 mg of a pale yellow 
solid (20%): TLC (hexanes/EtOAc, 25:75): Rf = 0.60; 1H NMR (400 MHz, d6-
DMSO) δ 12.40 (br, 1H), 7.47-7.43 (m, 2H), 7.38 (t, J = 7.6 Hz, 1H), 7.33 (t, J = 2.2 
Hz, 2H), 7.13 (d, J = 7.5 Hz, 1H), 6.26 (t, J = 2.2 Hz, 2H), 3.64 (s, 2H); 13C NMR 
(100 MHz, CDCl3) δ 172.5, 139.8, 136.7, 129.5, 126.4, 120.5, 118.9, 117.6, 110.4, 





2-Chloro-5-(pyrrolidin-1-yl)benzoic Acid (261).  5-Amino-2-chlorobenzoic acid 
(259) (100 mg, 0.583 mmol) was dissolved in HOAc (0.200 mL).  To this solution 
was added 1,4-dibromobutane (260) (139 mg, 0.076 mL, 0.641 mmol) and the 
mixture heated to 90 °C for 12 h.  The solution was then cooled to room temperature 
and the volatiles removed under reduced pressure.  The resultant material was 
dissolved in Et2O, filtered through filter paper, and purified by flash column 
chromatography (hexanes/EtOAc, 60:40) to yield 16 mg of a yellow solid (12%): 
TLC (hexanes/EtOAc, 25:75): Rf = 0.50; 1H NMR (400 MHz, d6-DMSO) δ 13.14 (br, 
1H), 7.24 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 3.0 Hz, 1H), 6.64 (dd, J = 8.8, 3.0 Hz, 1H), 
3.22 (t, J = 6.5 Hz, 4H), 1.95 (t, J = 6.5 Hz, 4H); 13C NMR (100 MHz, d6-DMSO) δ 
167.4, 146.1, 131.7, 130.7, 116.6, 115.1, 112.7, 47.4, 25.0; HRMS (ES+), m/z calcd 
for C11H13ClNO2: 226.0635 (M+H); found, 226.0638. 
 
2-Chloro-5-(2,5-dioxopyrrolidin-1-yl)benzoic Acid (263).  5-Amino-2-









To this solution was added succinic anhydride (262) (61 mg, 0.612 mmol) and the 
mixture heated to reflux for two h.  The solution was then cooled to room temperature 
and the volatiles removed under reduced pressure.  The resultant material was 
dissolved in Et2O, filtered through filter paper, and purified by flash column 
chromatography (hexanes/EtOAc, 60:40) to yield 59 mg of a yellow solid (40%): 
TLC (hexanes/EtOAc, 25:75): Rf = 0.50; 1H NMR (400 MHz, d6-DMSO) δ 13.50 (br, 
1H), 7.76 (d, J = 2.5 Hz, 1H), 7.68 (d, J = 8.6 Hz, 1H), 7.45 (dd, J = 8.6, 2.5 Hz, 1H), 
2.78 (s, 4H); 13C NMR (100 MHz, d6-DMSO) δ 176.6, 165.9, 131.7, 131.6, 131.2, 
131.2, 131.0, 129.4, 28.5; HRMS (ESI-), m/z calcd for C11H7ClNO4: 252.0069 (M-H); 
found, 252.0056. 
 
2-Chloro-5-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic Acid (265).  5-Amino-
2-chlorobenzoic acid (259) (500 mg, 2.914 mmol) was dissolved in HOAc (2.90 mL).  
To this solution was added maleic anhydride (264) (286 mg, 2.914 mmol) and the 
mixture heated to reflux for two h.  The solution was then cooled to room 
temperature, upon which time a yellow precipitate formed.  The precipitate was 
filtered and washed with water, dried under reduced pressure, and recrystallized from 
EtOH to yield 339 mg of a bright yellow solid (46%): TLC (hexanes/EtOAc, 25:75): 






7.68 (d, J = 8.6 Hz, 1H), 7.53 (dd, J = 8.4, 2.5 Hz, 1H), 7.21 (s, 2H); 13C NMR (100 
MHz, d6-DMSO) δ 169.5, 166.0, 134.8, 131.8, 131.2, 130.6, 130.4, 128.6; HRMS 
(ESI-), m/z calcd for C11H5ClNO4: 249.9913 (M-H); found, 249.9912. 
 
Methyl 2-Chloro-5-(1H-pyrrol-1-yl)benzoate (239).  2-Chloro-5-(1H-pyrrol-1-
yl)benzoic acid (226) (10 mg, 0.045 mmol) was dissolved in anhydrous MeOH (0.090 
mL) at room temperature.  A solution of TMSCH2N2 (0.113 mL, 0.226 mmol, 2.0M 
in Et2O) was added dropwise and a yellow color developed in the reaction medium.  
After five min of stirring, the reaction was quenched with three drops of HOAc and 
the volatiles were removed under reduced pressure.  The resultant material was 
purified by flash column chromatography (hexanes/EtOAc, 70:30) to yield 10 mg of a 
brown oil (94%): TLC (hexanes/EtOAc, 70:30): Rf = 0.75; 1H NMR (400 MHz, 
CDCl3) δ 7.68 (d, J = 2.7 Hz, 1H), 7.31 (d, J = 8.6 Hz, 1H), 7.26 (dd, J = 8.6, 2.7 Hz, 
1H), 6.90 (t, J = 2.2 Hz, 2H), 6.20 (t, J = 2.2 Hz, 2H), 3.79 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 165.6, 139.3, 132.3, 131.0, 130.4, 124.1, 122.9, 110.3, 111.5, 52.8; 






2-Chloro-N,N-dimethyl-5-(1H-pyrrol-1-yl)benzamide (240).  2-Chloro-5-(1H-
pyrrol-1-yl)benzoic acid (226) (30 mg, 0.135 mmol) and Me2NH2Cl (12 mg, 0.149 
mmol) were dissolved in anhydrous DMF (0.200 mL) at 0 °C.  EDCI (40 mg, 0.203 
mmol) was added in one portion and the reaction stirred for 16 h, allowing to warm to 
room temperature.  The reaction was the diluted with Et2O and quenched with cold 
10% HCl solution.  The organic layer was separated from the aqueous layer and the 
organic layer washed with water (3x), brine (1x) and dried over Na2SO4 to yield 10 
mg of a white solid (24%): TLC (hexanes/EtOAc, 25:75): Rf = 0.65; 1H NMR (400 
MHz, CDCl3) δ 7.44 (dd, J = 8.3, 0.6 Hz, 1H), 7.37-7.33 (m, 2H), 7.06 (t, J = 2.2 Hz, 
2H), 6.37 (t, J = 2.2 Hz, 2H), 3.17 (s, 3H), 2.92 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 167.8, 140.0, 137.7, 130.9, 127.1, 121.8, 119.6, 119.3, 111.4, 38.3, 34.9; HRMS 






4.3.3 Chapter 3 
 
(4,5-Dichloro-2-nitrophenyl)(2,4,5-trichlorophenyl)sulfane (277). 2,4,5-Trichloro-
thiophenol (275) (20.7 g, 97.0 mmol), 1,2-dichloro-4-fluoro-5-nitrobenzene (276) 
(22.4 g, 107 mmol), K2CO3 (67.0 g, 485 mmol), CaCO3 (7.31 g, 73.0 mmol) and two 
weight equivalents of activated 3Å mol. sieves were stirred and heated in refluxing 
CH2Cl2 (500 mL) for 21 h.  Upon cooling to room temperature, a yellow precipitate 
formed that was filtered and washed with CH2Cl2 to yield 37.1 g of a yellow solid 
(97%): TLC (hexanes/EtOAc, 95:5): Rf = 0.70; 1H NMR (400 MHz, CDCl3) δ 8.38 
(s, 1H), 7.80 (s, 1H), 7.72 (s, 1H), 6.76 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 139.8, 
138.8, 138.6, 136.8, 135.9, 132.9, 132.6, 131.3, 130.5, 129.1, 128.6, 127.8; GC/MS : 
tR = 43:08 min, 401 (10% (C12H4Cl5NO2S+·)), 354 (2% (C12H3Cl5S+)), 337 (3% 
(C12H4Cl5NO2S+·)), 302 (75% (C12H4Cl4NO2S+· - 64)), 276 (3% (C12H3Cl3NO2S+· - 
64)), 250 (13% (C12H4Cl2S+)), 176 (12% (C12S+)); melting point 162-164 °C. 
 
4,5-Dichloro-2-(2,4,5-trichlorophenylthio)aniline (278). To a refluxing solution of 
nitrobenzene 277 (44.4 g, 110 mmol) in HOAc (375 mL), acetone (1.5 L), and 
















h.  The reaction was refluxed for 30 additional min, then cooled.  Upon cooling to 
room temperature, the solution pH was adjusted to 8 with 1N NaOH solution.  The 
solution was then filtered through a pad of Celite and the rinsed with 1N NaOH 
solution, water, acetone and Et2O until the solvent became colorless.  The resulting 
eluent was then extracted with Et2O, dried over MgSO4 and concentrated under 
reduced pressure.  The crude material was washed with hexanes and the hexanes were 
decanted, yielding 35.3 g of the desired aniline product 278 as a bright yellow solid 
(86%): TLC (hexanes/EtOAc, 95:5): Rf = 0.35; 1H NMR (400 MHz, CDCl3) δ 7.50 
(s, 1H), 7.45 (s, 1H), 6.93 (s, 1H), 6.65 (s, 1H), 4.33 (s, 2H); 13C NMR (100 MHz, 
CDCl3) δ 148.4, 138.4, 136.5, 135.3, 132.2, 131.0, 130.4, 130.0, 127.3, 121.6, 116.8, 
111.4; GC/MS: tR = 44:13 min, 371 (57% (C12H6Cl5NS+·)), 335 (44% 
(C12H5Cl4NS+)), 301 (60% (C12H6Cl3NS+)), 266 (10% (C12H6Cl2NS+)), 230 (4% 
(C12H5ClNS+)), 192 (17% (C12H2NS+)); melting point 190-192 °C. 
 
2,3,7,8-Tetrachloro-10H-phenothiazine (274). Microwave conditions: A solution 
containing Pd(OAc)2 (4.65 mg, 0.0207 mmol) and 2-(dicyclohexyl-phosphano)-
biphenyl (14.5 mg, 0.0414 mmol) in anhydrous DMF (4.65 mL) was prepared and 
added to aniline 278 (75.0 mg, 0.207 mmol) and NaOtBu (27.0 mg, 0.282 mmol) in a 
microwave reaction vessel. The contents were flushed with argon for five min, 







reaction was complete, the DMF was removed by pouring the reaction solution into a 
separatory funnel containing aqueous sodium hydrosulfite (40 mL), the aqueous layer 
extracted with hexanes:EtOAc (50:50), concentrated under reduced pressure, and 
purified by flash chromatography hexanes:t-butyl methyl ether (90:10). The resultant 
product was then recrystallized from CHCl3 to yield 26 mg of an off-white solid 
(37%).  
Conventional heating: A solution containing Pd(OAc)2 (4.65 mg, 0.0207 mmol) and 
2-(dicyclohexylphosphano)-biphenyl (14.5 mg, 0.0414 mmol) in anhydrous DMF 
(4.65 mL) was prepared and added to aniline 278 (75.0 mg, 0.207 mmol) and sodium 
tert-butoxide (27.0 mg, 0.282 mmol) under an argon atmosphere. The reaction was 
stirred and heated at 150 °C for 1 h. After the reaction was complete, the reaction was 
cooled and diluted with a saturated solution of Na2SO3 then extracted with 
hexanes:EtOAc (50:50), concentrated under reduced pressure, and purified by flash 
chromatography as above. The solid was re-crystallized from CHCl3 to yield 25 mg 
of the off-white solid (35 %): TLC (hexanes/EtOAc, 95:5): Rf = 0.45; 1H NMR (400 
MHz, CDCl3) δ 7.01 (s, 2H), 6.63 (s, 1H), 5.83 (s, 1H); 13C NMR (100 MHz, CDCl3) 
δ 139.7, 131.1, 127.4, 125.9, 117.6, 115.7; GC/MS: tR = 49:34 min, 335 (73% 
(C12H5Cl4NS+)), 300 (62% (C12H5Cl3NS+)), 264 (11% (C12H4Cl2NS+)), 230 (9% 
(C12H5ClNS+)), 194 (4% (C12H4NS+)), 168 (12% ([CHClNS·]2+)), 132 (14% 
(CHClNS2+)); melting point 224-226 °C. 
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The dihedral angle between the two 6-membered carbon rings was 18.50(9)°.  The 
displacement ellipsoids were drawn at the 50% probability level.  
 
Experimental 
 A pink needle-shaped crystal of dimensions 0.41 x 0.10 x 0.08 mm was 
selected for structural analysis.  Intensity data for this compound were collected using 
a Bruker APEX ccd area detector1 mounted on a Bruker D8 goniometer using with 
graphite-monochromated Mo Ka radiation (l = 0.71073 Å).  The sample was cooled 
to 100 K.2 The intensity data were measured as a series of w oscillation frames each 
of 0.25 ° for 15 sec / frame.  The detector was operated in 512 x 512 mode and was 
positioned 5.054 cm from the sample.  Coverage of unique data was 99.9% complete 
to 25.99 degrees in q.  Cell parameters were determined from a non-linear least 
squares fit of 5247 peaks in the range 2.36 < q < 26.00°.  A total of 6689 data were 
measured in the range 1.96 < q < 25.99°.  The data were corrected for absorption by 
the semi-empirical method2 giving minimum and maximum transmission factors of 
0.6567 and 0.9158.  The data were merged to form a set of 2155 independent data 
with R(int) = 0.0233.   
 The orthorhombic space group Pna21 was determined by systematic absences 
and statistical tests and verified by subsequent refinement.  The structure was solved 
by direct methods and refined by full-matrix least-squares methods on F2. 3 
Hydrogen atom positions were initially determined by geometry and refined by a 
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riding model.  Non-hydrogen atoms were refined with anisotropic displacement 
parameters.  Hydrogen atom displacement parameters were set to 1.2 (1.5 for methyl) 
times the displacement parameters of the bonded atoms.  A total of 163 parameters 
were refined against 1 space group restraint and 2155 data to give wR(F2) = 0.0764 
and S = 1.065 for weights of w = 1/[s2 (F2) + (0.0600 P)2], where P = [Fo2 + 2Fc2] / 
3.  The final R(F) was 0.0284 for the  2122 observed, [F > 4s(F)], data.  The largest 
shift/s.u. was 0.001 in the final refinement cycle.  The final difference map had 
maxima and minima of 0.521 and -0.225 e/Å3, respectively.  The absolute structure 
was determined by refinement of the Flack parameter.4 The polar axis restraint was 
taken from Flack and Schwarzenbach.5 
 
References 
 (1) (a) Data Collection:  SMART Software Reference Manual (1994). Bruker-AXS, 
6300 Enterprise Dr., Madison, WI 53719-1173, USA. (b) Data Reduction:  SAINT 
Software Reference Manual (1995). Bruker-AXS, 6300 Enterprise Dr., Madison, WI 
53719-1173, USA.  
(2) G. M. Sheldrick (2000).  SADABS.  Program for Empirical Absorption 
Correction of Area Detector Data.  University of Göttingen, Germany.  
(3) (a) G. M. Sheldrick (1994). SHELXTL Version 5 Reference Manual. Bruker-
AXS, 6300 Enterprise Dr., Madison, WI 53719-1173, USA.  (b) International Tables 
for Crystallography, Vol C, Tables 6.1.1.4, 4.2.6.8, and 4.2.4.2, Kluwer:  Boston 
(1995).  
 267 
(4) H. D. Flack, Acta Cryst. A39, 876-881 (1983).  
(5) H. D. Flack and D. Schwarzenbach, Acta Cryst. A44, 499-506 (1988).  
 268 
Table A.  Crystal data and structure refinement for 03065a 
Identification code 03065a 
Empirical formula  C12 H5 Cl4 N S 
Formula weight  337.03 
Crystal system  Orthorhombic 
Space group  Pna21 
Unit cell dimensions  a = 20.7356(18) Å a= 90° 
 b = 15.4686(13) Å b= 90° 
 c = 3.7921(3) Å g= 90° 
Volume 1216.32(18) Å3 
Z, Z' 4, 1 
Density (calculated) 1.840 Mg/m3 
Wavelength  0.71073 Å 
Temperature  100(2) K 
F(000) 672 
Absorption coefficient 1.120 mm-1 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9158 and 0.6567 
Theta range for data collection 1.96 to 25.99° 
Reflections collected 6689 
Independent reflections 2155 [R(int) = 0.0233] 
Data / restraints / parameters 2155 / 1 / 163 
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wR(F2 all data) wR2 = 0.0764 
R(F obsd data) R1 = 0.0284 
Goodness-of-fit on F2 1.065 
Observed data [I > 2s(I)] 2122 
Absolute structure parameter 0.01(7) 
Largest and mean shift / s.u. 0.001and 0.000 
Largest diff. peak and hole 0.521 and -0.225 e/Å3  
 
Pertinent Equations 
wR2 = [ S [w(Fo2 - Fc2)2] / S [w(Fo 2)2] ]1/2 





Table B.  Atomic coordinates and equivalent isotropic displacement parameters for 
03065a. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
______________________________________________________________    
 x y z U(eq) 
_____________________________________________________________  
C(1) 0.57689(11) 0.77389(15) 0.5877(7) 0.0177(5) 
C(2) 0.51286(11) 0.79932(14) 0.5582(7) 0.0176(5) 
Cl(2) 0.49186(3) 0.90198(4) 0.69331(19) 0.02254(16) 
C(3) 0.46771(10) 0.74260(16) 0.4228(7) 0.0166(5) 
Cl(3) 0.38742(2) 0.77147(4) 0.37295(18) 0.02273(16) 
C(4) 0.48659(10) 0.66019(15) 0.3198(7) 0.0165(5) 
S(5) 0.57261(2) 0.53227(4) 0.17962(18) 0.01547(15) 
C(6) 0.67314(10) 0.43390(15) 0.4049(7) 0.0156(5) 
C(7) 0.73396(10) 0.42031(15) 0.5383(7) 0.0175(5) 
Cl(7) 0.76302(3) 0.31494(4) 0.56922(17) 0.02295(17) 
C(8) 0.77122(10) 0.48909(16) 0.6544(7) 0.0185(5) 
Cl(8) 0.84820(3) 0.47391(4) 0.8203(2) 0.02428(17) 
C(9) 0.74672(10) 0.57235(16) 0.6416(7) 0.0186(5) 
N(10) 0.66198(8) 0.67132(13) 0.4891(7) 0.0202(5) 
C(11) 0.59645(11) 0.69274(15) 0.4762(7) 0.0167(5) 
C(12) 0.55039(9) 0.63482(14) 0.3440(6) 0.0142(4) 
C(13) 0.64829(10) 0.51734(14) 0.3841(7) 0.0150(5) 
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C(14) 0.68528(10) 0.58688(15) 0.5071(7) 0.0157(5) 
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Table C.   Bond lengths [Å] and angles [°] for 03065a 
_____________________________________________________________ 
C(1)-C(11)   1.385(3) 
C(1)-C(2)    1.389(3) 
C(1)-H(1)    0.9500 
C(2)-C(3)    1.382(3) 
C(2)-Cl(2)   1.725(2) 
C(3)-C(4)    1.390(3) 
C(3)-Cl(3)   1.734(2) 
C(4)-C(12)   1.383(3) 
C(4)-H(4)    0.9500 
S(5)-C(12)   1.765(2) 
S(5)-C(13)   1.766(2) 
C(6)-C(7)    1.375(3) 
C(6)-C(13)   1.392(3) 
C(6)-H(6)   0.9500 
C(7)-C(8)   1.386(3) 
C(7)-Cl(7)   1.742(2) 
C(8)-C(9)   1.385(3) 
C(8)-Cl(8)   1.732(2) 
C(9)-C(14)   1.391(3) 
C(9)-H(9)   0.9500 
N(10)-C(14)   1.394(3) 
N(10)-C(11)   1.400(3) 
N(10)-H(10)   0.9499 
C(11)-C(12)   1.402(3) 
C(13)-C(14)   1.401(3) 
 
 
C(11)-C(1)-C(2)  120.8(2) 
C(11)-C(1)-H(1)  119.6 
C(2)-C(1)-H(1)  119.6 















C(7)-C(6)-C(13)  120.1(2) 
C(7)-C(6)-H(6)  119.9 
C(13)-C(6)-H(6)  119.9 










C(8)-C(9)-C(14)  119.9(2) 
C(8)-C(9)-H(9)  120.0 



















Table D.   Anisotropic displacement parameters (Å2x 103) for 03065a.  The 
anisotropic displacement factor exponent takes the form: 
-2 p2[h2 a*2 U11 + ... + 2 h k a* b* U12] 
______________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________  
 
C(1) 23(1)  16(1) 14(1)  -2(1) -1(1)  -3(1) 
C(2) 28(1)  11(1) 14(1)  2(1) 3(1)  3(1) 
Cl(2) 31(1)  14(1) 23(1)  -2(1) 1(1)  4(1) 
C(3) 18(1)  20(1) 12(1)  4(1) 2(1)  3(1) 
Cl(3) 20(1)  22(1) 25(1)  0(1) -1(1)  5(1) 
C(4) 21(1)  17(1) 12(1)  4(1) 0(1)  -3(1) 
S(5) 19(1)  14(1) 14(1)  -3(1) -1(1)  1(1) 
C(6) 19(1)  16(1) 11(1)  -1(1) 5(1)  -3(1) 
C(7) 23(1)  14(1) 16(1)  2(1) 5(1)  5(1) 
Cl(7) 24(1)  18(1) 27(1)  2(1) 3(1)  7(1) 
C(8) 16(1)  24(1) 16(1)  2(1) 2(1)  1(1) 
Cl(8) 17(1)  29(1) 28(1)  4(1) -1(1)  2(1) 
C(9) 19(1)  21(1) 16(1)  1(1) 0(1)  -4(1) 
N(10) 18(1)  15(1) 27(1)  -2(1) -2(1)  -4(1) 
C(11) 23(1)  15(1) 13(1)  5(1) 1(1)  0(1) 
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C(12) 21(1)  12(1) 10(1)  3(1) 2(1)  2(1) 
C(13) 17(1)  18(1) 10(1)  2(1) 2(1)  -1(1) 
C(14) 19(1)  16(1) 12(1)  2(1) 2(1)  -2(1) 
______________________________________________________________ 
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 Table E.   Hydrogen coordinates and isotropic displacement parameters for 03065a. 
______________________________________________________________  
x   y   z   U(eq) 
______________________________________________________________  
  
H(1)  0.6076  0.8126  0.6854     0.021 
H(4)  0.4553  0.6208  0.2317     0.020 
H(6)  0.6480  0.3862  0.3267     0.019 
H(9)  0.7719  0.6195  0.7246     0.022 
H(10)  0.6883  0.7077  0.6305     0.024 
______________________________________________________________ 
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Table G.  Hydrogen bonds for 03065a [Å and °]. 
______________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________  
N(10)-H(10)...Cl(7)#1 0.95 2.56 3.492(2) 168.0 
______________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2, y+1/2, z+1/2       
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